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In the ongoing quest to further expand the repertoire of drugs for cancer 
therapy, sights have turned on the machinations of the anti-malarial drug, 
chloroquine as an untapped prospective drug for use in such treatments.  
In order to establish the nature of chloroquine diphosphate (CQ) on 
differing breast cancers subtypes and to explore its relationship with tamoxifen 
(TAM) both in comparative effect and in conjunction, three phenotypically 
disparate cell lines were investigated; oestrogen receptor positive (ER+) MCF-
7 WT, tamoxifen resistant subtype MCF-7 TMX and oestrogen receptor 
negative (ER-) MDA-MD-231. In order to establish a baseline, each cell line was 
investigated first independently with various concentrations of tamoxifen (2-30 
μM) and chloroquine (10-140 μM) for 48 hours, the results of which were used 
to design a combined treatment modality to assay the effect of both drugs on 
the cells in tandem. The preliminary results showed that response to the initial 
two single drug treatment studies were dose dependent with lower 
concentrations of tamoxifen (2-10 μM) and chloroquine (10-20 μM) inhibiting 
growth and increasing vacuolation in all cell lines evidenced by increased 
uptake in Neutral Red (NR) stain and increased volume of acidic compartments 
(VAC). Higher treatment concentrations (12-32 μM TAM, 40-120 μM CQ) were 
seen to have a cytotoxic effect on all the cell lines in conjunction with a decrease 
in NR uptake and VAC. All three cell lines exhibited analogous response to CQ 
and singular treatment with tamoxifen resulted in similar dose-dependent 
responses albeit with higher doses of the drug necessary for MCF-7 TAM and 
MDA-MB-231 to develop any significant (P≤ 0.05, n=3) cytotoxic deviation. This 
effect on the ER- and oestrogen resistant cell lines imply exogenous cytotoxic 
pathways independent of the oestrogen receptor. Combination treatment, using 
the same range of TAM with a static dose (10 μM) Studies combining the two 
drugs were performed using the preliminary data as rationale for dosage. Using 
variable concentrations of tamoxifen (2-30 μM) and keeping that of CQ (10 μM) 
saw changes in cell morphology mimicking more closely that of high dose CQ 
treatment in qualitative NR and acridine orange (AO) staining from relatively 
low doses of TAM as well as substantially decreasing the ED50 (minimum 
dosage to kill 50% of cells) in all cell lines. Caspase 3 colorimetry and Annexin 
V ELISA was used for the quantification of apoptosis and to help determine the 
mechanism of cell death utilised by these drugs and implied Caspase 
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dependent apoptosis was occurring alongside the more visible caspase-
independent cytotoxic events. 
The results suggest that CQ may potentiate cell death of breast cancer 
cells treated with tamoxifen through the abrogation of autophagy and potentially 
re-sensitising resistant and ER- cells to hormone therapy treatment. 
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Chapter One 
 
Introduction to Breast Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 Introduction 
1.1 Epidemiology of Breast Cancer 
Although sexually biased in nature, breast cancer has remained the most 
common cancer in the United Kingdom (UK) since 1997 (CancerResearchUK, 
17 
 
2010), only occurring very infrequently in males (<400/year) yet accounting for 
31% of all new cancer incidences in females at a staggering rate of 
approximately 50,000 new cases per annum. This pattern is observed 
worldwide with 1.3 million annual new diagnoses and 465,000 deaths 
subsequent to the disease (Lloyd Davies, 2012).  
Extensive documentation of the disease has led to suggest a strong 
correlation with the increased incidence of disease and age; in the UK, 80% of 
all new diagnoses occur in women over 50 years of age with incidence rates 
rising steeply up until its peak at the 85+ age group (CancerResearchUK, 
2010). This pattern can be observed globally, with 89% of breast cancers 
diagnosed from the age of 40 onwards with a marked disparity between that of 
more economically developed countries (95% of cancers >40 years) vs. less 
economically developed countries (84% of cancers >40 years) which has been 
attributed to a number of factors, particularly in differences in that of lifestyle; 
variances in population levels of obesity, alcohol consumption, hormone 
replacement therapy and age of primary pregnancy and breast feeding status 
are all taken into consideration (Youlden et al, 2012). 
Relative breast cancer survival rates for the United Kingdom collated 
from a 2005-2009 cohort study made available by Breast Cancer Research UK 
(2010) have shown that 95.8% of women newly diagnosed are expected to 
survive at least one year. Subsequent 5 and10 year evaluations show this figure 
falling to 85.1% and 77.0% respectively due to late recurrences and metastatic 
disease (Youlden et al, 2012) 
In conjunction to typical cancer treatment through remedial surgical 
excision of aberrant tissue, adjuvant care regimes such as hormone therapy, 
radiation and chemotherapy exist; the purpose of which is to downgrade and 
downstage (Kaminsky-Forrett et al, 1998) existing neoplasia either prior 
surgery, the ‘neoadjuvant’ approach (Chuthapisith et al, 2006), or post-
surgically as a prophylactic measure to ensure the removal of as much aberrant 
tissue as possible (Cionini et al, 1996). Multiple adjuvant therapies can be used 
concurrently or sequentially for a more positive survival prognosis, the efficacy 
of which has been recognised and deliberated at length by many researchers 
(Peters et al, 2000; Zhang et al, 2009; Bedognetti et al, 2011). 
18 
 
A large percentage of patients do no respond well to neoadjuvant 
chemotherapy, with less than 30% of cancer patients responding completely to 
treatment (Chuthapisith et al, 2006); in 2009 a reported 11,728 patients died in 
the UK as a result in complications from breast cancer (CancerResearchUK, 
2016). Resistance to chemotherapeutic drugs is inevitable in most cases and 
is corollary with poor treatment response, subsequent remission and death. It 
is for this reason that most administered treatments are of a combined nature, 
with several classes of agents used at a time in an attempt to elongate the 
period between clinical efficacy and resistance (Bhosle & Hall, 2009). For this 
and other (socioeconomic) reasons, new chemotherapeutic analogues and 
classes are constantly being investigated to expand and sustain the current 
repertoire. 
Chloroquine (CQ) is one such drug that is now under the spotlight as 
having potential in chemotherapeutic medicine. Due to the emergence of CQ-
resistant Plasmodium falciparum, it has been largely discontinued in many 
countries as an antimalarial drug (Ginsburg, 2005; Gharbi et al, 2013) in favour 
of newer therapies for example, artemisinin-based combination therapy. 
Understanding and on-going research into the properties of CQ have led us to 
believe that it may hold some qualitative chemotherapeutic value in the 
potentiation of existing chemotherapeutic drug action through its unique 
mechanisms of lysosomotrophy and subsequent autophagy abrogation 
(Solomon & Lee, 2009). 
The pharmacodynamic relationship between the widely used anti-
oestrogen chemotherapeutic agent tamoxifen and CQ is largely unknown. It is 
the purpose of this investigation to test the effect of CQ, if any on hormone-
responsive (Levenson & Jordan, 1997) breast cancer cell line MCF-7 and in 
combination with tamoxifen in order to establish the mechanism of action and 
to explore whether or not CQ has any ability to potentiate the chemotherapeutic 
effects of tamoxifen.  
1.2 Aetiology of Breast Cancer 
The Cell Cycle 
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Although perhaps not yet understood in its entirety, the aetiological 
model for breast cancer is one that is constantly evolving as new ideas, 
concepts and findings have come to light. Studies documented on the aetiology 
of breast cancer from through by epidemiological studies that govern risk such 
as gender, age and weight has also contributed greatly to the aetiological 
model. Table 1.1 lends a summarized view of many of the known risk factors 
with indication to relative strength and risk of cancer. The basic understanding 
on the developmental biology of breast cancer is almost always attributed to 
the (somewhat ambiguous) somatic mutation of a single cell/group of cells and 
may be expressed as a singular continuum and has been summarised in 
Figure1.1. 
 
 
 
One such highly referenced and constantly updated model is brought 
forward by Adami, Trichopoulos and collaborators in their multiple publications 
over the past two decades (1995, 1998, and 2008). Their model collates what 
Figure 1.1: The continuum of cancer development (Adapted from 
Caldas, 2012). The grey circle represents a normal cell, the dotted 
grey circle represents the initiating somatic mutation and the 
coloured circles represent accumulative generations with 
individual characteristics and oncogenotypes. 
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we know about the epidemiological factors of breast cancer into three distinct 
components which emphasise the early life circumstances and determinants of 
breast cancer, these components include: 
 
i.) Mammary Gland Mass- The likelihood of breast cancer depends on 
the number of mammary tissue-specific cells determined in the 
intrauterine period of life; the mammographic mass of the mammary 
glands may infer the total number of mammary cells (Kuchiki et al, 
2010), this first component can be substantiated by evidence such 
as the disparity of incidence of the disease between Western and 
Asian populations (Huang et al, 2009) and even between that of man 
and woman.  
ii.) Growth Hormone levels- Much investigation has been undergone 
in ascertaining the roles between growth hormones such as 
oestrogens and progesterone in breast cancer (Hulka & Moorman, 
2001; Da Silva & Lakhani, 2010; Adami et al, 1995, 1998, 2008; 
Gusterson & Stein, 2012). Growth factors and hormones are 
responsible for the replication of mammary tissue and specific 
progenitor cells, they increase the likelihood of retaining cells with 
spontaneous somatic mutations as well as the expansion of initiated 
clones making marked or atypical levels of such hormones through 
developmental stages increase the risk of cancer. Growth hormone 
levels may be directly correlated with the increased risk of breast 
cancer in taller individuals (Cold et al, 1998) 
 
iii.) Terminal Differentiation- Pregnancy is known to convey a long-
term protection through the differentiation of a large proportion of 
mammary-tissue specific progenitor cells (Trichoupolos et al, 2008; 
Gusterson & Stein, 2012). It is thought that the later a woman 
becomes pregnant, the higher the number of cells would have 
already initiated, thus the less protection she would gain. 
Additionally, this protection is a double-edged sword due to the 
natural increase of mammotropic hormones during pregnancy, which 
as Trichoupolos (2008) put it would overshadow the terminal 
21 
 
differentiation of mammary cells. This could be the reason why the 
risk women in more developed countries who choose to set up a 
family later on in life (past the age of 35) is higher than nulliparous 
individuals.  
 
This model further differentiates the factors of the epidemiological risk 
previously listed in Table 1.1 depending on their relationship to general 
principles of carcinogenesis, number of mammary tissue specific progenitor 
cells, growth enhancing mammotropic hormones and terminal differentiation of 
the tissue. 
Risk factor Category/change Strength 
Gender Women vs. men ++++ 
Age Increase ++++ 
Ethnic group Caucasian vs. 
Asian 
+++ 
Family history Yes vs. no +++ 
Specific genes Yes vs. no ++++ 
Cancer in other breast Yes vs. no +++ 
Height Increase ++ 
Birth weight Increase + 
Growth in early life Increase + 
Mammographic density 
(mammary gland mass) 
High vs. low density 
(increasing mass) 
+++ 
Age at menopause Later ++ 
Type of menopause Natural vs. artificial ++ 
Age at 1st full term 
pregnancy 
Later +++ 
Age at other pregnancies Later + 
Parity overall Lower ++ 
Plant foods and olive oil Reduced intake + 
Saturated fat Increased intake + 
 
 
 
Further research into the perinatal, infant and adolescent periods and their 
relationship with the aetiology of breast cancer has been done by other 
investigators expanding the current base of risk factors. Ruder and colleagues 
(2008) have collated together scores of cohort studies into the links between 
factors such as gestational age, birth weight and length along with other 
Table 1.1: Epidemiological risk factors for breast cancer, 
association: ++++ very strong; +++ strong, ++ modest, + weak.  
            (Adapted from Trichopoulos et al, 2008) 
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childhood statistics and lifestyle to ascertain their relevance to which they found 
an inverse correlation in gestational age and a positive correlation in birth 
weight and length. Research into the clinical and molecular nature of breast 
cancer utilising cDNA microarrays and immunohistochemical (IHC) assays 
have been used to classify breast cancer into that of five distinct subtypes 
based on expression (or lack thereof) of cellular markers: 
BC Subtype ER PR HER2 CK 5/6 EGFR 
Luminal A + +/- - - - 
Luminal B + +/- + - - 
HeR 
Overexpressing 
- - + - - 
Basal-like - - - + + 
Normal-like n n N N N 
 
 
 
 
Approximately 70% of ‘triple-negative’ breast cancers express basal markers 
thus triple negative subtype may often be used as an indicator for the basal-like 
subtype. 
According to the highly accessed epidemiological research article 
published by Kwan and colleagues (2009), luminal tumours are more often 
associated with more favourable outcomes to its sister subtypes such as Her2-
overexpressing, basal-like and otherwise triple negative tumours which are 
associated with much poorer prognoses. 15% of all invasive breast cancers in 
the United States can be attributed to the triple negative subtype, which is often 
associated with the African-American demographic, patients presenting at 
younger ages of the disease, more advanced grading and staged cancers, 
diseases with higher mitotic indices and those with a familial history of breast 
cancer. 
1.3 The Oestrogen Receptor (ER) 
Steroid hormone receptors such as oestrogen receptors (ER) and 
progesterone receptor modulate the transcription of target genes when bound 
Table 1.2: The “Classic” Intrinsic Gene List; illustrating 5 known subtypes of breast 
cancer with respects to the presence of specific markers. ER, Oestrogen Receptor, PR, 
Progesterone Receptor; Her2, Human endothelial growth factor receptor 2; CK 
(Cytokine) 5/6, Cytokeratin 5 and 6; EGFR, Epidermal growth factor (Adapted from 
Kwan et al, 2009). 
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to their respective ligands to modulate physiological processes such as 
reproductive organ development and function, and bone density (Pearce & 
Jordan, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O 
 
 
Fig 1.2 Illustrating the distribution of ERα & ERβ in the human body. 
Adapted from Pearce & Jordan, 2004. 
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Oestrogen receptors exist as two characteristic subtypes, ERα & ERβ; 
the abundance and distribution of which, determines the effect of the binding 
ER ligand on the target tissues. Oestradiol (E2, the most potent and bioavailable 
of the three major cholesterol derived naturally synthesised oestrogens), has a 
large and diverse functional role, not only in female reproductive functions but 
also in the mediation of many metabolic processes in various tissues of the 
body (Figure 1.1) such as cell growth, pubescence and epiphyseal plate closure 
(Weise et al, 2001; Janfaza et al, 2006), cell differentiation as well as intricate 
roles in the metabolic processes of the liver, brain, linear bone growth, 
cardiovascular system and the regulation of male physiology (Ascenzi et al, 
2006). Target tissues which express a higher level of ER are predicted to 
produce a greater response to the presence of ER ligands (Pearce & Jordan, 
2004). Further plasticity for the cell’s response to oestrogens is brought about 
by the fluid mobility of the oestrogen receptor which is able to migrate 
spontaneously intracellularly between the membranes of the organelles, for 
instance, between the nucleus and the plasma membrane allowing for 
oestrogens to generate different and synergetic signal transduction pathways 
on both a genomic and non-genomic level (Ascenzi et al, 2006; Gouglet et al, 
2007). Work done with the ‘knockout mouse’ (KO) model, i.e. transgenic mice 
where the genes pertaining to the protein/molecule of interest (in this case, ER 
α & β) has been performed to demonstrate the different effects and sensitivities 
of oestrogen on target tissues and organ systems, including the male and 
female reproductive tract, mammary gland, bone and the phenotypic changes 
that it incurs (Couse et al, 2000; Curtis Hewitt et al, 2000; Pearce & Jordan, 
2004). 
Through their interplay at the receptor expression and signalling level, 
oestrogens play an integral part in the modulation of growth hormone (GH) 
which plays a fundamental role in the regulation of growth and development of 
the body (Leung et al, 2010). Oestrogen and GH levels are tightly correlated 
during puberty, with increases in oestrogen levels such as those observed 
during the periovulatory phase resulting in a similar marked increase in GH; the 
administration of exogenous oestrogen is also seen to cause an increase in 
circulating GH, however, it has been found that depending on the route of 
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administration the exogenous E2 is found to dissociate the growth hormone/ 
insulin-like growth factor-1 (IGF-1) axis, resulting in a marked decrease in the 
metabolic activity of peripheral tissues as is the case with orally administered 
oestrogen (Leung et al, 2010). 
 
 
 
 
 
 
 
 
Figure 1.3 highlights the structure of the oestrogen receptors; oestrogen 
receptors consist of 6 domains (A-F, F being a domain exclusive to the ERs 
which are members of the nuclear receptor superfamily of which domains A-E 
are common). Oestrogens bind to the hormone binding domain (HBD) which in 
turn causes a trans-conformational change of the molecule in which unmasks 
activating function 1 (AF1) within the A/B domain through the removal of 
chaperone protein HSP90, receptor dimerization and activation of activating 
function 2 (AF2) which resides within the C-terminus of the domain. This allows 
DNA binding domain (DBD) C to then bind to oestrogen-responsive elements 
(ERE) on target genes. The ERE-bound ER-dimers modulate the transcription 
of target proteins through the interaction of co-activators and co-expressors. 
(Platet et al, 2004) 
The role of ER and its ligands in the development of normal breast tissue 
have been shown to be crucial from the embryonic state with maternal 
oestrogen levels governing the degree of development of aforementioned 
tissue at birth (Gusterson & Stein, 2012). Low levels of oestrogen receptor have 
been reported in the luminal cells of pre-pubertal/perimenarchal glands of 
females, however due to available profiles being based on limited, post mortem 
tissues, may not be representative of ER profile of periadolescent breast tissue 
status in vivo .The work done on ERα & -β knockout mice (αβERKO, βERKO & 
αERKO models respectively) show that pubertal mammary development does 
not occur without the presence ERα, thus expressing its importance in 
Fig. 1.3: The structure and function of oestrogen receptors 
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mammary development (Pearce & Jordan, 2004; Gusterson & Stein, 2012), 
furthermore in these studies, ERβ was found to be integral for fertility in female 
mice, especially follicular maturation, yet extraneous to mammary growth, 
leaving its role in the physiology of breast in question (Shyamala et al, 2000). 
 
 
 
 
1.3.1 ER in Cancer 
Due to the aforementioned effects of oestrogens on the facilitation of cell 
proliferation, ERs thus have a very involved relationship when present in 
proliferative disease of the breast. It has been long understood that the 
agonistic interaction of oestrogens with ERα resulting in a direct increase in cell 
proliferation; increasing the number of G0/G1 cells entering the cell cycle in-
vitro (Cullen et al, 2001; Pearce & Jordan, 2004; Platet et al, 2004) and thus is 
a strong prognostic and predictive marker for endocrine therapy for the clinical 
management of the disease (Mandusic et al, 2012). Understanding the 
relationship between ERα and breast cancer has led to the development of 
endocrine treatments as a means of treating hormone responsive breast 
cancers (Pearce & Jordan, 2004) and will be discussed at length in a later 
chapter.  Conversely, it has been described in recent literature that ERβ 
agonists elicit inhibitory effects on hormone-dependent tumours (Lattrich et al, 
2013) which has promising implications in future avenues of hormone mediated 
breast cancer control. 
In addition to the discussed wild-type oestrogen receptors, numerous 
splice variants have been identified for both ERα and ERβ and have found to 
be frequently co-expressed with their wild-type counterparts (Ascenzi et al, 
2006), moreover, several splice variants of ERα have been found in a variety 
of tissues and disease states including, intriguingly, ER- classified breast 
cancer (Herynk & Fuqua, 2004). The most common splice variants of both ERs 
may exhibit frame deletion mutations, specifically of exons 3, 4 or both although 
many other truncations and insertions along the coding gene have also been 
characterised; the mRNA expression of many ERβ isoforms are in fact found in 
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higher quantities in human breast tissues than their wild-type variant with much 
documented evidence to suggest the possibility of protein expression of several 
isoforms of ERβ in vivo (Herynk & Fuqua, 2004, Ascenzi et al, 2006). One 
uniquely characterised ERβ splice variant is that of ERβ2, which has been 
accepted as a naturally occurring isoform of ERβ in several species 
(Froehlicher et al, 2009; Davis et al, 2010; Mandusic et al, 2012) and largely 
shares the same structural conformation as its wild-type variant, save for an 18 
amino-acid disparity as 26 unique amino-acid residues described as ‘exon 9’ 
replace exon 8 (Ascenzi et al, 2006); the result is a receptor which does not 
bind ligand characteristically favours heterodimeric bonding to ERα over typical 
ERβ-ERβ dimerization, where it actively inhibits the ability of ERα to bind to 
DNA. It is of note to mention that whilst many ER splice variants have been 
uncovered the genetic level, there is little supporting evidence as to whether or 
not all other splice variants are expressed as proteins or further modified  nor 
as to their physiological activity (Ascenzi et al, 2006) if any. 
1.3.2 ER Splice Variants 
It has been posed that due to the antagonistic nature the two ERs 
present in the breast that the exact nature of oestrogens in breast cancer 
progression may be dual in nature; affected by the expression ratio of ERα and 
ERβ as opposed to their absolute levels (Platet et al, 2004; Mandusic et al, 
2012). It has been evidenced that as a luminal (ER+) carcinoma progresses 
from carcinoma in situ to further stages, its ER profile changes significantly, 
with pre-malignant and normal tissues expressing ERα at a generally lower 
level (10-20%) and increasing in proliferative ductal carcinoma in situ (DCIS), 
suggesting a correlation with an increased receptivity of oestrogen with 
increased risk of tumorigenesis (Travis & Key, 2003). Alongside this increase 
in expressed cytoplasmic ERα, the cellular concentration of ERβ1 (i.e. Wild-
type) is seen to fall from normal tissue through to proliferative ductal hyperplasia 
and into DCIS. Of note, it has been observed for high-grade DCIS to display a 
marked decrease in both oestrogen receptors down to negligible or absent 
levels where once they may have been in abundance (Platet et al, 2004); this 
association allows to make the inference that the presence of estrogens and 
their receptors may in fact help protect against cancer cell invasiveness; this is 
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made more plausible due to the fact that overexpression of ERβ2 in advanced 
disease is found to associated with better patient outcome (Mandusic et al, 
2012). 
 
 
 
1.4 Genetic Risk 
The notion that familial inheritance may play role in breast cancer 
susceptibility has been widely accepted and has been evidenced with figures 
suggesting at least a two-fold increase in the risk of female breast cancer when 
as little as one first-degree relative is found to suffer the disease (Antoniou & 
Easton, 2006; Oldenburg et al, 2007). A number of high penetrance germline 
mutations exist such as the BRCA1 (BReast CAncer early onset) and BRCA2 
mutations, however, these only counts for 15-20% of breast cancers which 
cluster in families and less than 5% of all reported cases of the disease 
(Nathanson et al, 2001; Antoniou & Easton, 2006; Oldenburg et al, 2007).  
Germline mutations of the BRCA1 gene, are often oncogenic, displaying a 
high penetrance; being present in around 15-20% of women with family 
diagnosed with breast cancer and 60-80% of women who has a family history 
of both breast and ovarian cancer and is linked with an increased risk of both 
breast and ovarian cancer within an individual’s lifetime (Nathanson et al, 
2001). BRCA1, located on chromosome 17q21, is a relatively large gene coding 
for a 220kd protein of 1863 amino acids with implicated functions in DNA repair 
and cell cycle regulation. Often referred to as a “Caretaker Gene”, BRCA1 is a 
well-known tumour suppressor with multiple interacting partners and a number 
of functions mentioned herein; it binds to BRCA2, p52 and has an epigenetic 
role in tumour suppression (Nathanson et al, 2001; Chang et al, 2011). It also 
serves as a transcriptional regulator with the ability to bind with several 
transcriptional regulatory proteins such as  ZBRK1, STAT1, Myc, p53 and ERα 
receptor (Maclachlan & El-Deiry, 2000) and is involved in chromatin remodelling 
and ubiquitylation (Nathanson et al, 2001; Oldenburg et al, 2007; Da Silva & 
Lakhani, 2010) thus, cells without a functioning BRCA1 gene are unable to 
arrest development in the G2 growth phase after DNA damage and 
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subsequently cannot undergo other functions such as transcription coupled 
repair. As of yet it is still not evident as to why germline mutations of BRCA1 
have such an affinity to malignancies of the breast and is due to the suggested 
metabolic importance of its protein not seen as commonly in other cancers, that 
being said, the relative lifetime risk of other cancers such as of the colon, 
Mullerian, pancreatic and prostate cancers in BRCA1 carriers and gall bladder, 
biliary, gastric, bone and pharyngeal cancers in BRCA2 carriers in addition to 
breast cancer which remains the focal pathology (Oldenburg et al, 2006). 
BRCA2 germline mutations of chromosome 13q12 carry a similar lifetime 
risk as BRCA1 from 60-85% with an increased ovarian cancer risk of about 10-
20% and a 100 fold increase from the norm in the likelihood of male breast 
cancer (Ottini et al, 2010). Unlike BRCA1 mutations, variants of BRCA2 are 
also observed in a number of other cancers involving the gastrointestinal 
system (GIT) (Nathanson et al, 2001; Rafnar et al, 2004; Karhu et al, 2006). 
The large 3418 amino acid protein (larger than the BRCA1 by 160kd) for which 
the BRCA2 gene encodes is known to bind to BRCA1 and RAD51 (involved in 
the homologous recombination of DNA), inferring a relationship in gene repair 
and chromosome integrity. Research done on rat models have also led to 
inference of possible involvement in chromosome segregation as well as gene 
repair (Nathanson et al, 2001; NCBI, 2013). Of note it has been documented 
that whilst multiparity (bearing multiple children) in BRCA1 mutation carriers 
appears to be protective, it has been observed to have the contrary effect in 
BRCA2 mutation carriers which are observed to have an overall increased risk 
of breast cancer (Narod, 2006). 
The clinical detection of amplified HER2 (Human Epidermal Growth Factor 
Receptor 2) (to be discussed in the next section), a cell surface protein present 
in most is often associated with certain aggressive types of breast cancer. 
Other well documented high penetrance gene mutations at risk of causing 
breast cancer are mostly associated with cancer syndromes and disease 
states, they include the serine-thronine kinase STK11/LKB1 mutation of Peutz-
Jehger syndrome with a 20.3 relative risk compared to normal carriers; 
Cowden’s syndrome’s PTEN mutation (of which belies a 20-30% lifetime risk) 
and mutations of p53 from which Li-Fraumeni syndrome manifests with 
childhood leukaemias, brain tumors and a 100% breast cancer penetrance past 
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childhood along with other  (Nathanson et al, 2001; Antoniou & Easton, 2006; 
Da Silva & Lakhani, 2010) however such gene mutations are as rare as they 
are lethal. Although these high penetrance mutations carry a significant risk, 
they only account for 25% of familiar clustered cases, with sporadic, idiopathic 
breast cancers being the dominant cause, inclining or to the evidence that 
perhaps other breast cancer susceptibility genes may be in play in mammary 
oncogenesis; such as the elusive ‘BRCA3’ or the more charily named ‘BRCAX’ 
which are the topic of much research and discussion (Burns et al, 2003; 
Swisher, 2004; Da Silva & Lakhani, 2006;Spellman & Gray, 2011). 
1.5 Breast Cancer Profiling 
 Due to the complex biologic heterogeneity of breast cancer, it has been 
widely accepted not as being a singular disease, but a cacophony of different 
diseases of the breast, each with their own distinct clinical, pathological and 
histopathological features, genetic and genomic variability and each pertaining 
to their own unique treatment responses and survival outcomes  yet all originate 
from and affect the terminal duct lobular unit (TDLU) of the breast (Perou et al, 
2000; Sørlie et al, 2001; Robinson et al, 2004; Vargo-Gogola & Rosen, 2007; 
Weigelt et al, 2010).  
 It was through the seminal enquiry of Perou and colleagues in 2000 and 
their high-throughput microarray-based gene expression profiling assays which 
gave rise to the ‘intrinsic’ gene list (pertaining to genes which vary the most 
between tumours from different patients compared to samples of the same 
tumour and is now known as Stanford  taxonomy) through which the molecular 
classification of breast cancers (represented in table 1.2); including luminal A, 
luminal B, Basal-like, HER-2 positive and normal subgroups, discussed below, 
was initially conceptualised, each of which pertaining to their own distinct 
prognoses and treatment responses (Sørlie et al, 2001; Sørlie et al, 2003; Hu 
et al, 2006). 
 The so-called luminal A and B (named thusly due to their molecular 
signature which bears a strong resemblance to the luminal cells of the breast 
duct (Robison, Perreard and Bernard, 2004) breast cancer subtypes; 
characterised by the presence of ER (and ER activation related genes such as 
estrogen-regulated LIV-1) and PR expression are the most commonly 
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diagnosed and account for 60% of all breast cancers (40% and 60% 
respectively)(Cyr & Margenthaler, 2014). These two subtypes are distinguished 
by a higher expression of proliferation genes a much lower expression of ER-
related, luminal and basal-like genes and overall worse progosis in luminal B 
cells to luminal A (Alizart et al., 2012; Cyr & Margenthaler, 2014).  Ki67 is a 
proliferative marker associated with ribosomal RNA transcription and 
production and is highly expressed in all cancer subtypes save for luminal A 
which may be an attributing factor to prognosis (McCubrey et al., 2014). 
 The HER2-enriched subtype constitutes for around 10-15% of all breast 
cancers and are naturally characterised by a high expression of the oncogene 
HER2 (Human Epidermal Growth Factor 2) and other proliferation-related 
genes with a low expression of luminal and basal-like genes. It is significant to 
note however, that not all HER2-enriched subtypes pertain to clinically defined 
HER2-positive breast cancer; that is to say, not all HER2 mutations lead to 
protein overexpression and cancerous statue of the tissues and vice versa  
(Robison, Perreard and Bernard, 2004; Alizart et al., 2012; Cyr & Margenthaler, 
2014). 
The Basal subtype (15-20% of all breast cancers) is characterised by the 
high expression of genes of the proliferation cluster such as  PCNA, BUB1, and 
CDC2 and  expression of transcription factors such as  c-fos, c-jun, and fos B 
with negligible PR/ER/HER2 (triple negative) expression. Again, although most 
basal-like cancers are triple negative; not all triple negative cancers are basal-
like. Of all the subtypes within the intrinsic list, cancers categorised as triple 
negative (HER2, Basal) are linked with the worst overall survival prognoses 
(Robison, Perreard and Bernard, 2004; Cyr & Margenthaler, 2014). 
Finally, the normal-like subtype is characterised by gene expression 
typical of normal breast adipose tissue. Previously suggested to be an artefact 
of tumour sampling, it is now widely accepted as being a genuine cancer 
subtype (Alizart et al., 2012). 
Although never intended as having any prognostic value during its 
inception (Cyr & Margenthaler, 2014), it has been observed that within the 
intrinsic list, cancers of luminal A subtype have the best prognosis, followed by 
luminal B, with the others following suite. It has however, not enough during 
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clinical assessment to prognosticate a patient’s survival using molecular profile 
alone as decided in a consensus conference in 2012 (Schwartz et al., 2012). 
As technology continues to advance, newer, more precise array 
technologies arise, and knowledge expands and disseminates, new multigene 
classifiers have emerged to reduce heterogeneity within the existing cancer 
subtypes of the intrinsic list as well as to define new subgroups, namely claudin-
low, molecular apocrine and interferon subgroups (Alizart et al., 2012).  The 
claudin-low subtype is defined by low HER2 and low activity of the proliferative 
gene clusters associated with basal and luminal B identification. The molecular 
apocrine group (mApo), characterised by the presence of androgen receptors 
(AR) and associated genes serves to further categorise non-basal triple 
negative cancers that fall under luminal B and HER2 taxonomy and accounts 
for about 15% of all invasive cancers (Alizart et al., 2012). The following table 
serves to consolidate the subtypes of Stanford taxonomy as well as claudin-
low, mApo and interferon subgroups, their common histological types and 
additional features. 
ER 
Division 
Molecular 
Subtype 
HER2 
Ki-
67 
Histological 
Grade 
Additional 
Features 
ER+ Luminal A (-) low 1 or 2 
Luminal 
cytokeratin +; E-
cadherin +/− 
  Luminal B (-/+) high 2 or 3 
Luminal 
cytokeratin 
+;TP53 mutations 
ER- HER2 (+) high 2 or 3 TP53 mutations 
  Basal-like (-) high 3 
Basal cytokeratin 
+;TP53 mutations 
  
Normal-
like 
n high n 
normal adiposic 
features 
  
Claudin-
low 
(-) high 3 
Cancer stem cell-
like; EMT-like; 
  mApo (-) high 3 
Androgen 
receptor + 
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Interferon-
related 
(-) high 3 STAT1 
 
1.6 Diagnosis of Breast Cancer 
Women are urged by organisations such as breastcancercare.org to be 
vigilantly aware of the changes that may occur in their breasts in order to 
address pathogenesis as soon as possible For many women, the prospect of 
breast cancer diagnosis can be emotionally and psychologically distressing; as 
such it is imperative that the diagnostic methods and techniques offered are 
fast and reliable (Azu et al, 2007).  The evaluation of possible breast 
abnormalities is typically executed with a triple assessment process which 
should include a thorough clinical examination, imaging techniques such as 
mammography, ultrasound and tissue sampling by fine needle aspiration or a 
core needle biopsy (Oldenburg et al, 2006). As the risk of breast cancer is 
understood to be directly correlated with age and subsequent survival rates 
positively correlated with timely diagnoses, it is imperative that the disease be 
screened for at earlier ages for better treatment and prognostic prospects 
(Trichopoulos et al, 2008; Jalalian et al, 2013) 
 
X-ray mammography and ultrasonography are the two chief imaging 
techniques used in the screening of non-palpable lesions and the detection of 
breast cancer (Flobbe et al, 2001) and are ubiquitous worldwide due to their 
relatively inexpensive cost of operation. Ultrasonography may often be used as 
an adjunct imaging technique following mammography, serving to differentiate 
cysts from solid breast tumours in the clinic. These techniques often fall short 
however, as their sensitivity greatly depends on largely variable factors such as 
breast density, which can occasionally lead to falsely negative images resulting 
in patients with even so much as palpable breast cancers being treated as 
normal or benign on investigation (Chen & Hsiao, 2008). Ultrasonography is 
also very operator dependent and requires a keen eye and a knowledgeable 
practitioner for good diagnosis. Technical advances such Doppler 
ultrasonography, and computer aided diagnostic (CAD) systems are becoming 
increasingly implemented and widely used to great effect to the benefit of the 
Table 1.3: Characteristics of Molecular Subtypes (Stanford and new subtypes); 
illustrating 5 known subtypes of breast cancer, (Adapted from Alizart et al., 2012). 
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radiologist, allowing for greater scope and detection of mammographic 
abnormalities (Fujita et al, 2008; Oliver et al, 2010; Jalalian et al, 2013) 
 More precise imagery techniques that are readily preceding these classic 
techniques include magnetic resonance imaging (MRI) demonstrated below in 
Figure 1.4 which has been proven in clinic to yield results with greater acuity to 
that of older techniques (Morrow et al, 2011; Davies, 2012). Other techniques 
include chest radiography, computed tomography (CT) and positron emission 
tomography (PET). Prospects for future diagnostic techniques include one 
which recently made its rounds on the medical scene which stems off widely 
studied circulating tumour DNA analyses which utilise biomarkers such as 
cancer antigen 15-3 used to determine patient’s response to treatment; the 
assessment of circulating, cell-free DNA with tumour-specific somatic 
alterations in the bloodstream may be (given the inherent specificity of the 
somatic mutations) an important biomarker for both metastatic breast cancer 
(Dawson et al 2013).  
 
 
 
Figure 1.4: Comparison of X-ray Mammography vs. MRI (A) Negative X-
ray mammogram of 43-year old woman. (B) contrast enhanced MRI of the 
same breast identifying multifocal carcinoma (C) saggital X-ray 
mammogram revealing abnormal tissue density. (D) contrast enhanced 
MRI of same patient identifying (Morrow et al, 2011; Davies, 2012) 
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The TNM staging system, in which (T) denotes tumour size; (N), the extent 
of local spread of the disease to the lymph nodes and (M), the occurrence and 
extent of distant metastasis, is a widely employed stratagem by healthcare 
professionals to evaluate the extent or severity of cancers from the evidence 
given to them from the techniques previously discussed in order to ascertain 
treatment regimens and prognostic estimation (Compton, 2003). Cancers, such 
as adenocarcinomas that arise from the TLDU of the breast are characterised 
by tissue invasion and metastasis to distant soil and as such the application of 
the TNM system is ideal (Oldenburg, 2007). T,N and M are all evaluated in 
stages, cancer size (T) is gauged in 7 possible stages from TX/0 in which no 
primary tumour can be evaluated or seen to T1-4 which is a qualitative 
assessment of tumour size. (N), Designates the number of lymph nodes to 
which the tumour has spread and can range from NX/0 to N3 whilst (M), which 
signifies the distant travel only ranges from MX/0 to M1. The end result is a 
TNM which could read T4N0M0 meaning a very large tumour with no lymph or 
metastatic involvement that would then confer a specific stage, 0, carcinoma in 
situ, to IV which can vary depending on the type of cancer being evaluated due 
to inherent discrepancies in aggression(Cancer.gov (2012). The routine staging 
of patients in the absence of signs or symptoms of metastatic onset is 
considered superfluous in some circles due to the relatively low incidence of 
disease of 2% (James et al, 2012), however, CT staging may be necessary in 
certain groups of patients with higher risk of metastases at time of presentation 
and must be put into consideration (James et al, 2012) 
By far the most reliable survival indicator in patients with breast cancer is 
the presence of axillary node metastases (Robertson et al, 2011). Among the 
techniques thus far mentioned, relatively more invasive biopsy procedures of 
the axillary and sentinel lymph nodes (by either core or fine needle aspiration) 
may also be performed in order for the pathologist to visualise and assess the 
nature of the cells in question and is a crucial member of the diagnostic triad 
that helps to direct decisions in treatment. Whilst several types or subsets of 
grading systems are in place in different laboratories, there is ultimately little 
difference (Dalton et al, 2000; Saha et al., 2013). During investigation, biopsy 
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sections are assigned a grade based on cell and tissue differentiation, such as 
tubule and gland formation, nuclear polymorphism and mitotic counts 
(Oldenburg et al, 2007). In the Nottingham Criteria; a grading system most 
commonly used in the UK, uses these three measures in order to produce a 
final grading score ranging from 1 (well differentiated) to 3 (poorly 
differentiated)(NHS, 2005).  
 
1.7 Treatment 
Up until the turn of the 20th century, surgical intervention had been the only 
known curative treatment option available for tumescent growths, and only up 
until the advent of anaesthesia and antibiotics had it been significantly useful 
due to apparent factors of pain and infection. Radiation therapy followed shortly 
after the discovery of x-rays by Wilhelm Roentgen in 1895 (which won him the 
Nobel Prize in 1901) which inspired hope to the population of a non-invasive 
cure for malignancy (Weber, 2000), the first documented success of which was 
recorded in 1879 where it was employed to cure severe cases of head and neck 
cancer (Sansare, Khanna and Karjodkar, 2011) 
 
Today, in the modern school of cancer treatment the surgical excision of 
malignancy is still considered to be one of the main treatment options wherever 
possible (Wood, 2007). Adjuvant therapies such as radiotherapy and 
chemotherapy may be given in conjunction to surgery as a prophylactic (also 
known as salvage) measure to reduce the risk of relapse. This treatment may 
be given preoperatively (Neoadjuvant therapy) where applicable in order to 
make attempts to down grade and down stage cancerous masses prior to 
surgery (Chuthapisith et al, 2006; Yamaguchi et al, 2012).  The direction of 
treatment is governed by information gained during the diagnosis of the 
individual patient, taking into consideration factors such as the grade and stage 
of the cancer and also factors such as the cancer location (as not all cancers 
are feasibly operable) (Mitra & Khoo, 2009).  
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1.7.1 Chemotherapy 
Chemotherapy (in relation to cancer), first coined by Paul Ehrlich in the early 
1900’s (DeVita, 2008), can be defined as the clinical use of systemic chemical 
compounds to arrest the proliferation of cancerous growth through the 
mediation of cell apoptosis (programmed cell death) (Becker et al, 2009). At 
first, the idea of treating cancer with chemotherapy from the early days of its 
conceptualisation, even up to the discovery of its utility post WWII was met with 
much vitriol in its initial debut on the medical scene (DeVita & Chu, 2008) and 
was not until the 1970’s that adjuvant chemotherapeutic methods were widely 
applied in cancer treatment. 
 
 
 
 
 
 
Figure 1.5: The effect of antitumor antibiotics on 
different phases of the cell cycle, adapted from 
Brown et al (2011) 
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Chemotherapeutic treatment can be subdivided into four separate schools; 
Curative chemotherapy, for which the disease state can be effectively cured (in 
a very small number of cancers) by a combination of chemotherapeutic agents; 
the previously discussed adjuvant and neoadjuvant approaches and finally 
palliative care, which while not curative may help to extend prognosis of the 
patient (Parnell & Woll, 2003; Sridhar & Syomnds, 2009; English, 2010). 
 
The cytotoxic drugs that make up the known list of chemotherapeutic drugs 
are divided into several classes based on their method of action, they consist 
of; 
 
i.) Vinca alkaloids- administered intravenously, these drugs inhibit cell 
division by binding to tubulin within cells preventing the synthesis of 
mitotic spindles. Vincristine and vinblastine are both members of this 
family (English, 2009). 
 
ii.) Antimetabolytes- such as methotrexate are used intrathecally in the 
chemotherapeutic treatment of CNS derived malignancy such as 
non-Hodgkin’s lymphoma or acute lymphoblastic leukaemia. They 
act by inhibiting DNA and RNA synthesis through the inhibition of 
metabolic processes (Sridhar & Symonds, 2009; English, 2009). 
 
iii.) Alkylating agents- are used in a wide range of malignancies, they act 
by covalently bonding with DNA bases causing single or double 
stranded DNA breaks (Sridhar & Symonds, 2009) 
 
iv.) Taxanes- which include paclitaxel and docetaxel; they act against 
microtubules to inhibit mitotic activity of cells (English, 2009) 
 
To much the disdain of the pharmacologist, chemotherapeutic drugs act 
upon healthy cells as well as malignant tissues which may cause side effects 
such as bone marrow suppression, nausea and vomiting, hair loss, kidney and 
heart failure and even neurotoxicity (Sridhar & Symonds, 2009) 
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1.8 Tamoxifen 
Tamoxifen has been used as the first port of call in the treatment of advanced 
breast cancer for the last 40 years. Since its discovery in the 1970’s its uses have 
expanded to include early breast cancer, ductal carcinoma in situ (DCIS) and more 
recently in the chemoprophylaxis of breast cancer. Due to tamoxifen’s good tolerability 
profile and efficacy in both pre and post-menopausal women, it has managed to retain 
its position as number one hormonal treatment of choice in patients with ER+ 
(oestrogen receptor positive) breast cancers thus making it the benchmark for which 
newer endocrine therapies are tested against (Clemons et al, 2002) 
1.8.1 History of Tamoxifen 
 The use of tamoxifen as an endocrine based chemotherapeutic agent 
emerged in the wake of an era of cytotoxic chemotherapy heralded by Cooper 
(1963) with the American Association for Cancer Research. Venturing further 
back towards the dawn of the 20th Century, Beatson (1897) discovered that 
advanced breast tumours in premenopausal women were sometimes 
responsive to bilateral oophorectomy, thus the hypothesis could be formed that 
the progress of oestrogen dependent tumours could be truncated through 
subsequent deprivation of oestrogen (Clemons et al, 2002). 
 Subsequent to this discovery, ablative surgical treatments such as 
hypophysisectomies and adrenalectomies were commonly employed in the 
treatment of advanced breast cancer, however, in light of these developments, 
a non-surgical endocrine approach was still sorely needed; the forerunners of 
which, although efficacious, were limited by their toxicity. Initially developed as 
a post-coital contraceptive, tamoxifen, (formerly ICI 46,474), emerged in the 
1960’s during a series of anti-hormone efficacy tests spearheaded by Arthur L. 
Walpole on triphenylethylene derivatives following the development of the two 
anti-oestrogens MER-25 and clomiphene (Fig 1.5) through the substitution of 
the chlorine in clomiphene with alkyl groups. At the time, clomiphene, although 
showing promise as an effective anti-oestrogen agent, was being linked with an 
increased incidence in cataracts in animal models (Newberne et al, 1966) 
necessitating the development of an analogue with similar dose-response 
efficacy but with decreased morbidity. Tamoxifen proved to be just that drug, 
although the discovery of its truly anti-oestrogenic conformation came later after 
the prior discovery of its cis-isomer which acted as a pure oestrogen much like 
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its predecessors before it, making it potent fertility agent. It was only after a 
study on the pharmaceutical effects of cis vs trans isomer conformation that the 
trans-isomer was shown to play a primarily anti-oestrogenic role, the first of 
such discovery of its kind which heralded the dawn of targeted therapy as we 
know it today (Clemons et al, 2002).  
 
 
 
It is the work of the eminent pharmacologist Craig Jordan, who’s vital 
exploits and commitment to the field helped transform ICI 46,474 from failed 
contraceptive to the gold standard for targeted therapy in breast cancer that it 
is today, whose work includes but is not limited to the discovery of 4-
hydroxytamoxifen with its 100x greater binding affinity over the non-
hydroxylated drug, the determination of tamoxifen’s prophylactic benefit in a rat 
model and the specialisation of tamoxifen from palliative drug to the long-term 
adjuvant it is currently used as today (Jordan, 2008). 
Figure 1.6: Oestrogen with antioestrogen competitors, Clemons et al, 2002 
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1.8.2 Properties of Tamoxifen 
The anti-oestrogen tamoxifen (a triphenylethylene derivative) is a 
selective oestrogen receptor modulator (SERM) which competes with 
oestrogens for the binding to the two homologous oestrogen receptors ERα & 
ERβ thus negating the cytotropic effects of oestrogens. 4-Hydroxytamoxifen (4-
OHT), formed by the hydroxylation of tamoxifen that exhibits a higher affinity to 
oestrogen receptor (50 to 100x) to that of its parent metabolite and exists as 
both Z (trans) and E (cis) isomers, with the latter (cis) exhibiting a weaker affinity 
akin to that of tamoxifen (Singh et al, 2007; Brauch & Jordan, 2009). Endoxifen 
(4-hydroxydesmethyltamoxifen), which exhibits a similar ER affinity to that of 4-
OHT, is the latter product of tamoxifen metabolisation and is thought to be the 
principal antioestrogenic metabolite for antitumour activity in breast cancer 
patients due to higher serum levels of endoxifen compared to 4-OHT after 
treatment with tamoxifen of up to six fold (Lim et al, 2006); Brauch & Jordan, 
2009) 
 
 
    
 
Figure 1.7: Mode of action of oestradiol and tamoxifen. Clemons et al, 2002 
42 
 
 
Additionally, it has been reported in recent years that tamoxifen exhibits 
ancillary oestrogen receptor independent processes such as the inhibition of 
PKC pathways which contribute to the overall chemotherapeutic outcome of the 
drug as postulated from the effect of tamoxifen on oestrogen negative and 
oestrogen independent cancer cell lines in which cell migration, invasion and 
metastasis was markedly inhibited (Matsuoka et al, 2009). 
 
1.8.3 Tamoxifen in Cancer Therapy 
To this day, SERMs such as tamoxifen remain the most prescribed anti-
neoplastic for ER-positive breast cancers worldwide for both men and women. 
Studies by the NCI report the reduction of invasive breast cancer by 50% in 
postmenopausal women when used in prophylaxis to the disease (Vogel et al, 
2006). It is generally well tolerated with acute side-effects similar to the 
symptoms of menopause, such as hot flushes, irregular menses etc. (Loprinzi 
et al, 2000) however one of the more serious adverse effects it may cause is 
that of an increased incidence of endometrial cancer; a likely result of its 
oestrogenic activity (Clemons et al, 2002). Tamoxifen has also emerged as a 
potential management option for symptoms of non-steroidal anti-androgenic 
treatment for males with prostate cancer where it may be considered in lieu of 
surgical or radiotherapy options to prevent or reduce neoplastic breast events 
(Kunath et al, 2012). 
 Although new ways and strategies are constantly being devised to target 
oestrogen and ERs, approximately, 30% of ERα-positive breast cancers do not 
respond to tamoxifen therapy, with the majority of initially responsive tumours 
soon developing resistance and following suit over the course of treatment 
despite the continued presence of ERα (Riggins et al, 2007). Additionally, small 
numbers of ERα-negative but PR-positive tumours have been found to respond 
to antioestrogen treatment made feasible by the assumption that PR-positive 
tumours may retain a functional ERα signalling pathways due to the fact that 
PR expression is oestrogen regulated (Riggins et al, 2007). 
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1.9 Chloroquine 
 There is an ever increasing need to develop and refine the current 
repertoire of effective cancer treatments with newer, more effective modalities.  
A study of 68 then approved drugs in 2003 by DiMasi and colleagues estimated 
that the cost of developing a single effective cancer antibiotic to be put at an 
average of 15 years and $800 million. With such a substantial toll to pay, it has 
become fashionable for researchers to comb the pre-existing annals of drugs 
which have long had their pharmacokinetics and safety profiles clarified, and 
approved by regulatory bodies for human use which would allow any novel uses 
to be hastily appraised in phase II trials in the hopes of repurposing them for 
chemotherapeutic use (Solomon & Lee, 2009). 
With the current limitation of drug concentrations used in therapy (mainly due 
to side effects), it is speculated that combinational modalities consisting of a  
 
suite of drugs with synergistic effect may provide a better response to that of 
conventional practice. 
 
 
 Chloroquine (CQ) is a 4-aminoquinoline (possessing a 4-aminoquinoline 
scaffold) renowned world-wide for its use in the prophylaxis and treatment of 
malaria for which, since its discovery has enjoyed six decades of unrivalled 
usage in the treatment of the disease due to its economical nature, both fiscally 
and in its efficacy. Amongst its primary application, CQ’s anti-inflammatory 
properties have seen to it being used in the treatment rheumatoid arthritis, 
systemic lupus erythematosus and amoebic hepatitis (Jiang et al, 2010) with 
further clinical trials exploring its use in realms of antiretroviral treatment, 
Figure 1.7: Molecular Structure of Chloroquine 
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radiation therapy as well as in combinational modalities in chemotherapy (Hu 
et al, 2008). Several recent studies have shown that the drug has an extensive 
range of biological effects on human cells and tissues such as cell growth 
inhibition and/or lysis seen in human leukaemia K562 cells, human breast 
cancer Bcap-37 cells, human lung cancer A549 cells and also in the mediation 
of radiosensitivity in the MDA-MB-231 breast cancer cell line (Jiang et al, 2010) 
   
 
 
1.9.1 Properties of Chloroquine 
CQ is conventionally prepared as a diphosphate salt, a diprotic weak 
base that can exist in both a protonated (i.e. charged) and unpronated (i.e. 
uncharged) (Solomon & Lee, 2009). Uncharged at neutral pH, CQ enters the 
cell by passive diffusion and can freely diffuse across cell and into the 
endosome pathway or through the cytosol to other organelle membranes. Once 
inside an acidic vesicle such as a lysosome, CQ becomes protonated, 
preventing it from diffusing out of the vesicle. The trapped chloroquine 
molecules accumulate within the lysosomes which purportedly results in an 
increase in lysosomal volume; a change that often heralds the apoptotic or 
necrotic cell death response. It is thought that the increase in lysosomal volume 
by any means either intrinsic or otherwise can change the mode of cell death 
from apoptosis to necrosis and that disparity in lysosomal pH may influence 
endocytosis, exocytosis and phagocytosis (Hu et al, 2008). 
As a lysosomotropic agent, CQ causes dynamic changes in intracellular 
protein processing and extensive trafficking of autophagic vacuoles within the 
cell (Zaidi et al, 2001). This property has seen chloroquine and its derivatives 
and analogues in the quinine family be redefined as late-stage inhibitors of 
autophagy. 
Macroautophagy (hereafter referred to as autophagy) is the catabolic 
process commonly associated in the recycling of damaged and general 
turnover of cytoplasmic components (Levine and Klionsky, 2004). Referred to 
as a ‘housekeeping mechanism’ (Donohue et al., 2011), the process entails the 
formation of phagophores; sequestering membranes which expand and engulf 
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cytoplasmic material to then fuse into double membrane autophagosomes. 
Autophagosomes then fuse with lysosomes which result in the degradation of 
the autophagosomes and their contents by the acidic hydrolases of the 
lysosomes, the products of which are then released into the cytosol where they 
are then recycled by the cell through macromolecular synthesis (Cufí et al., 
2013).  
 
 
 
Autophagy may also function adaptively in the maintenance of cellular 
homeostasis and may be stimulated in response to cellular stress and insult 
such as in the case of  oxidative stress, amino acid depletion and 
chemotherapeutic agents and is thought to be thoroughly exploited in cancer 
cells, attributing to the resilience of several cell lines (Mizushima, 2007; 
Donohue et al., 2011; Esteve and Knecht, 2011).  
Persistent, excessive autophagy such as that in response to causes 
stated above may result in caspase-independent (type II) programmed cell 
death through the extensive catalysis of organelles (Bursch et al., 2000; 
Amaravadi and Thompson, 2007). To further delineate the role of autophagy, it 
may be subdivided into “basal autophagy” and “induced autophagy”; basal 
being the typical ‘housekeeping’ role in the general turnover of organelles 
whereas induced autophagy refers to autophagy following starvation in the 
requisition of amino acids (Mizushima, 2007). 
 
1.9.2 Quinines in Cancer Therapy 
As stated before, it has been the effort of various teams to work on 
elucidating the worth of CQ as a modality in chemotherapeutic medicine; of 
note are Fan and colleagues’ (2006) extensive examination on the effects of 
Figure 1.8: The progress of macroautophagy in mammalian cells (Mizushima, 
2007) 
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CQ on the A549 lung cancer cell line. Their findings described not only 
morphological impact on the cell line in presence of CQ, with cell shrinkage, 
detachment and blebbage apparent at concentrations surpassing 64 µM, but 
also pronounced findings in regards of cell cytotoxicity and inhibition of cell 
proliferation, with MTT and LDH assays exhibiting antiproliferative and cytotoxic 
effects upon the cells in a time dependent manner, with concentrations 
exceeding 32 µM exhibiting significant cytotoxicity. Of note in their 
investigations, the volume of acidic compartments (endosomes, lysosomes and 
the like) were seen to be increased in concentrations less than 32 µM but 
decreased when investigated in higher concentrations by which point apoptosis 
had already occurred. Lee & Tannok (2006) advocated that through raising the 
pH of acidic compartments with CQ, the sequestration of other anti-cancer 
drugs within the endosomes would be limited due to an increased permeability 
of the vesicles, potentially increasing the bioavailability of co-mediated drugs 
which would otherwise have been stored and metabolised within the 
lysosomes, potentially increasing the efficacy of such drugs through solid 
tumour masses where the effect of such drugs may otherwise have a lesser 
effect. 
 
1.10 Drug Resistance 
 In cancer treatment, we are always faced with the harsh reality that, over 
time and in the absence of resolution of the disease, resistance to 
chemotherapy will occur. As a result, much research has been done in the effort 
to understand the evolutionary dynamics of resistance (Bozic et al, 2013), with 
one central conclusion being that within any large solid tumour exists a small 
number of cells resistant to any targeted agent and are selected for and thus 
clonally expand once therapy has been administered, resulting in tumour 
recurrences particularly following treatment with a single agent (Diaz et al., 
2012; Bozic et al, 2013). 
Multidrug resistance is the term given to the mechanisms by which 
cancers develop resistance to chemotherapeutic drugs and is a contributing 
factor to their failure. It has been observed that tumours may consist of a mixed 
population of drug resistant and drug sensitive cells; in an uncanny similarity to 
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the resurgence of drug resistant microbes such as MRSA (Gould, 2007), 
chemotherapy kills drug-sensitive cells, however a large proportion of drug-
resistant cells will be left behind and form more resistant tumours in relapse 
which may cause future therapies to fail (Persidis, 1999). Paclitaxel has been 
reported to manifest multidrug resistance in many incidences of relapse after 
initial favourable response, likely due to inefficient bioavailability allowing for 
resurgence of resistant cells (Yao et al, 2011). Two molecular pumps which are 
believed to commonly confer drug resistance to these cells, namely P-
glycoprotein (P-gp) and the aptly named multidrug resistance-associated 
protein (MRP) (Gottesman et al, 2009). 
P-gp (encoded by the MDR1 gene) is reportedly responsible for 
multidrug resistance in about 50% of all human cancers (Gottesman et al, 
2009). Besides from being expressed by chemoresistant cancer cells, P-gp is 
also expressed in other tissues of the body, especially in the gastrointestinal 
tract where it highly expressed and involved in the low peroral bioavalibility of 
drugs such as paclitaxel (Panchanglula, 1998; Yao et al, 2011). It is still a 
mystery as to how the P-gp pump recognises and expels hundreds of different 
drugs (Gottesman et al, 2009), the bright side is that we know it cannot expel 
them all (Persidis, 1999) 
MRP is another proteinaceous pump that confers drug resistance to 
cells. Initially isolated in a small cell lung cancer cell line (Stewart et al, 1996; 
Persidis, 1999) studies have shown that it is synthesised in the same tissues 
as P-gp however it is not expressed in the liver (Sugawara et al, 1997). There 
is a dilemma in multidrug resistance and the treatment thereof in that whilst 
these proteins confer resistance to tumours, they also protect the 
chemosensitive tissues of the body such as the bone marrow, there making 
targets for tissues a difficult process (Persidis, 1999) 
The possible mechanisms which may confer resistance to tamoxifen 
span much more than the over-expression of drug efflux pathways and are well 
documented. Such pathways for resistance include but are not limited to the 
altered expression and/or modification of any number of growth factor receptors 
and downstream signalling molecules (Riggins et al, 2007). 
Research by Bozic and colleagues (2013) on a mathematical model of 
chemotherapy resistance presented the conclusion that no matter the nature of 
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resistance, the presence of a mutation that may confer cross-resistance to two 
or even three targeted agents will not result in sustained benefit, thus it is 
imperative for the future development and application of combination therapies 
in which the various drugs act through distinct pathways to offer the largest 
chance of survival.  
 
1.10.1 Drug Combination and Resistance 
Due to the swift and inevitable phenomenon of chemotherapeutic 
selection that occurs from the moment of treatment, subsequent resistance to 
any one particular drug during long-term therapy is expected to occur within a 
matter of months (Bozic et al, 2013; Munck et al., 2014). Through treatment 
with drugs which target different pathways it is inferred that the onset of 
resistance to such treatments would be much slower than any individual 
modality; conversely, studies show that if there is any possibility for cross-
resistance between combination modalities, such treatments would have the 
resistivity as if just a singular drug were to be used (Bozic et al, 2013) 
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1.2 Aims & Objectives 
 
The aim of this investigation was to investigate the chemotherapeutic 
effects of both tamoxifen and chloroquine and the possible collaborative effects 
between them, studies were performed on the cell lines MCF-7 WT, MCF-7 
TMX and MDA-MB-231 first independently (single drug) in order to attain 
benchmark readings for latter investigation. These readings; chiefly the ED50 
values, that is, the half maximal effective concentration for are key to 
determining the necessary concentrations for use in conjunctional study of the 
two drugs in combination to effectively witness the differences in response 
between ER+ and ER- breast cancer cell lines.  
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Chapter Two 
 
2.0 Methods & Materials 
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2.0 Materials and Methods 
2.1 Materials 
2.1.1 Safety Measures 
 Howie-style lab coat with cuffed sleeves for cell culture 
 Safety glasses 
 Nitrile powder-free gloves 
 Sleeve protectors 
 
2.1.2 General Equipment Required 
 Water bath OLS200 (Grant, UK) 
 Centrifuge Allegra X-15R (Beckman Coulter, UK) 
 Inverted microscope Eclipse TE2000-S (Nikon UK) 
 Fluorescence microscope (Nikon, UK) 
 Incubator Galaxy R CO2 
 Class II Microbiological Safety Cabinet TriMAT2 (Medical Air technology, 
UK) 
 Vortex Mixer (Clifton) 
 Falcon tubes, 14ml & 50ml (Corning, US) 
 Eppendorf tubes (Sarstedt, Germany) 
 0.45µm filter (Sterilin, Bargoet) 
 Cell scrapers (Sarstedt, Germany) 
 Automatic pipettes: P1000, P200 & P20 (Gilson, USA) 
 Pipette tips: P1000, P200 &P20 (Neptune CLP, USA) 
 Pasteur pipettes (Iasa, Spain) 
 Pipette holder (IBS Integra Biosciences, Switzerland) 
 Tissue culture flasks T25cm2  
 Timer (Quantum) 
 Beakers; 100ml. 200ml & 800ml (Pyrex) 
 Kimcare medical wipes (Kimberly-Clark Professional, UK) 
 Test tube rack 20mm (Nalgene, UK) 
 Measuring cylinder 500ml (SIMAX Technologies, UK) 
 Deionised Water 
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 70% Alcohol (3:7 distilled water to absolute alcohol) (Fisher Scientific, 
UK) 
 Phosphate Buffered Saline (PBS)1X Concentration PH7.4-7.6 (Sigma, 
UK) 
 Virkon 500g (Antec International, UK) 
 Forceps 
 Ice 
 Kitchen foil paper 
 Cling film 
 
2.1.3 Reagents used for cell culturing 
 MCF-7 WT Cell line 
 MCF-7 TMX Cell line (Johns Hopkins University) 
 MDA-MB-231 
 Iscov’s modified Dulbecco’s medium, IMDM (Sigma, UK) 
 Foetal calf serum (Sigma, UK) 
 Penicillin-Streptomycin (Sigma, UK) 
 Amphoterecin-B (Sigma, UK) 
 Glutamine (Sigma, UK) 
Preparation of complete culture medium: foetal calf serum (100ml/L), 
antibiotics (10ml/L) and glutamine (2mM) were added to the IMDM basal 
medium and mixed thoroughly to produce what is to be referred to as 
complete cell culture medium.  Once made, the complete medium should 
be used within one week. 
 Filtered phosphate buffered saline (Fisher BioReagents, UK) 
 Trypsin solution (0.25%), containing 0.02% EDTA (Sigma-Aldrich) 
stored in 10ml aliquots at -20°C to be thawed at 37°C when needed. 
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2.1.4 Reagents and equipment used for cell counting 
 Filtered 0.4% Trypan blue (Sigma Alrdich, UK) 
 Filtered PBS (Fisher Bioreagents, UK) 
 Pipettes (Gilson, UK) 
 Chosen cell suspension 
 Inverted Microscope (Nikon, JP) 
 
 
For Manual Cell Counting 
 Haemocytometer (Hawksley, England)  
 Microscopy cover slips; 22mm x 22mm 
 Tally counter  
 
For Automatic Cell Counting 
 TC-20 Automatic Cell Counter (Bio-Rad, UK)  
 Disposable cell counting slides (Bio-Rad, UK)  
 
2.1.5 Reagents and equipment used for cryostorage 
 Dimethyl sulfoxide (DMSO) (Sigma, UK) 
 Isopropanol (70%) freezing container (Sigma, UK) 
 Complete cell culture medium 
 1.8ml cryopure tube 
 Foetal calf serum (Sigma) 
 Ultra low temperature freezer KR10 (New Brunswick scientific, UK) 
 Liquid nitrogen cryogenic storage dewar 
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2.2 Methods 
2.2.1 Safety note- All investigations took place within a level 2 
microbiology laboratory under strict hygienic protocol for the protection of both 
scientists and research alike; lab coats, nitrile gloves, forearm protectors and 
protective eyewear were worn at all times whilst in the laboratory. The majority 
of work took place within a sterilised level 2 microbiology cabinet wherever 
possible to ensure an axenic environment when working with the cells. 
2.2.1 Aseptic technique 
In addition to all cell culture work being carried out in the cell culture 
cabinet, all instruments, including glassware and pipette tips were sterilised by 
autoclaving at 120ºC for 15 minutes at 10lbs/in2. All instruments were to be 
wiped down with 70% ethanol prior to introduction to the cabinet to reduce the 
possibility of introducing exogenous pathogens. Apparatus marked as sterile 
disposable were used once before being discarded for incineration. Unless 
otherwise stated, most non-sterile reagents for use in tissue culture were 
filtered before use through 0.45µM pore size filter (Sterilin, Bargoet). 
2.2.2 a Culture media preparation 
The necessary reagents for the culture medium are all taken from storage and 
brought to room temperature in a waterbath. The complete cell culture medium 
consists of Iscove’s modified Dulbecco’s medium (IMDM) which is prepared 
with 10% foetal calf serum (FCS), 1% penicillin/streptomycin and 2mM of L-
glutamine. To prevent phenotypic drift of tamoxifen resistant MCF-7 TMX, these 
cells are cultured with a modified complete medium containing an addition 1µM 
of 4-hydroxytamoxifen. 
2.2.2 b Cell Culture Procedure 
All culturing of MCF-7 WT and JH MCF-7 TAM cell lines was carried out 
in vented 25 cm2 tissue culture flasks (Sarstedt, Germany). The cells were 
maintained in complete cell culture medium at pH 7.3 in a humidified incubator 
which was kept at 37 ºC with 5% CO2 and 95% air (Wolf Laboratories, UK). 
Media and all reagents for cell culture were heated in a water bath at 37 ºC 
before being used. Every day, the flasks were observed for changes in to colour 
of the culture medium and overall cell confluency through the use of an inverted 
microscope (Nikon, UK). The medium was changed every 3-4 days by adding 
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4ml of complete cell culture medium. Once 90-100% cell confluency has been 
obtained, the cells were subsequently subcultured in a 25cm2 culture flask. 
2.2.2 c Subculture 
The cell lines were to be sub-cultured once reaching +90% cell 
confluency. As MCF-7 is an adherent cell line, cell detachment was necessary 
through the use of 0.25% trypsin containing 0.02% EDTA (Sigma-Aldrich). The 
trypsin, which was stored at -20ºC in 10ml aliquots was thawed in the water 
bath at 37 ºC and vortexed to ensure homogenicity before use. 
Once ready for subculture, flasks were to be taken from the incubator 
using aforementioned aseptic techniques (2.2.2) and placed into the cell culture 
cabinet. The cell culture medium was extracted from the flasks with a 10ml 
serological pipette and cells were washed with PBS to remove any trace of the 
old medium. Washing was performed through the addition of 5ml filtered PBS 
to the empty flasks which were then gently rocked manually for 10 seconds and 
then removed with another pipette (this process was generally repeated at least 
3 times).  5ml of 0.25% trypsin was then to be added to the flasks which were 
then incubated for around 5 minutes (a stopwatch timer is always used to keep 
the time as trypsin is known to have cytotoxic effect after prolonged exposure). 
Once 5 minutes had elapsed, the cells were then gently rocked manually 
before examination under the inverted microscope to ensure detachment. Once 
returned to the cabinet, the trypsinised cells were then introduced to a 14ml 
falcon tube (using a 10ml serological pipette) containing an equal (5ml) amount 
of basal medium which is used to neutralise the effect of the trypsin. Residual 
cells were a rare occurrence in the flask and thus a cell scraping was never 
necessary. The cells were the centrifuged at 1200rpm for 12 minutes at ambient 
room temperature. After discarding the supernatant, the cell pellet was then 
dislodged in 1ml of complete cell culture medium. Cell counting may be 
performed through haemocytometry. After this procedure, the cells were then 
placed in T25cm2 cell culture flask (labelled with the appropriate cell line, date 
and passage) containing 5ml of complete cell culture medium using an 
automatic pipette. In general, subcultures were established using 1/10 of the 
reconstituted pellet (100µl). 
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2.2.3 Cell Counting 
Following cell detachment with trypsin and centrifugation, it is necessary 
to count the cells in order to establish the necessary volume of cells required 
for any individual assay. To this end, the cells were counted using a 
haemocytometer and the vital stain trypan blue (Sigma Aldrich) which may be 
used to establish cell viability. Trypan blue achieves this effect through the 
selective colourization of dead cells.  
Use of an automated cell counter such as the TC-20 (Bio-Rad) in the image 
provides a quick high throughput way to assess cell number and viability as well 
as overall growth. The peaks shown on the display show the population of cells 
within specific diameters; the three closely grouped peaks represent the MCF-
7 cells, the middle and largest peak illustrates the majority population of cells, 
the two outlying peaks the cells which are slightly smaller or larger being those 
on either on the cusp of mitosis or new daughter cells, thus it is possible to 
determine at what point in the cell division cycle the majority of the cells are. 
25µl of the reconstituted cell suspension was transferred to a 500µl Eppendorf 
tube and then mixed well with an equal number of trypan blue through 
aspiration and ejection with a pipette. 10µl of this trypan blue/cell suspension 
would then be ejected onto a haemocytometer mounted with a 22x22mm 
coverslip for counting underneath a light microscope. The cells within the 16 
squares of an individual quadrant of the haemocytometer would then be 
counted and the final sum multiplied by the dilution factor (2) and then by 1x104 
to give the total number of cells within 1ml of the original reconstituted cell 
suspension. From this point it is then possible to determine the volume of the 
reconstituted cell suspension necessary for any subsequent assay 
 
 
 
 
 
2.2.4.5 Using the Haemocytometer 
This procedure uses the reagents and apparatus described in 2.1.4. Prior to 
usage, the haemocytometer is cleaned with 70% ethanol to minimize false 
positives from previous counts. To affix the coverslip to the haemocytometer, 
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the corners are gently moistened before carful application to the 
haemocytometer field.  Newton’s rings may be observed when the coverslip is 
correctly affixed. An alternative method of affixing the coverslip is by exhaling 
on to the back of the coverslip as to cause condensation before carefully 
applying it to the haemocytometer. Prior to counting, the supernatant 
trypsin/culture medium supernatant must be discarded and the remaining pellet 
resuspended to make up a 1ml cell suspension solution. In order to achieve the 
most reliable results from counting, the harvested cell suspension must be 
thoroughly mixed through gentle aspiration and ejection with a serological 
pipette (Gilson). Shortly after mixing to prevent sedimentation, 50µl of cell 
suspension should be extracted from the cell suspension and transported to an 
Eppendorf tube. 50µl trypan blue is then added to the Eppendorf tube making 
100ul trypan blue/cell suspension. From the 100µl trypan blue stained cell 
suspension, 10µl is drawn up using a Gilson pipette. The haemocytometer is 
then gently filled as the tip of the pipette rests at the edge of the chamber to 
ensure stability. It is important to make sure that the haemocytometer chamber 
is not overfilled and, to that extent, not all 10µl of trypan blue may be necessary; 
allow the cell suspension to be drawn out by capillary action until the chamber 
is completely filled. Once filled, the haemocytometer may then be observed by 
either upright or inverted light microscopy at 10X objective magnification. 
Figure 2.2 illustrates grid layout. 
 
 
of the haemocytometer chamber. 
The focus should be set to the set 
of 16 squares that made up one of 
the four corner quadrants of the 
chamber on that half of the 
haemocytometer. The cells within 
the 16 squares are then counted 
Figure 2.1: The gridlines of a 
haemocytometer chamber. 16 squares 
make up each corner quardrant (blue) 
in a chamber. (Abcam 2015) 
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using a hand tally; dead and dying cells show up stained blue whereas the 
healthy ones remain unstained by the trypan blue dye. It is important to only 
count cells that are within the square and any positioned on the right hand or 
bottom of the boundary line. By counting the dead cells, it is possible to also 
calculate the viability of the cell population. This process is repeated for the 
other 3 remaining quadrants of the chamber until all 4 sets of 16 squares are 
counted. The haemocytometer is designed so that the number of cells in one 
corner quadrant is equivalent to the number of cells x104ml, thusly, to 
calculate the number of cells from a harvest the following equation must be 
made: 
 
𝑆𝑢𝑚 𝑜𝑓 4 𝑄𝑢𝑎𝑑𝑟𝑎𝑛𝑡𝑠
4
∗ 2 ∗ 10000 
 
The sum of the four quadrants are divided by 4 to give an average, this figure 
is then multiplied by 2 to account for the 1:1 dilution of cells to trypan blue dye. 
Finally, the figure is multiplied by 104 to give the total amount of cells within the 
original 1ml cell suspension. In order to calculate total cell viability, the following 
calculation is made. 
 
𝐿𝑖𝑣𝑒 𝐶𝑒𝑙𝑙 𝐶𝑜𝑢𝑛𝑡
𝑇𝑜𝑡𝑎𝑙 𝐶𝑒𝑙𝑙 𝐶𝑜𝑢𝑛𝑡
= 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
 
 
2.2.4 Cryostorage and Recovery 
The cryogenic solution consisted of 900μl of foetal calf serum (Sigma, UK), 
100μl of DMSO (Sigma, UK) which was used as a cryoprotectant, and 950μl of 
the cell suspension. The solution was then mixed gently with a Pasteur pipette 
in a cryogenic capsule and then placed within a freezing container with propan-
2-ol and placed in the -80 freezer overnight to gradually step down the 
temperature of the constituents. After 24 hours the cryogenic tube was then 
placed within the cryogenic compartment containing liquid nitrogen with an 
appropriate entry filled within the laboratory catalogue. 
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In order to recover the cells from storage, they are first taken from the liquid 
nitrogen compartment and left to acclimatise for 1 minute in atmosphere 
(preferably in the Class II cabinet) and a further 5 minutes stood in a water bath 
at 37ºC before being transferred to 5ml of complete medium in a T25 (or T75, 
if the known cell number is over half a million cells) and left overnight to attach 
to the flask. After 24 hours, the flask should be washed with PBS and replaced 
with 5ml of new complete medium in order to eliminate toxic DMSO from the 
flask. 
 
2.2.5 Waste Disposal 
All biological waste is to be disposed of as mandated by the facility. Biological 
waste includes pipettes, Eppendorf tubes, tissue culture flasks, syringes and 
cell culture media and any other disposable equipment that interfaces with 
these instruments. All biological waste is treated with a Vircon solution before 
being deactivated by autoclaiving before disposal in marked receptacles for this 
class of refuse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
Cytotoxicity Assay 
 
2.2.6.1 MTT Cell Preparation 
For this assay, cultures of MCF-7, MCF-7 TAM and MDA-MB-231 are 
harvested from their respective cell culture flasks. For all colorimetric assays, 
cells were seeded into 96 well plates in complete medium. An optimal seeding 
density of 10,000 had been previously standardised by the cell culture 
laboratory for these cell lines. 
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2.2.6.2 MTT Assay Specific Reagents and Setup 
MTT Stock Solution 5mg/ml- Desiccated MTT powder is dissolved 5mg:ml in 
autoclaved dH2O. It may be stored at -20°C. 
MTT Assay Solution 1mg/ml- Complete medium is added to MTT stock 
solution. This assay solution must be used on the day. 
2.2.6.3 Preliminary Investigation 
As stated previously, each quantitative assay was to be performed in two 
parts; the preliminary assessment, in which the cell lines were given singular 
treatment in order to attain IC values necessary to calibrate functional 
combination therapy assays. As such, the methods detailed below will be 
discussed accordingly. 
For all the preliminary MTT assays each drug dose was recorded in duplicate, 
that is, two wells per concentration of drug per cell line. Additionally, all MTT 
assays were performed in duplicate, that is, each plate assaying concentrations 
in triplicate were run with an identical sister plate to allow for a fairer test and 
more reliable results. Typically, when plating out the cells into the microtitre 
plates, the outer ring of wells was filled with distilled water or basal medium in 
order to protect the central wells from desiccation during incubation periods. 
Figure 2.1 illustrates the basic template used for conducting the preliminary 
MTT assay. The blanks are left empty until reading. 
 
 
 
 
 
 
Figure 2.2: Preliminary MTT schematic 
for tamoxifen schematic. Blue line – 
dH20; C – control with complete medium 
blank, figures – drug concentration (µM), 
B- Empty blank 
Figure 2.3: Plate freshly set up for 
preliminary MTT testing. Peripheral wells 
filled with basal medium to protect the 
central wells from desiccation. 
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Early preliminary work served to establish the effective range for the 
drugs under investigation with reference to data collected from other 
laboratories (Fan et al., 2006; Zheng, Kallio and Härkönen, 2007) to cast that 
‘net’. Through the course of this early investigation and in the tests that follow, 
the incremental difference of drug concentrations was narrowed (i.e. from every 
10µM to every 5µM and so on) to increase the resolution of results and highlight 
critical junctures. The MTT procedure will be discussed in the plural with the 
assumption of two plates being used for reasons discussed above. 
 
2.2.6.4 MTT Procedure 
After a 24-hour incubation period (@37°C, 5%CO2) in which the cells 
become adhered and acclimatise to the 96 well plates reaching near confluency 
of about 90%, the plates are checked under inverted light microscope to ensure 
uniformity between the wells. They are subsequently aspirated, save from the 
peripheral ‘guard’ wells and filled with drugged medium at increments 
discussed in the previous section before being returned to incubation (@37°C, 
5%CO2). Although no drug is added to the control wells, their complete medium 
is still refreshed. During the earliest preliminary work for this assay, the post-
inoculation incubation times for each drug and cell line was assessed with both 
24, 48 and 72 hours being considered. It was determined that a 48-hour 
incubation period was ideal for comparative studies between the two drugs. The 
remainder of this assay is to be performed in a darkened environment as the 
formazan product is light sensitive. Following this 48-hour incubation period, all 
wells, again save for the barrier wells were gently aspirated of drugged medium 
and replaced with 50µl of 1µg/ml of MTT in complete medium. 100µl of DMSO 
was used for each of the blank wells. The plates are then incubated for 3.5 
hours, a time previously standardised by the laboratory for MTT assays. Foil 
paper is used to cover the plates at this juncture to further protect the process 
from any discrepancies from reacting with light in a shared laboratory. Following 
incubation, the wells are then aspirated with great care as to not disturb any 
living cells which remain adherent to the microtiter plate and 150µl of DMSO is 
added to each well including the blanks. The plates, still covered in foil are then 
placed on a rocker at moderate speed for 10-20 minutes to ensure the complete 
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dissolution of the formazan product. Once the formazan-DMSO solution is 
adequately homogenised, the plates are then read at 540nm in a colorimetric 
plate reader. From the data attained from the assay, dose-response curves may 
be then drawn out using a spreadsheet application (In this case, Microsoft 
Excel). Using the information gathered from latter preliminary tests, it should 
then be possible to extrapolate the ED50 of the drugs which may then be used 
for determining the values to be used in drug combination assays. 
 
2.2.6.5 MTT Combination Assay 
Once the ED50 values of tamoxifen and chloroquine were determined for 
all three cell lines, investigation in to combination treatment could then be 
performed. The initial stage of this assay began with high resolution (increments 
of 2µM) tamoxifen MTT assays similar to previous tests however with 
chloroquine being used as a constant variable. This has been illustrated by 
Figure 2.3 where the concentration of tamoxifen (black) increases as 
chloroquine (red) remains constant. Initially tests were performed to 
standardise the concentration to be used for the chloroquine constant and to 
that extent, a plate assembled (in duplicate) which kept the typical ascending 
order of tamoxifen while in addition using the ED50 of chloroquine (40µM), 
employing the hypothesis that without either pharmacodynamics inhibition or 
potentiation between the two drugs, one can assume that the combined ED50 
of one metabolically separate drug and another would lead to IC100; complete 
cell death. 
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Once it became apparent through a massive discrepancy in the sum of 
ED50 between tamoxifen and chloroquine that there was some form of drug 
interaction taking place, MTT assays utilising smaller titres (10µM, 20µM 
&30µM) of chloroquine were used to further investigate this relationship. The 
information gathered from this detailed MTT analysis paved the way for a 
streamlined approach to the remainder of the investigation.  Table 2.1 highlights 
the nine individual experiments completed as well as minimum work required; 
each experiment was performed in duplicate with additional efforts to ensure a 
high sample number and repeatability of results. 
Modality 
Cell Line Tamoxifen Chloroquine TAM+CQ 
MCF-7 WT 2n 2n 2n 
MCF-7 TMX 2n 2n 2n 
MDA-MB-
231 2n 2n 2n 
 
 
 
 
 
2.2.7 Neutral Red Assay 
Second to the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) and MTT protocols, the Neutral Red assay is one 
Figure 2.4: Typical 
template for drug 
combination assay. 
Blue = dH2O, Black 
Figures = tamoxifen 
(µM) Red Figures = 
chloroquine (µM). 
Note all doses are 
done in triplicate. 
Table 2.1: Illustrating the 
minimum work required for both 
MTT and Neutral Red evaluation 
of the breast cancer cell lines. 
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of the main cytotoxicity tests used in environmental and biomedical sciences 
(Repetto, del Peso and Zurita, 2008). This technique is able to provide both a 
quantitative and qualitative estimation of cell viability through both absorbance 
spectrometry and light microscopy respectively. The assay depends on the 
ability of viable cells to integrate and bind this weakly cationic exogenous stain 
within acidic compartments such as lysosomes where they become positively 
charged, preventing egression. As perished cells may not take up the stain, 
overall cell viability may be assessed through the extraction of the dye from the 
population. 
 
Because cell viability and proliferation (and thus cytotoxicity) may be 
demonstrated through pathways very dissimilar to that of the MTT, the Neutral 
Red assay allows us to support any developments on the relationship between 
chloroquine and tamoxifen with the aforesaid breast cancer cell lines. 
 
2.2.7.1 NR Specific Reagent Setup 
Neutral Red Stock Solution 4mgml-1 - Neutral Red dye (Sigma Aldrich 
N4638) is dissolved in PBS 4mg: 1ml. This solution may be stored for up to 2 
months at room temperature (20-30°C) protected by light with foil paper. 
Neutral Red medium 40µg ml-1 – The stock solution is diluted 1:100 with 
complete culture medium, for example, 12 ml of complete medium with 0.12 ml 
of stock solution (An ideal volume for one microtitre plate worth of work). This 
must be incubated at the culture temperature of the cells to be assayed to be 
used strictly the day before use. 
Neutral Red Destain Solution- for extraction of dye from viable cells consisting 
of 50% 96%-ABV ethanol (Fisher Scientific), 49% deionized water and 1% 
glacial acetic acid (Fisher Scientific). 
 
 
 
2.2.7.2 NR Cell Preparation 
The MCF-7 WT, MCF-7 TMX and MDA-MB-231 cell lines were cultured and 
prepared in 96 well plates for fluorescence colourimetry as described in the 
previous chapter for MTT. 
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2.2.7.3 NR Preliminary Investigation 
Due to the Neutral Red staining technique being similar in the fashion to the 
MTT assay as a measure of cell viability, much of the initial groundwork such 
as to narrow down effective dosage and attain the IC/ED values has already 
been done. However, it is still necessary to standardise this test to attain the 
varaibles for which to attain quantitative results supportive of the initial MTT. 
Two major variables were seeding density and incubation time 
 
Figure 2.4 highlights visually the colorimetric difference in seeding density 
when MCF-7 cells were exposed steady to increments of chloroquine. This 
equivocal test, was performed by setting up a 96 well plate into two halves and 
seeding each half in duplicate to the dosing scheme used in the preliminary 
chloroquine MTT tests (0-140µM) with one half at a seeding density of 10,000 
cells and the other at 15,000 cells after which they were subject to the Neutral 
Red assay (described below). This particular plate was intentionally incubated 
longer than recommended (Repetto, del Peso and Zurita, 2008) with the neutral 
red dye to visualise if and when either of the two sample sets reach saturation. 
As the sample set on the left had statistically significant gaps between each 
drug dose and the right sample set less so, it was decided that 10,000 cells per 
well was to be used as standard. Additionally, having many more than 10,000 
of these cells per well may be damaging to the test as confluency is reached at 
a much faster rate leading to cell stress which may impact results accordingly. 
 
2.2.7.4 NR Procedure 
Figure 2.5:  Visual 
colorimetric difference 
between seeding 
densities for 
chloroquine with MCF-
7 WT after 4 hours 
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Once the preliminary assessment of the Neutral Red stain for compatibility with 
the cells at hand and the determination of necessary variables such as 
incubation time and seeding densities (with the help of the IC and ED figures 
attained from the previous MTTs) are complete, it is then possible to move on 
to the primary Neutral Red procedure.  
Note: As with the MTT protocol, the following method is described with the 
assumption of working with a pair of sister plates. 
Following the cell culture and seeding (see Figure 2.3 for typical plate layout) 
procedures laid out in the previous sections, the plates were then left to set and 
incubate for 24 hours (@37°C, 5%CO2). The following day, the culturing 
medium is extracted from the wells by gentle aspiration and replaced by 150μl 
of medium drugged according to the template laid out in fashion identical to that 
in 2.2.6. Going ahead 48 hours, the previously made Neutral Red/Complete 
Medium was centrifuged for ten minutes at 600g to eliminate any precipitated 
dye crystals. The centrifugate is then decanted into a reservoir ready for use. 
All wells are drained of the drugged medium through gentle aspiration, after 
which 100μl of the 40μg/ml-1 Neutral Red staining solution was added and left 
to incubate at 37*C for 2.5 hours after which point, the staining solution was 
then removed and 150μl of PBS (1x) was added to each well. At this juncture, 
each microtitre well may then be examined microscopically and images could 
be captured for qualitative assay of cellular morphology. All wells were 
photographed from each plate for each of the nine drug/cell modalities. Shortly 
after microscopic investigation, the PBS is then decanted from each of the 
treated wells including the blank and controls and 150μl of acidified ethanol 
destaining solution was then added to the wells to liberate the dye from the 
cells. After this stage, the plates would then be placed on a plate shaker at 
moderate speed for 10-20 minutes wrapped in foil as to avoid direct contact 
with light whilst separating the dye into the wells. After this point, the plate may 
then be inspected in a spectrophotometer at 540nm, the data from which can 
then be stored for subsequent quantitative analyses. 
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2.2.8 Caspase 3 Colorimetry Assay 
The quantitative colorimetric analysis of the apoptosis biomarker caspase 3 is 
achievable in this assay through the observation of the hydrolysis of the peptide 
substrate acetyle-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) by caspase 
3 and the subsequent release of p-nitroaniline (pNA) functional group as shown 
in this equation. 
 
As pNA has a high absorbance (405nm), it may be easily assayed through the 
use of a spectrophotometer, thus caspase 3 activity may be easily observed 
through the cleavage of pNA from Ac-DEVD-pNA.  
Caspase 3 belongs to a family of proteases important for the mediation of 
programmed cell death (apoptosis) for which it is a critical member. Caspase 3 
is classed as an effector caspase and is one of the most widely investigated of 
the caspase family with is mechanism of action firmly characterised thus 
making it a key metabolite in the investigation of cell death. 
 
2.2.8.1 Caspase 3 Assay Kit Components 
5x Lysis Buffer 
10x Assay Buffer 
Caspase 3 powder 
Ac-DEVD-pNA substrate 
Ac-DEVD-CHO Inhibitor 
p-Nitroaniline Standard 
Water (17 megohm) 
 
 
 
2.2.8.2 Caspase 3 Assay Cell Preparation 
The kit insert for this procedure suggested using a volume of cells equal to 107 
Jurkat cells thus, for this assay, a population of around 5 million MCF-7 WT, 
MCF-7 TMX and MDA-MB-231 cells were needed for each drug modality used 
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thus a total of four 6 well microplate wells are necessary per cell line as 
illustrated in Figure 2.8. Due to the sheer number of cells required, plates are 
seeded with around 2 million cells per well and incubated at 5% CO2 at 37°C 
After seeding to the 6 well plates, cells are incubated until 90+ confluency is 
reached in each of the plates, generally between 24 to 48 hours. 
 
2.2.8.3 Caspase 3 Assay Procedure 
Once the cells have reached 90+% confluency, the complete media in all the 
wells is discarded and replaced with drugged media respective to the ED50 
values of each drug for the cell line to be assayed and left to incubate at 5% 
CO2 at 37°C for 48 hours. After this incubation period, all the cells are pelleted 
by centrifugation at 600 x g for 5 minutes at 4°C. With the supernatant gently 
removed by aspiration, the cell pellets are then washed with 1ml of PBS by 
centrifugation. With the supernatant removed once more, the cells are then re-
suspended in 100µl lysis buffer and incubated on ice for 20 minutes before 
centrifuging the lysed cells once more at 20,000 x g for 15 at 4°C. The 
supernatants (containing the now exposed intracellular components of cells) is 
then transferred to new Eppendorf tubes. These samples may then either be 
frozen at -80°C or used immediately for analysis. A 96 well plate is prepared as 
described in Table 2.2 which is adapted from the kit insert illustrates the 
reaction scheme for the assay. As illustrated in Figure 2.9, the plate should 
consist of 4 wells per cell line, in duplicate, as to include the sample lysates 
from the control and three drug modalities. Wells should also be prepared for 
the positive and negative controls, also in duplicate. 5µl of cell lysate or 
Figure 2.6: General 
seeding layout for 
cells in 6 well plate 
for c3pNA 
colorimetry assay 
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Caspase 3 Positive Control are added to their respective wells as indicated in 
Table 2.2 and Figure 2.9 and Caspase 3 Inhibitor to the negative control wells. 
The reaction is started by adding 10µl of caspase 3 substrate to each well and 
mixed by gentle shaking whilst avoiding foaming of the reagents. The plate was 
then covered and incubated at 37°C for 90 minutes to allow for cleavage and 
liberation pNA from its parent molecule. Incubation may be left overnight if 
signal is too low. The plate was then read at 405nm absorbance. 
 
 
 
 
 
 
 
 
2.2.9 Annexin V ELISA 
Enzyme Linked 
Immunosorbent Assays 
(ELISA) were 
conducted with the 
three cell lines MCF-7 WT, MCF-7 TMX and MDA-MB-231 to quantify the 
presence of concentrations of Annexin V. Annexin V belongs to the Annexins; 
Table 2.2: 96 well plate microarray reaction scheme. 
Figure 2.7: Showing 
the plate scheme for 
the 96 well plate 
Caspase 3 analysis.  
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a family of calcium dependent phospholipid binding proteins. Although the 
Annexins as a whole have been well investigated in structure, their exact nature 
as a whole has yet to be determined however, Annexin V specifically has been 
found to play a major role in matrix vesicle-initiated cartilage calcification as a 
collage-regulated calcium channel (Abcam). It has been determined that 
Annexin V has a high affinity to procoagulant phospholipids, specifically 
phosphotidylserine. It is the nature of phosphotidylserine (PS) and its 
relationship with Annexin V which makes Annexin V a metabolite of interest in 
this investigation. PS is housed intracellularly and is exposed during apoptotic 
events where it binds to Annexin V thus endogenous levels of Annexin V may 
be used as a market for the initiation of apoptotic events. 
 
2.2.9.1 Annexin V ELISA Assay Kit Components 
20X Assay Buffer Concentrate 
20X Wash Buffer Concentrate 
Adhesive Films 
Biotin-Conjugate anti-human Annexin V monoclonal antibody 
Human Annexin V Standard 
Microplate coated with monoclonal antibody to Human Annexin V (12x8) 
Sample Diluent 
Stop Solution (1M Phosphoric Acid) 
Streptavidin-HRP 
TMB Substrate Solution 
 
 
 
 
 
 
 
2.2.9.2 Annexin V ELISA Cell Preparation 
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For this procedure, only the culture medium from MCF-7 
WT, MCF-7 TMX and MDA-MB-231 cells was needed in 
order to investigate extracellular Annexin V expression as 
the usage of cell lysate would be unspecific to apoptotic 
role of PS/Annexin V. To this extent, the cell lines were 
cultured in a 12 well microplate as illustrated in Figure 2.6 
a seeding density of 250,000 cells per well. These wells are then incubated for 
24 hours in 5% CO2 at 37°C (or until around 95% confluency is attained. 
 
2.2.9.3 Annexin V ELISA Procedure 
24 hours after the initial incubation period, the cell culture medium of all the 
cells is discarded and refreshed. Wells in row B and C were then treated with 
their ED50 concentration values for each cell line respectively attained from the 
prior 48 hour MTT assays (Row A was the control row and thus cells in this well 
were not treated). After administration of treated medium to the wells, the plate 
was then returned to the incubator for a further 48 hours. 
On the day of assay all materials and reagents were equilibrated to room 
temperature before being prepared and diluted to their appropriate 1x 
concentrations. In total, 6 microplate strips were to be used; four for the sample 
assay and two for the standard, both in duplicate. Figure 2.7 overleaf illustrates 
the general layout of the assay. The necessary micro well strips for all the 
samples, standards and controls were twice washed by thorough pipette 
aspiration with 400µl of 1X Wash Buffer for 10-15 seconds each per wash 
taking care not to scratch the surface of the microplate. After washing, the wash 
Figure 2.8: The 12 well 
microplate cell culture 
template used in cell 
culture for the Annexin V 
ELISA assay. 
Figure 2.9: The 
ELISA strip layout 
for Annexin V assay. 
This is repeated in 
duplicate.  
WT    = MCF-7 WT  
TMX = MCF-7 TMX 
MDA = MDA MB 231  
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buffer was removed by gentle percussion onto an absorbent paper towel and 
left facing face down. 100µl of prepared standards and negative control were 
applied to the microplate strip marked for it. 50µl of cell culture medium taken 
from the cultured cells in the 12 well plate was added to the appropriately 
marked wells with 50µl of sample diluent. 50µl of 1X Biotin Conjugated Antibody 
was applied to all wells. The assay strips (on the ELISA plate provided) were 
then allowed to incubate in room temperature (18°C to 25°C) for 2 hours on a 
plate shaker set to 100rpm. After this incubation period, the adhesive film was 
removed and the wells carefully emptied and washed four times with 1X Wash 
Buffer solution before 100µl of 1X Streptavidin-HRP was added to the wells, 
including the blanks. The wells were then further covered with adhesive film 
and left to incubate again at room temperature for 1 hour on a shaker set to 
400rpm. After incubation, the strip was removed and the plates washed a 
further four times before they are refilled with 100µl of Tetramethylbenzidine 
(TMB) Substrate Solution for ten minutes in the dark. To monitor the colour 
progression of the TMB Substrate Solution, the plate was left to incubate within 
the plate reader until the primary standard reaches an optical density (OD) of 
0.9-0.95 (which should be around the region of 10 minutes after the addition of 
TMB). Once this critical point is reached, 100µl of stop solution is added to each 
well in a quick, uniform manner through the use of a multi-channel pipette 
(Gilson) and read at 450nm with a spectrophotometer. 
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2.2.10 Acridine Orange Assay 
Acridine Orange (AO) is a nucleic acid binding dye permeable in both living and 
dead cells and stains nucleated cells to create a green fluorescence. It may be 
used in the qualitative assessment of cell viability where nuclear fragmentation 
and lysosomotrophy may be visualised thus making it a valuable adjuvant to 
the continuing investigation. Like Neutral Red, AO is slightly cationic allowing it 
to exploit the pH gradients of cells however once protonated causes the dye to 
become trapped within the acidic compartments of cells such as the lysosomes 
and nucleoli. Through proton pump driven lysosomal acidity in living cells, AO 
becomes efficiently concentrated within these organelles; this aggregation may 
result in the precipitation of AO within the lysosomes into aggregated oligomeric 
granules which exhibit a red shift (640nm) compared to the monomeric AO 
which emits elsewhere at 525nm allowing for effective differentiation of the 
lysosomotrophy from the surrounding cellular structures (Immunochemistry, 
2013). Through fluorescence microscopy it is possible to create composite 
images from both 640 and 525nm wavelengths to differentiate acidic 
compartments (orange) from the rest of the cellular bodies (green) such as in 
Figure 2.5. 
 
2.2.10.1 AO Specific Reagent Setup 
Acridine Orange Stock Solution 1mM (266 μgml-1)-  Acridine Orange (Sigma 
Aldrich) stain dissolved in filtered PBS to make 1mM AO stock solution 
Acridine Orange Staining Solution 2.7uM (1 ugml-1)- The AO Staining 
solution is diluted with complete medium to a final concentration of 1ug/ml 
 
2.2.10.2 AO Cell Preparation 
The MCF-7 WT, MCF-7 TMX and MDA-MB-231 cells are harvested from their 
respective cell culture flasks. Prior to subculture, Circular 13mm diameter 
coverslips (Fisher Scientific) are sterilised in absolute ethanol for ten minutes 
in a petri dish and then washed twice with autoclaved PBS. The discs are then 
placed individually in a 24 well plate as shown in the template of Figure 2.6. It 
may be advisable to coat the coverslips in poly-l-lysine (Sigma Aldrich) for 
several minutes and rinse with PBS to ensure cellular attachment to the 
coverslip. Each well is then seeded with 100,000 cells to ensure an even +-80% 
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confluency in 1ml of complete medium and left to incubate overnight (@37°C, 
5%CO2).  
 
2.2.10.3 AO Procedure 
The following day after seeding, the 24 well plate is inspected by light 
microscopy to assess and record cell adhesion and overall morphological state. 
Depending on confluency and how well the cells take to the coverslip, it is 
permissible to allow the cells one more day. On the day of testing, the wells are 
drained of culture medium and 500ul of medicated media is added to the wells 
as illuminated by Figure 2.6 and left to incubate for 48 hours (@37°C, 5%CO2). 
The drug concentrations chosen for this assay include the IC/ED 50 values 
ascertained from the prior MTT assay. 
The wells were treated with 1ml of drugged medium (as detailed in Figure) and 
left to incubate for 48 hours at 37*C. 
Following incubation with drugs, wells may be decanted of medium and 
coverslips removed (in succession) and transplanted on to a microscopy slide. 
The slide is then carefully bathed in 1μg/ml Acridine Orange/complete medium 
solution for 15 minutes before being gently aspirated off again. The coverslip is 
then washed very gently twice with distilled water being viewing under a 
fluorescent microscope. 
 
 
 
2.2.11 Statistical Analysis 
 
Two-way ANOVA followed by Tukey’s multiple comparisons test was performed 
using GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com”. The data was presented as mean 
standard error (±SE) with values of P<0.05 being considered to be statistically 
significant and p<0.01 as highly significance. 
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Chapter Three 
 
3.0 Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0 Results 
3.0.1 Subculture & Counting 
Subculture of the three breast cancer cell lines; ER+ MCF-7 wildtype, 
MCF-7 TMX (tamoxifen resistant analogue) and ER- MDA-MB-231 (oestrogen 
resistant line) was carried out as previously mentioned in chapter 2.2.3 b. The 
cell confluency was observed throughout culture period in order to both 
document and monitor the proliferation of the cells prior to subculture (Figures 
3.1-3.3). MCF-7 WT and TMX cells would reach a confluence of around 80% in 
about 3 days of culture (@37ºC,5% CO2) seeded at 2.5x105 while MDA-MD-
231 cells took about 5-6 days to reach optimal subculture confluence. A typical 
low passage of either MCF-7 or MDA-MD-231 cells are strongly adherent and 
thus scraping may be necessitated in order to achieve maximum harvest during 
subculture.  
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Figure 3.1: MCF-7 WT with grape-cluster morphology typical of luminal 
breast cancer cells after four days of culture. Magnification x10 
Figure 3.3: MDA-MB-231 cell line with characteristic invasive processes, four 
days after culture. Magnification x10 
Figure 3.2: MCF-7 TMX cell line with four days after culture.  Magnification 
x10 
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3.0.2 Doubling time assay 
This basic proliferation assay is crucial when investigating any cell line in a 
laboratory; the understanding of doubling times for the cells permits a 
researcher more intimate knowledge of the cell lines and gives one the ability 
to estimate the time it will take to achieve a certain number of cells in 
preparation and execution of an assay. Independently, the number cell lines for 
each cell line was recorded over each day from an initial seeding density of 
2x104 over the course of a week in 24 well plates. The results revealed MCF-7 
TMX as the fastest rate of proliferation and MDA-MB-231 to be the slowest as 
evidenced from the images in section 3.1.1. 
3.1 Quantitative Assay 
3.1.1 MTT 
Overleaf are the results achieved from the MTT assay (Figures 3.1.1.1- 
3.1.1.1.9) used to determine the cell viability and proliferation of the three breast 
cancer cell lines (MCF-7 WT. MCF-7 TMX and MDA-MB-231). Three drug 
modalities were investigated per cell line (with tamoxifen alone, with 
chloroquine alone and with a combination of chloroquine and tamoxifen) a total 
of three times per cell line (n=3). The data has been normalised to be 
represented in terms of cell survival as a percentage rather than absorbance in 
order to present the data in a way which all data sets may then be comparable 
with each other.
Cell type MCF-7 WT MCF-7 TMX MDA-MB-231 
Doubling Time (hours) 37 25 40 
Table 3.1: Doubling times of the three cell lines MCF-7 WT, MCF-7 TMX and MDA-MB-
231 as extrapolated from proliferation assay (±SE,n=3) 
Table 3.2: ED50 values for MTT assay of each cell line with drug modalities TAM, CQ & 
TCQ 
TAM (μl) CQ (μl) TCQ (μl of TAM + 10 μl CQ)
MCF-7 WT 15.4 54 12
MCF-7 TMX 18 72 12
MDA-MB-231 18.5 44 12
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3.1.1.1 MTT MCF-7 WT with Tamoxifen 
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Figure 3.4: MTT cytotoxicity assay showing the effect of tamoxifen on MCF-7 WT (±SE, n=3). ED50 concentration reads at 15.4µM of tamoxifen. 
Signal fall significantly from 14µM onwards. There is near 100% cell death by 22µM 
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3.1.1.2 MTT MCF-7 WT with Chloroquine 
Figure 3.5: MTT cytotoxicity assay showing the independent effect of chloroquine on MCF-7 WT (±SE, n=3). The ED50 concentration reads at 52µM 
of chloroquine. 
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3.1.1.3 MTT MCF-7 WT with Tamoxifen and Chloroquine combined  
Figure 3.6: MTT cytotoxicity assay showing the combined effect of tamoxifen and chloroquine on MCF-7 WT (±SE, n=3 For this assay, the 
concentration of chloroquine is a static 10µM. The ED50 concentration reads at 12µM of tamoxifen. 
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3.1.1.4 MTT MCF-7 TMX with Tamoxifen 
Figure 3.7: MTT cytotoxicity assay showing the independent effect of tamoxifen on MCF-7 TMX (±SE, n=3). ED50 concentration reads at 18µM of 
tamoxifen. 
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3.1.1.5 MTT MCF-7 TMX with Chloroquine 
Figure 3.8: MTT cytotoxicity assay showing the effect of chloroquine on MCF-7 TMX (±SE, n=3). ED50 concentration reads at 72µM of chloroquine. 
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3.1.1.6 MTT MCF-7 TMX with Tamoxifen and Chloroquine combined 
Figure 3.9: MTT cytotoxicity assay showing the combined effect of tamoxifen and chloroquine on MCF-7 TMX (±SE, n=3). ED50 concentration 
reads at 11.8 µM of tamoxifen. 
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3.1.1.7 MTT MDA-MB-231 with Tamoxifen 
Figure 3.10: MTT cytotoxicity assay showing the independent effect of tamoxifen on MDA-MB-231 (±SE, n=3). ED50 concentration reads at 18.5.µM 
of chloroquine. 
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3.1.1.8 MTT MDA-MB-231with Chloroquine 
 
 
 
 
 
 
 
 
Figure 3.11: MTT cytotoxicity assay showing the independent effect chloroquine on MDA-MB-231 (±SE, n=3). ED50 concentration reads at 44µM 
of chloroquine. 
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3.1.1.9 MTT MDA-MB-231 with Tamoxifen and Chloroquine combined 
Figure 3.12: MTT cytotoxicity assay showing the combined effect of tamoxifen and chloroquine on MDA-MB-231 (±SE, n=3). Chloroquine kept as 
a static dose of 10µM. The ED50 concentration reads at 12µM of tamoxifen. 
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3.1.2 Neutral Red 
 
The Neutral Red viability assay was performed on the three cell lines (MCF-7 WT, MCF-7 TMX and MDA-MB-231) as described 
in the Methods section. The data has been normalised to present the results as a percentage of total lysosomal/acidic compartment 
volume relative to that of the initial control values. 
 By serving as an alternative viability assay, NR staining was chosen as a means to verify the findings from the MTT assay. As 
seen in Figures 3.1.2.1 to 3.1.2.9, Neutral Red staining tends to exhibit initial absorbance peaks above that of the control when 
treated with the three drug modalities. In the MTT assay, the doses which present these NR peaks do not change significantly, 
implying a cytostatic drug effect; the NR assay allows one to witness the autophagic events that occur during this period which would 
have otherwise been mistaken as senescence. The exception, however is seen in MDA-MB-231 which presents more classical kill-
curve when treated singularly with tamoxifen. All cell lines present the highest initial rise in signal when exposed to the tamoxifen-
chloroquine drug combination with MCF-7 WT, MCF-7 TMX and MDA-MB-231 respectively reaching lysosomal volume levels of 170, 
240 and 175% greater than that of their initial controls. These results suggest that all three drug modalities elicit autophagic events 
and that the combined effect of the two drugs is potentiative. 
 In a similar fashion to that of the MTT assay, each drug modality conducted to at least 3 individual times (n=3), doses within 
each individual plate were also applied in triplicate and the mean value attained. 
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3.1.2.1 Neutral Red MCF-7 WT with Tamoxifen  
 Figure 3.13: NR viability assay showing the effect of tamoxifen on MCF-7 WT (±SE, n=3). Peaking becomes evident at 12µM tamoxifen 
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3.1.2.2 Neutral Red MCF-7 WT with Chloroquine 
Figure 3.14: NR viability assay showing the effect of Chloroquine on MCF-7 WT (±SE, n=3). Peaking becomes evident after the first dose at 10µM 
of Chloroquine. 
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3.1.2.3 Neutral Red MCF-7 WT with Tamoxifen and Chloroquine Combined 
Figure 3.15: NR viability assay showing the effect of variable doses of tamoxifen (µM) with a static concentration (10µM) of chloroquine on MCF-
7 WT (±SE, n=3). Peaking becomes evident after the first dose at 10µM of Chloroquine. 
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3.1.2.4 Neutral Red MCF-7 TMX with Tamoxifen 
Figure 3.16: NR viability assay showing the effect of tamoxifen on MCF-7 TMX (±SE, n=3). Signal increases immediately after the first dose at 2µM 
of TAM and peaks at 8µM of TAM 
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3.1.2.5 Neutral Red MCF-7 TMX with Chloroquine 
Figure 3.17: NR viability assay showing the effect of chloroquine on MCF-7 TMX (±SE, n=3). Signal increases immediately after the first dose at 
10µM of TAM and peaks at 40µM of TAM 
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3.1.2.6 Neutral Red MCF-7 TMX with Tamoxifen and Chloroquine combined 
Figure 3.18: NR viability assay showing the effect of chloroquine on MCF-7 TMX (±SE, n=3). Signal increases immediately after the first dose at 
10µM of TAM and peaks at 40µM of TAM 
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3.1.2.7 Neutral Red MDA-MB-231 with Tamoxifen 
 Figure 3.19: NR viability assay showing the effect of tamoxifen on MDA-MB-231 (±SE, n=3). Signal increases immediately after the first dose at 
10µM of TAM and peaks at 40µM of TAM 
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3.1.2.8 Neutral Red MDA-MB-231with Chloroquine 
Figure 3.20: NR viability assay showing the effect of chloroquine on MDA-MB-231 (±SE, n=3). Signal increases immediately after the first dose at 
10µM o TAM and peaks at 40µM of TAM 
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3.1.2.9 Neutral Red MDA-MB-231 with Tamoxifen and Chloroquine Combined 
Figure 3.21: NR viability assay showing the effect of chloroquine (10µM) with a variable dosage of tamoxifen on MDA-MB-231 (±SE, n=3). Signal 
increases immediately to peak after the first dose at 2µM of TAM 
 
 
0 2 4 6 8
1
0
1
2
1
4
1
6
1
8
2
0
2
2
2
4
2
6
2
8
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
N R  A s s a y  o f M D A -M B -2 3 1  w ith  T a m o x ife n  a n d  C h lo ro q u in e  (1 0 µ M ) C o m b in e d
C o n c e n tra tio n  o f T a m o x ife n  (µ M )
L
y
s
o
s
o
m
a
l 
V
o
lu
m
e
 (
%
 o
f 
c
o
n
tr
o
l)
M D A  x  T C Q
98 
 
3.1.3 Caspase 3 Colorimetry Assay 
 
 
 
 
 
 
 
 
Caspase-3 colorimetry was employed in order to envisage the presence of caspase-dependent phenomena.The results from the 
colorimetric assay pictured below in figure 3.22 captures the findings from this assay. Caspase-like activity is detected in low levels 
throughout with the greatest expression being seen in cells treated with the combination (TCQ) modality. The most apparent 
caspase activity is visible from the MCF-7 WT cell line in response to combination treatment (P≤0.001). There is no real significant 
difference between the two controls and the treatment with tamoxifen yet chloroquine is seen to elicit a significant increase in 
caspase-like activity in both MCF-7 WT (P≤0.001) and MCF-7 TMX (P≤0.05) compared to untreated control. These results suggest 
that combined treatment has a high affinity for Caspase-3 activity relative to singular treatment. 
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Figure 3.22: Relative caspase 3 activity after 48 hours’ treatment with the 3 
drug modalities on breast cancer cell lines MFC-7 WT, MCF-7 TMX and MDA-
MB-231 with their respective ED50 dosage values. (C: control; T: tamoxifen; 
CQ: chloroquine; TCQ: tamoxifen/chloroquine combination) 
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3.1.4 Annexin V ELISA 
 
The presence of Annexin V expression is thought to be associated with apoptosis, thus Annexin V ELISA (Figure 3.23) was 
performed 48 hours after treatment to give a snapshot of its activity at this time. The most significant Annexin V expression 
compared to its control sample is P≤0.001 was MCF-7 TMX’s response to chloroquine. Conversely, there are visibly significant 
drops in Annexin V expression for the cell lines MCF-7 WT and MCF-7 TMX in response to tamoxifen (P≤0.01) and MDA-MB-
231 in response to chloroquine (P≤0.05) compared to the readings of the untreated controls. These results are inconsistent with 
the high caspase-3 activity detected in combination treatment at this time and suggest low apoptotic activity present at this time 
point. 
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Figure 3.23: Relative Annexin V activity after 48 hours’ treatment with the 3 drug modalities on breast cancer cell lines MFC-7 WT, MCF-7 TMX 
and MDA-MB-231 with their respective ED50 dosage values. (C: control; tamoxifen; CQ; chloroquine; TCQ: tamoxifen/chloroquine combination) 
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3.2 Qualitative Assay 
The quantitative assays presented in the previous chapter were 
supplemented by a series of qualitative assays using light microscopy and 
fluorescence microscopy which would serve to better visualise the drug 
interaction with the three cell lines  
  3.2.1 Neutral Red Microscopy 
Neutral red images (Figures 3.2.2.1 - 3.2.2.4) were attained 
simultaneously during the NR proliferation assay after the first wash step with 
PBS following incubation with the NR dye as stated in the chapter in the 
methods and materials (2.2.7), the wells were read under inverted microscope 
(Nikon) with phase contrast. Images were taken within ten minutes of 
immersion with PBS before the wells were subsequently aspirated and refilled 
with the NR destaining solution to continue the quantitative portion of the assay. 
 
Qualitative analysis of Neutral Red serves to help visualise the uptake of 
the stain prior to spectroanalysis. For all cell lines, it was observed that of all 
the drug modalities, TAM conferred the least NR uptake, with CQ and TCQ both 
exhibiting a much greater uptake at comparable levels. The findings show that 
the treated cell lines convey a dose dependent response to the drugs, which 
peak in NR absorption at around their respective ED50 values and to almost 
negligible levels at higher doses. This implies that autophagic events (And thus 
Type II Apoptosis) only occur up to a critical value before cells begin to take die 
through primarily caspase dependent or necrotic pathways. 
 
 
 
 
 
 
 
 
3.2.2.1 Neutral Red Controls (All Cell Lines) 
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Control images were taken with an inverted light microscope from the 
sample plates on the same day which the Neutral Red assay was to be 
performed and thus were also subject to the NR Staining process. The red rods 
visible these images are neutral red crystals which get cleared after the second 
wash of PBS before detaining occurs. Faint neutral red uptake seen in all 
controls indicates the presence of lysosomes at rest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2.2 Neutral Red MCF-7 WT 
Figure 3.24: Neutral Red panel of control samples for MCF-7 WT, TMX and MDA, very low yet 
present neutral red uptake visible within cells indicating low lysosomal activity. Magnification x10  
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Figure 3.25: Panel illustrating the effect of TAM (A,B,C) CQ (D,E,F) and TCQ (G,H,I) on 
lysosomal profile of MCF-7 WT cells with Neutral Red. The cells were treated with TAM, 8, 
16 and 24 µM; 10, 40, 80 µM; and TCQ 8, 16 and 24 µM TAM with a static dose of 10 µM 
Chloroquine. Cell death was most apparent in all rightmost slides with minimal NR 
retention. The richest lysosomal signal per-cell is visible in the ED50 (centremost slides) in 
dead cells are also present. (x10) 
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3.2.2.3 Neutral Red MCF-7 TMX 
 
 
Figure 3.26: Panel illustrating the effect of TAM (A,B,C) CQ (D,E,F) and TCQ (G,H,I) on 
lysosomal profile of MCF-7 TMX cells with Neutral Red. The cells were treated with TAM, 8, 
16 and 24 µM; 10, 40, 80 µM; and TCQ 8, 16 and 24 µM TAM with a static dose of 10 including 
controls (not pictured). Cell death and was most apparent in all rightmost slides with 
minimal NR retention. The richest lysosomal signal per-cell is visible in the ED50 
(centremost slides) in dead cells are also present. (x10) 
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3.2.2.4 Neutral Red MDA-MD-231 
Figure 3.27: Panel illustrating the effect of TAM (A,B,C) CQ (D,E,F) and TCQ (G,H,I) on 
lysosomal profile of MDA-MB-231 cells with Neutral Red. The cells were treated with TAM, 
8, 16 and 24 µM; 10, 40, 80 µM; and TCQ 8, 16 and 24 µM TAM with a static dose of 10 
including controls (not pictured). Cell death and was most apparent in all rightmost slides 
with minimal NR retention. The richest lysosomal signal per-cell is visible in the ED50 
(centremost slides) in dead cells are also present. (x10) 
 
 
 
107 
 
3.2.2 Acridine Orange Assay 
 The AO stain as described in Chapter 2 was the second qualitative 
assessment tool used in this investigation to visualise lysosomotropy; one of 
the primary mechanisms believed to facilitate cell death after exposure to CQ. 
Multiple images were taken of each slide; as AO is a dichromatic stain, each 
individual field was captured twice, once with the green (525nm) and red 
(640nm) filters and then compiled to produce composite images which allow 
differentiating acidic compartments within the cells from the rest of the cellular 
tissue. 
 The following images (Figures 3.2.2.5- 3.2.2.8) are a selection of 
composites of the green and red filtered micrographs taken from each cell line 
and drug combination assayed in the present study. The drug doses selected 
for the images taken were determined by the initial reactions observed from the 
Neutral Red spectroanalysis. Images were taken to include the control, the 
dosage of peak NR response, midway through the decay of signal and just 
before the final plateau. The control images for all the three cell lines presented 
with largely plain green fields with the faint presence sparse of orange spheres 
would represent the latent lysosomic population. There was a faint dose 
dependent response to tamoxifen relative to activity conveyed by NR 
quantitative study. All cell lines were very reactive to chloroquine with a vibrant 
orange signal apparent; however lysosomic signal was seen to drop at the 
higher dosages of the drug. The tamoxifen-chloroquine drug combination 
yielded images of very high orange signal for all cell lines at relatively lower 
levels of tamoxifen with lysosomotropic response at 4µM tamoxifen/10µM 
chloroquine being comparable of response seen at 40µM of independent 
tamoxifen exposure. These findings corroborate that of the NR stain and 
demonstrate a decreased affinity to lysosomic activity at higher doses and also 
serve to show that combined therapy appears to increase lysosomotrophic 
response in all cell lines. 
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3.2.2.5 Acridine Orange Controls (All Cell Lines) 
Control images are compiled from the 525 and 640nm filter pictures 
taken with the fluorescent microscope. The controls are subject to the same 
staining process as described in the Methods section of Chapter 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: Acridine Orange panel of control samples for MCF-7 WT, TMX and MDA, 
monochromatic appearance of slides indicates low-volume of acidic compartments without drug 
treatment. Magnification x10  
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3.2.2.6 Acridine Orange MCF-7 WT 
 
3.2.2.7 AO MCF-7 TMX with Tamoxifen 
Figure 3.29: Panel illustrating the effect of TAM (A,B,C) CQ (D,E,F) and TCQ (G,H,I) on 
lysosomal profile and nuclear fragmentation of MCF-7 WT cells With Acridine Orange. The 
cells were treated with TAM, 8, 16 and 24 µM; 10, 40, 80 µM; and TCQ 8, 16 and 24 µM TAM 
with a static dose of 10 including controls (not pictured). Cell death and nuclear 
fragmentation was apparent in all rightmost slides. The greatest lysosomal signal is visible 
in the ED50 (centremost slides) and especially in the samples treated with CQ (D-I) in which 
nuclear fragmentation is also apparent. (x10) 
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Figure 3.30: Panel illustrating the effect of TAM (A,B,C) CQ (D,E,F) and TCQ (G,H,I) on 
lysosomal profile and nuclear fragmentation of MCF-7 TMX cells with Acridine Orange. The 
cells were treated with TAM, 8, 16 and 24 µM; 10, 40, 80 µM; and TCQ 8, 16 and 24 µM TAM 
with a static dose of 10 including controls (not pictured). Cell death and nuclear 
fragmentation was apparent in all rightmost slides. The greatest lysosomal signal is visible 
in the ED50 (centremost slides) in which nuclear fragmentation is also apparent. (x10) 
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3.2.2.8 AO MDA-MB-231 with Tamoxifen 
Figure 3.31: Panel illustrating the effect of TAM (A,B,C) CQ (D,E,F) and TCQ (G,H,I) on 
lysosomal profile and nuclear fragmentation of MDA-MB-231 cells with Acridine Orange. 
The cells were treated with TAM, 8, 16 and 24 µM; 10, 40, 80 µM; and TCQ 8, 16 and 24 µM 
TAM with a static dose of 10 including controls (not pictured). Cell death and nuclear 
fragmentation was apparent in all rightmost slides. The greatest lysosomal signal is visible 
in the ED50 (centremost slides) in which nuclear fragmentation is also apparent. (x10) 
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4.0 Discussion 
 As stipulated in Chapter 1.2, the aim of this investigation was to elucidate 
and explore the possible relationship between the anti-oestrogen tamoxifen and 
chloroquine through individual and combined study on their effect on the three 
cell lines MCF-7 WT, MCF-7 TMX and MDA-MB-231 in order to see any 
discrepancies or similarity in effect on cells lines with differing oestrogen 
receptor profiles.  The convincing findings of Fan and colleagues (2006) of 
Shandong University on the effect of chloroquine on A549 lung cancer cell lines 
laid down the framework to the question as to the cytotoxic effect (and thus 
medical application) of chloroquine on models of breast cancer cells. As of 
writing, the singular effects of quinine products on breast specific cancer cells 
have been slowly surfacing, with studies presenting that the lysosomotropic 
events initiated through chloroquine activity may cause drug sensitisation 
(Maycotte et al., 2012; Cufí et al., 2013) while researchers at George Mason 
University, Virginia in their clinical trials hope to see, independent 
chemotherapeutic activity on breast cancer precursor cells (Paid Clinical Trials 
- Clinical Trial News and Opinion, 2015). Specific drug interaction/sensitisation 
of any breast cancer cell line with chloroquine is therefore new ground with no 
currently available literature on the synergistic effects of chloroquine on 
tamoxifen in particular which is why that called for the design of this three 
pronged (three drug modalities per cell line) investigative approach. The aim of 
this study was in fact two fold; both cellular and molecular; to elucidate the effect 
of the drug on a cellular population and then to observe the intracellular 
molecular phenomena which occur. To this extent, the first objective was to 
investigate the unique effects of tamoxifen and chloroquine on three breast 
cancer cell lines; MCF-7 WT, an oestrogen dependent breast cancer 
adenocarcinoma cell line isolated from 69 year old Caucasian woman Frances 
Mallon which is a popular candidate for hormone studies due to its ER+ profile; 
an analogue, MCF-7 TMX developed with apparent tamoxifen resistance at 
John Hopinks University, USA; and MDA-MB-231 an invasive (in vitro) 
adenocarcinoma line characterised as ER- (Holliday & Spiers, 2011) for which 
to serve as a benchmark for further experiments. The mechanisms that lend to 
the cytotoxicity of tamoxifen and chloroquine are known to be molecularly 
disparate, with tamoxifen acting as an intracellular oestrogen receptor 
114 
 
modulator and cell growth inhibitor and chloroquine as an inducer of 
lysosomotrophic apoptosis. The hypothesis is that the chloroquine mediated 
lysosomotrophy would increase the bioavailability of tamoxifen due to the 
disruption of autophagic mechanisms of the cell resulting in increased 
tamoxifen sensitivity and thus overall synergistic cytotoxicity, indeed 
chloroquine has been found in this way to restore Transtuzumab in HER-2 
positive breast cancers (Cufí et al., 2013). Through the use of the ED50 values 
attained from the primary investigation, analysis of the effects of drug 
combination could be commenced using concentrations inference from the 
initial study. Subsequent tests would then be made to narrow down the effective 
range of drug interaction. Molecular investigation revolved around the study of 
lysosomes, specifically the presence of and stimulation of lysosomic activity 
through the use of light and fluorescence microscopic techniques. 
4.1 Cell Culture Characteristics  
The characteristic behaviour and morphologies of the cells lines detailed 
in this report (MCF-7 WT, MCF-7 TMX & MDA-MB-231) were recorded 
throughout the investigative process. Images as seen in the previous chapter 
as well as surplus imagery in the appendix were taken with an inverted 
microscope at various stages of cell development as well as after exposure to 
the various drug modalities at various time periods. All cell lines grew as an 
adherent monolayer with morphological traits following much the same 
expected patterns as in supervisory and advisory literature h). Proliferation data 
for each cell line was recorded (Table 3.1) and population doubling times (PDT) 
were extrapolated. The PDT of MCF-7 was 37 hours which is in line with the 
ATCC (American Type Culture Collection). MCF-7 TMX cells have an induced 
resistance, that is to say that they stem from a parent cell line of MCF-7 WT 
and slowly gain resistance after many passages. The PDT of MCF-7 TMX was 
24 hours which is similar to that of MCF-7 cells examined in their 299th passage 
by Sutherland and colleagues (1983). The PDT of MDA-MB-231 which was 40 
hours was also consistent with the ATCC. The discrepancy in doubling times 
between the breast cancer cells may harken to the school of understanding that 
directly correlates slower doubling times with increased tumorigenicity and 
aggressiveness as would be the case of MCF-7 WT and MDA-MB-231 
115 
 
however, in vitro morphology may not always defer the same traits in an in vivo 
model as would be the case of MDA-MB-231 which conveys invasive 
characteristics in vitro however in several xenograft assays has given rise to 
highly  metastatic in in vivo models after direct introduction to the circulation 
(Kang et al, 2003; Holliday & Speirs, 2011).  
4.2 The Effect of Tamoxifen on Breast Cancer Cells 
 Tamoxifen is renowned the world over by researchers and clinicians as 
the gold standard treatment, adjuvant and preventative therapy of ER+ cancers 
(Cowell et al., 2006). As an oestrogen receptor antagonist, it acts chiefly by 
halting or inhibiting the mitogenic processes by the competitive binding of the 
oestrogen receptor resulting in cytostatic or cytotoxic effect, especially in 
oestrogen dependent disease. The ED50 is the median effective dose of a 
substance or chemical that elicits 50% of the desired effect (cell death). The 
ED50 of tamoxifen was determined for each of the three cell lines investigated 
(Figures 3.4, 3.7 & 3.10) through their exposure to various doses of the drug 
over 48 hours. 
 The ED50 of tamoxifen observed for MCF-7 WT cells as acquired from 
the MTT assay after 48 hours was low (relative to that of the other two cell lines) 
at 15.5µM; this response is insightful of tamoxifen’s importance in hormonal 
therapy as an oestrogen receptor antagonist (Cowell et al., 2006) and highlights 
the dependence of the MCF-7 WT cell line to oestrogen. In comparison, at the 
same drug dose of 15 µM, the MCF-7 TMX cell line with its meticulously 
acquired resistance to tamoxifen had a mean cell population of 80% with a 
relatively unchanged/statistically insignificant cell survival when exposed to 
concentrations of up to 12 µM of tamoxifen with its own ED50 set at 18µM of 
tamoxifen. This change in character from its parent cell line, from its change in 
susceptibility to tamoxifen to its radically different mean cell volume (MCV) and 
PDT is not atypical of cell lines with induced resistance which are known to 
acquire all new phenotypes differing in DNA content and expression of intra 
and extracellular markers (Leung et al., 2010). The response and ED50 of the 
ER- cell line MDA-MB-231 was similar to that of the tamoxifen resistant MCF-7 
TMX cell line, yet disparate to the ER+ subject, highlighting the significance of 
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the use of tamoxifen in the inhibition and treatment of such cancers (Kang et 
al, 2003; Cowell et al., 2006; Cufí et al., 2013) 
Although primarily characterised and hailed for its cytostatic efficacy as 
an oestrogen receptor antagonist, in actuality, tamoxifen has been documented 
as exhibiting a duality of both antagonistic and agonistic effect on ER+ cancers. 
This paradoxical nature is why tamoxifen is called as a selective oestrogen 
receptor modulator (SERM). Research has shown that tamoxifen shares many 
of the same ER agonistic characteristics as its analogue oestrogen, in breast 
cancer cells effectively recapitulating a very similar gene expression profile 
including many transcription factors that ordinarily promote cell cycle 
progression such as fos, myc, myb, cdc25a (Hodges et al., 2003) which may 
attribute to the positive response of MCF-7 WT observed in Figure 3. In 2003, 
Kisanga reported of the oestrogen receptor agonistic behaviour of tamoxifen on 
the expression of the sex hormone binding globulin (SHBR) in patients at higher 
relative clinical doses (the typical clinical titre tamoxifen being 1µM) of the drug 
which falls under the lower end of the dosage spectrum used where an 
agonistic response was observed which helps to support this narrative. All cell 
lines exhibited a dose dependent response to tamoxifen with the response from 
the tamoxifen resistant cell lines MDA-MB-231 and MCF-7 TMX responding 
later at higher doses; a narrative supported by other research on the dose and 
time specific response of the drug to ER- cell lines (Zhang et al., 1999; Zheng, 
Kallio and Härkönen, 2007; Zhu, 2013, Liu et al., 2014). Interestingly, Cook and 
colleagues in 2014 when performing a knockdown of ERα on antioestrogen 
resistant LCC9 and susceptible LCC1 cell lines reported not only increased cell 
mortality in ER+ cell lines (highlighting their oestrogen dependence) but also an 
increased apoptosis in their antioestrogen resistant cell line thought to be most 
likely instigated by inhibition of certain survival mechanisms for which 
cytoplasmic ERα is thought to be responsible for. The marked response of the 
antioestrogen resistant cell lines MCF-7 TMX and the ER- cell line MDA-MB-
231 in the absence of functional oestrogen receptors is likely due to 
cytostatic/cytotoxic oestrogen receptor independent pathways (Liu et al., 2014). 
Indeed, much research has been undergone to elucidate the role and nature of 
tamoxifen’s ER independent pharmacology. The work of Zhen and colleagues 
in 2007 suggest that much of the immediate cytotoxic effects of tamoxifen at 
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pharmacological levels on the MCF-7 cell line linked tamoxifen exposure with 
sustained ERK (extracellular regulated kinase) activation which was prohibited 
by ERK inhibitors suggesting extracellular pathways at play even in oestrogen 
sensitive cell lines. Quite paradoxically, they proved that the presence of 
oestrogen receptors provides a semblance of resistance to tamoxifen in regard 
to the prevention of ERK phosphorylation and acute tamoxifen cytotoxicity, a 
trait which MDA-MB-231 does not have. As phenol red, the pH indicator present 
within the complete culturing medium is known to act a weak oestrogen; it is 
possible that through conveyed partial resistance to tamoxifen in the ER+ MCF-
7 WT could have affected their immediate susceptibility to the drug at lower 
titres suggesting that the disparity in sensitivities between MCF-7 WT and the 
latter two cell lines investigated may have been  (Berthois, Katzenellenbogen 
and Katzenellenbogen, 1986; Węsierska-Gądek et al., 2006; Węsierska-Gądek 
et al., 2007). Other studies have conveyed the significance of tamoxifen’s ER 
independent cytotoxicity through the modulation of various other cell signalling 
proteins as well as oxidative stress (Nazarewicz et al., 2007; Cho et al., 2012), 
nevertheless the findings from the present study show an obvious and 
significant susceptibility of the ER+ MCF-7 WT to tamoxifen. 
Resistance to tamoxifen both in vitro and in vivo is assumed to fall hand 
in hand with a marked rise in CD44+/CD24-/low cancer stem cells which are 
known to exhibit highly enhanced invasive properties and darken prognoses 
(Sheridan et al., 2006; Hiscox et al., 2012; Sun et al., 2012). Untreated strains 
of MDA-MB-231 are known to exhibit comparatively proliferous amounts of 
CD44+/CD24-/low (Around 30% according to Sheridan et al, 2006) which may be 
attributive of the disparate ED50 values observed in the MTT assay between the 
three cell lines.  
The Neutral Red (NR) viability staining assay served equally as both an 
accessory quantitative cell viability assay to the MTT test, but also in a 
qualitative capacity as a differential stain for the visual representation of the 
apparent changes in certain intracellular events, namely the lysosomes and 
other acidic cellular compartments (Fan et al., 2006; Repetto, del Peso and 
Zurita, 2008). Through the differential staining of the lysosomes, it was possible 
to observe the documented lysosomotropic fate of tamoxifen exposure which is 
purported to perturb autophagic function and induce cell death (Codogno and 
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Meijer, 2005; Kohli et al., 2013; Ashoor et al., 2013). The NR control images 
from figures 3.16, 3.19 and 3.22 illustrated the latent presence of lysosomes 
within the three cell lines at rest. MDA exhibited the highest visual signal at rest 
highlighting the ever present role of autophagy in aggressive cancers 
(Hunakova et al., 2009; Tu et al., 2011). Both MCF-7 cell lines exhibited a rise 
in signal (Figures 3.16, 3.19) relative to control levels in response to tamoxifen 
demonstrating an increased lysosomotropic response between these two cell 
lines. The relative response to tamoxifen and gradual decline of NR retention 
in the MDA-MB-231 cell line in comparison to the two MCF-7 cell lines is 
indicative of cell death mediated by cytostatic or cytotoxic mechanisms 
independent of tamoxifen facilitated lysosomotropy. MCF-7 TMX (Figure 3.19) 
exhibited the highest positive response to tamoxifen exposure with NR signal 
suggesting a 50% increase in lysosome volume/capacity at 8µM compared to 
the relatively static NR expression from MCF-7 WT and the gradual decline 
from MDA-MB-231. This rampant rise in lysosomotropy in lieu of cell death 
suggests MCF-7 TMX’s high affinity for autophagy as a mechanism for 
tamoxifen resistance. When comparing the disparity in percentage changes 
between MTT and Neutral Red signal in the MCF-7 cell line (Figures 3.4 and 
3.16); cell viability appears to recede earlier, from about 10µM of tamoxifen 
dosage while the level of lysosomes represented by NR sequestration appears 
to be steadier for longer. This may be due to the fact that in lieu of cell 
population decline, an increase in lysosomotropic response to tamoxifen is 
being triggered in the surviving cells. Indeed, this hypothesis is further 
supported by Figures 3.29 and 3.30 in which NR signal between 8 and 16 µM 
becomes visually more intense in the surviving cells. Indeed, a similar 
phenomenon may be observed in MCF-7 TMX between figures 3.7 and 3.19 
which present an unwavering cell population/viability with a simultaneous 
increase of NR uptake. This correlation is similar to that observed by Fan and 
colleagues (2006) in an assay of a similar nature. 
The use of Acridine Orange (AO) fluorescence staining (Figures within 
chapters 3.2.2.2, 3.2.2.5 and 3.2.2.9) for supplementary imagery of lysosomic 
activity served to further the support findings achieved through qualitative NR 
assessment by illustrating the lysosomotropic nature of tamoxifen. The 
increase in presence and intensity of the orange vesicles in using the 
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dichromatic stain were tantamount with that of neutral red intensity in the 
images taken serving to further exemplify this mechanism. In both stains, the 
higher dosages of tamoxifen (past the ED50 for the respective cell lines) resulted 
in decrease of signal alluding to cell death being mediated now not by type II 
autophagic cell death but through other mechanisms linked to dose dependent 
cell necroptosis and necrosis (Bursch et al., 1996; Fan et al., 2006). 
Caspase 3 is the terminal ‘executor caspase’ of the in the apoptotic 
cascade which is induced by the decrease in Bax:Bcl-2 ratio and whose up-
regulation is linked with the irreversible upregulation of Type I apoptosis (Somai 
et al., 2003). Tamoxifen has been shown to induce apoptosis in both ER+ and 
ER- cancers from various origins through exposure to low levels of the drug in 
certain studies using lower levels of the drug relative to the ED50 values 
investigated in the present study (Zartman et al., 2004). Exposure to tamoxifen 
at the ED50 for the three cell lines showed little change to the amount of caspase 
3 expressed relative to the latent levels in the control. This may be due to the 
immediate cytotoxic effect of tamoxifen being caspase 3 independent; Kohli and 
colleagues in 2013 detailed a dose dependent rise in Caspase 3 up-regulation 
in ER+ malignant peripheral nerve sheath tumours however their findings 
showed that caspase inhibition did not protect the cells from apoptosis but 
rather that tamoxifen induced death was associated to autophagic induction 
which supports the narrative detailed in the present study from the neutral red 
and Acridine Orange assays and the rise in lysosomotropic activity within these 
breast cancer cell lines. 
Contrary to expectations, treatment with tamoxifen presented a 
decrease in the presence of Annexin-V in all the cell lines. This could be as a 
result of the relatively high doses (compared to that of clinical treatment) 
necessary to examine the ED50 values of the cell lines which, at the 48-hour  
time point may cause cells to engage in death mechanisms independent of 
Annexin-V. Indeed, Salami and colleagues in 2003 in the investigation of ER- 
cell lines reported the existence of a dose-dependent peak value of Annexin-V 
expression after which a marked drop similar to that of the present study is 
observed. 
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4.3 The Effect of Chloroquine on Breast cancer cells 
The synthetic quinolone chloroquine’s therapeutic potential has been 
exploited over the past century from the treatment of malaria and rheumatism 
(Jamshidzadeh et al., 2007; Teka et al., 2008; Manic et al., 2014; Wallace, et 
al., 2015) to the more recent inquiry of its employment as a chemotherapeutic 
agent (Fan et al., 2006). Its principal mechanism, even in that of the treatment 
of malaria, has been characterised by the abrogation of macroautophagy and 
subsequent cell death through accumulation and perturbation of lysosome 
synthesis; a primordial response seen in both Plasmodium and human species 
alike (Chinappi et al., 2010; Sui et al., 2013; Manic et al., 2014; Choi et al., 
2014). As a direct result, CQ has been repositioned as a putative anti-cancer 
drug against breast cancer, as well as other aggressive cancers such as 
CD44+/CD24-/low Cancer Stem Cells CSCs (Choi et al., 2014), glioblastoma 
multiforme (Sotelo, 2006) and chronic myeloid leukaemia (Bellodi et al., 2009). 
In the present study, the overall effect of chloroquine on the viability of 
the three cell lines MCF-7 WT, MCF-7 TMX and MDA MB 231 was assessed 
with the MTT assay. There was a uniform dose-dependent response observed 
overall between the cells in response to exposure to chloroquine with the ED50 
value of MDA-MB-231 being the lowest at 44µM compared to the relatively 
higher ED50 values of the MCF-7 cell lines which signifies the importance of 
autophagy in aggressive cancers as a primary form of resistance. The ED50 
values of MCF-7 WT and MCF-7 TMX, 52µM and 72µM respectively after 48 
hours showing the susceptibility of these drugs in a dose dependent manner. 
MCF-7 TMX’s greater apparent comparative tolerance to chloroquine 
compared to that of its parent cell line is perhaps anticipated given its nature as 
a drug resistant sub-group and suggests that its mechanism of intended 
tamoxifen resistance is not simply dependent on altered ER phenotype which 
is plausible given the exceptionally heterogeneous nature of MCF-7 and its sub-
lines (Leung et al., 2010).  
The nature of chloroquine’s lysosomotropic nature is even more evident 
given the findings from the present study using Neutral Red uptake analysis 
and Acridine Orange fluorescence microscopy. Through quantitative NR 
spectroscopy (Figures 3.17, 3.20 & 3.23) it is possible to visualise the how the 
cells mount a rapid lysosomotropic response to chloroquine from the lowest 
121 
 
doses. Both ER+ and ER- wild-type breast cancer variants MCF-7 WT and 
MDA-MB-231 are seen to exhibit a similar severe response to low doses of 
chloroquine which, when compared to their similar responses from the MTT 
underlines the necessity of autophagy for their survival. The tamoxifen resistant 
MCF-7 TMX cell line’s disparate initial NR response to chloroquine from the 
other two cell lines is compounded by its unique response in from the MTT 
assay. Although, as with the other two cell lines an increase in lysosomotrophy 
was apparent; MCF-7 TMX displayed a slighter, but sustained increase in over 
neutral red signal. The steeper decrease in MTT signal to the NR hints at an 
increased degree of lysosomotropy in the tamoxifen resistant cell line, albeit 
less dramatic than in the latter lines. This is supported by the NR and AO 
images in subchapter 3.2 which show a dramatic increase in lysosomotropy 
within each cell line compared to the relative senescence of the controls. Such 
response to chloroquine as seen in these images are a textbook response to 
the immediate effects of chloroquine which is plainly and beautifully displayed 
here and has been documented with familiarity in other cell lines (Fan et al., 
2006; Repetto et al., 2008).   Aside from autophagy, chloroquine has also of 
late been found to regulate cancer stem cells in triple negative breast cancers 
through the inhibition of Janus kinase 2 (JAK2) and DNA methyltransferase 
synthesis (Choi et al., 2014; Manic et al., 2014; Watson and Hughes, 2014). 
Autophagy independent cytotoxicity may also be apparent in this study as Fan 
and colleagues (2006) described reduced lysosomotropy at higher 
concentrations of chloroquine when working on A549 lung cancer cells which 
is substantiated by the same reduction of lysosome signal in the three cell lines 
of the present study when subject to the same or higher levels of chloroquine. 
This may suggest that at higher (albeit clinically unfeasible) concentrations of 
chloroquine, cell cytotoxicity is being driven by as of yet unknown or poorly 
characterised autophagy independent cell death mechanism.  
Choi and colleagues of the Houston Methodist Hospital (2014) described 
chloroquine as having a profoundly positive effect on the on the population of 
CD44+/CD24-/low cancer stem cell population in triple negative breast cancers. 
As MDA-MB-231 has been previously characterised as having a relatively high 
population of such CSCs (>30%), it is fitting to assume this as an apt reason 
for why the MDA-MB-231 cell line in the present study had such a lower ED50 
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dose response in comparison to the other two MCF-7 breast cancer cell lines 
(Choi et al., 2014). 
As chloroquine has been highly characterised as being a facilitator of 
Type II autophagic cell death, it is interesting to note that the drug also appears 
to solicit a measurably high response in caspase-like activity when it came to 
performing the caspase 3 analysis after 48-hour incubation of the cell lines with 
ED50 concentrations. Several publications have given inference to the overlap 
of specific apoptotic pathways including the activation of caspase 3 in certain 
cell lines, however many of the same articles have also established that the 
inhibition of caspase 3 had no effect on the rate or degree of cell death in these 
cell lines, leading to the consensus that the presence of caspase 3 by CQ to be 
incidental and not primary to cell death (Geng et al., 2010; Kim et al., 2010).  
The marked upregulation Annexin-V expression in the present study for 
the cell lines MCF-7 WT and MCF-7 TMX is testimony to chloroquine’s ability 
to facilitate cell death through not only autophagic apoptosis (as evidenced from 
both quantitative and qualitative Neutral Red investigation and Acridine Orange 
assay). Again the lack of any significant change in Annexin-V expression in the 
MDA-MB-231 cell line may be a result of the 48-hour time point which was 
chosen specifically as a snapshot to illustrate the processes occurring at the 
same time in the MTT, NR and AO experiments. Peak expression for MDA and 
the MCF-7 cell lines included may as inferenced by Salami and Karami-Tehrani 
(2003) thus be at an earlier point in time. 
Several other pathways have been characterised as being activated by 
chloroquine through mechanisms disparate from its characteristically described 
potentiation of Type II Cell death; chloroquine has been reported to affect breast 
cancers through the induction of mitochondrial damage through oxidative stress 
(Liang et al., 2015), the normalisation of tumour vessels through the increased 
signalling of Notch1 in endothelial cells (Maes et al., 2014) and immune 
response manipulation including rheumatism and lupus (Thomé et al., 2013). It 
may be pertinent to add that all experiments in the present study were 
performed in vitro, and that due to the stark differences between the systemic 
and controlled environment, one must not conclude any findings in vitro would 
be directly corollary of a live model; indeed this is the case with the response 
of MDA-MB-231 and chloroquine, which the present study presents a clear and 
123 
 
favourable effects on cell viability, however in that of an in vivo mouse model 
study of the cell line with chloroquine by Tuomela and co-authors evidenced 
the contrary which, was explicated  to be caused by some as of yet 
unestablished systemic response to chloroquine. 
 
4.4 The Combined Effect of Chloroquine and Tamoxifen on Breast Cancer 
Cells 
Due to the complex and often heterogeneous nature of cancers, the 
treatment of such diseases with single drugs focussed on a single receptor is 
commonly considered suboptimal as in many cases acquired resistance soon 
follows, leading to poor prognosis of the patient (Hiscox et al., 2012; 
Pourkavoos, 2012). Thus, the usage and development of combination 
modalities for the optimal treatment of breast cancers and other heterogeneous 
diseases such as diabetes, cardiovascular disease and HIV/AIDS is not only 
favourable, but necessary. Chloroquine has been at the forefront of much 
research in the concerted efforts of drug combination research, chiefly for its 
role in the abrogation of autophagy which has been found to be a central 
mechanism of drug resistance in many cell lines (Sui et al., 2013). It is the key 
premise of the present study that chloroquine may act in a potentiative manner 
to circumvent primary tamoxifen resistance and may thus translate as a 
promising therapeutic strategy for the improved treatment of breast cancers. 
Through first obtaining the ED50 dosage values from the two 48-hour 
treatment modalities of tamoxifen and chloroquine for each of the three cell 
lines MCF-7 WT, MCF-7 TMX and MDA-MB-231, the first initial combination 
studies were made (Figures, 3.13, 3.14 and 3.15). The initial experiment 
involved the combination of incremental fractions of tamoxifen (2-30µM) as 
prepared in earlier independent assay of the drug with the ED50 dosage of 
Chloroquine (40µM). The rationale behind this decision was analogous to that 
of isobolic experimentation in which combined fractions of ED values add up to 
ED100 (i.e. ED25+ED75 or ED50+ED50). Data from the dose-response graph was 
thus used to extrapolate the nature of drug-drug interaction. It was believed that 
a shift in the curve to the right would infer inhibitory pharmacokinetic interaction 
and a shift to the left would infer synergistic combination while no shift at all 
would infer additive effect (Meyerson, Went and Fultz, 2009; Prueksaritanont 
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et al., 2013). There was a unanimously positive response from all three cell 
lines with this initial combined treatment of tamoxifen with 40µM of chloroquine 
with ED50 values dropping profoundly. In an additive response, one would 
expect the new ED100 (that, is the minimum dose with which to kill all the cells) 
of tamoxifen with 40µM of chloroquine to fall at the current ED50 values for each 
cell line; this, however is not the case with the ED50 values for each cell line 
dropping to an unprecedented 1µM for MCF-7 WT and 2µM for MCF-7 TMX 
and MDA-MB-231 implying significant synergistic behaviour between the two 
drugs.  
In an attempt the further establish the immediate cytotoxic effect of the 
two drugs in combination and better visualise any difference in response 
between the cell lines, a lesser concentration of chloroquine (10µM) was 
elected for use (Figures 3.6,3.7 & 3.12). The results showed a drop in ED50 
values across the board, all curiously settling at 12µM of tamoxifen with the 
MDA-MB-231 cell line exhibiting the greatest fall from its previous ED50 of 18.5 
with MCF-7 TMX falling in line shortly after. The drop of the ED50 values of both 
MCF-7 cell lines to a common figure suggests that chloroquine may serve to 
overcome primary resistance and restore sensitivity to tamoxifen in these cell 
lines in a similar fashion to findings published by Cufí and colleagues (2013) in 
their investigation into the combined effect of CQ with trastuzumab; an anti 
HER-2 monoclonal antibody through which they deduced that chloroquine 
mediated cell death may occur through the inhibition of autophagic resolution 
of autophagosomes formed in the presence the herceptin drug (or in the case 
of the present study, tamoxifen) resulting in initiation of cell death through 
apoptosis. It has already been stated that, due to the largely unspecific nature 
of tamoxifen which has been documented as eliciting many (less well 
documented) oestrogen receptor independent pathways, an albeit lesser 
immediate response to the drug may be observed in conjunction with the ER- 
MDA-MB-231 cell line.  It is very likely that the response observed in the present 
study between MDA-MB-231 and the combination drug treatment many be 
similarly caused by chloroquine mediated sensitisation.  
Results from the quantitative NR analysis of the three cell lines, as 
evidenced by Figures 3.18, 3.21 and 3.24 serve to further support this narrative 
of cell death facilitated through lysosomotropy and autophagic gridlock. There 
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is a similar delayed response observed between MFC-7 cell lines WT and TMX 
before a surge in signal which signifies the increased retention of the Neutral 
Red pigment within the cells as instigated by an increase in the size and volume 
of acidic compartments within the cells. The shared delay of 8µM of tamoxifen 
may indicate the critical dose of tamoxifen where lysosomotropic synergy with 
chloroquine is most apparent. This observation is further supported through 
further light and fluorescence imagery of the cells in Chapter 3.2 which present 
a visibly pronounced increase in NR and AO acidity from the cell lines in 
comparison with the single drug modalities. The orange colour from the AO 
stems from the dichromatic nature of the stain; upon entering lysosomes and 
becoming protonated in the low pH environment, the dye emits more strongly 
at 640nm contrasting against the green surrounding environment. The signal 
potency of the orange vesicles from the composite images of the combined 
treatment (Figures 3.61, 3.68 & 3.75) are comparable with that seen in 
treatments of 40µM is an indication which highlights the synergistic effect of the 
drug couplet on lysosomotropic events. Going back to the NR quantitative 
assay, as MCF-7 cell lines WT and TMX were both seen to share a similar 
delayed response before peaking; MDA-MB-231 was seen to exhibit a more 
immediate response to the drug combination (Figure 3.24). This may be 
attributed to MDA-MB-231’s apparent heightened sensitivity to chloroquine as 
evidenced from its lower ED50 in Figure 3.11 and may infer as to why the 
combination elicits such a dramatic drop in viability (as recorded from the ED50) 
relative to the other cells lines. 
Results from the Caspase 3 DEVD-Pna colorimetric analysis presented 
with a marked increase in Caspase-like activity across the board for each of the 
three cell lines after treatment with their respective tamoxifen-chloroquine ED50 
doses (Figure 3.25). It was stated before that in cell death mediated by both 
drugs independently, while Caspase 3 specific activity may be present in a dose 
dependent manner, the inhibition of caspase activity did not prevent cell death. 
That being said, the high presence of Caspase 3 activity in the combination 
assays confirms that while in the confines of the present study tamoxifen and 
chloroquine do not independently display Caspase 3 activity, in conjunction 
they elicit a high Caspase 3 up-regulation greater than the sum of both drugs 
individually. From these findings, one may thus infer that tamoxifen-chloroquine 
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combination treatment facilitates cell death through both Type 1 caspase 
mediated apoptosis and Type II autophagic apoptosis. The experiment 
however only provides a snapshot of events at the 48 hour time period and may 
not be representative of peak Caspase-3 expression in response to the drug 
modality.  
Combination therapy yielded a visible, yet statistically insignificant 
increase in Annexin-V expression for all the cell lines investigated which may 
either result as stated before from Annexin-V’s fleeting presence post peak 
expression (Salami and Karami-Tehrani, 2003) or due to the interplay of 
different cell death mechanisms resulting from this modality such as the marked 
increase of autophagic events evidenced from Acridine Orange study. Results 
from the Caspase-like activity analysis however would beg the former as these 
are both investigative procedures for the detection of Type I apoptosis.  
 
 
 
 
4.5 Conclusion 
The endogenous factors at play of the SERM tamoxifen on breast 
cancers are a topic of constant study and ones that have been further 
exemplified in the present study through the nature of its reaction with both ER+ 
and ER- cancer cell lines alike albeit at disparate concentrations pertaining to 
oestrogen receptor status. The cytotoxic effects of tamoxifen were found not to 
be limited by mitochondrial apoptosis but also through the mediation of 
autophagic cell death which was visualised through both qualitative and 
quantitative Neutral Red assay and further investigation with Acridine Orange. 
Through independent treatment, the cytotoxic nature of chloroquine on breast 
cancers was elucidated and was found to have a significantly higher dose-
response ratio than that of tamoxifen. It was deduced that the more aggressive 
oestrogen receptor negative cell line MDA-MB-231 had a significantly stronger 
response to chloroquine than the ERα+ cell line and its tamoxifen resistant 
strain. 
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 When used in conjunction, the tamoxifen-chloroquine treatment 
displayed an undisputed potentiation of cell death characterised by the chaotic 
perturbation of autophagic phenomena. This combination demonstrated that 
small doses of chloroquine in combination with the antioestrogen tamoxifen 
could elicit lysosomotropic effects only seen at doses of up to four times of as 
much chloroquine in single use. Through its unanimous display of cytotoxicity 
across all three cell lines, the treatment combination shows its efficacy in not 
only overcoming primary resistance as seen in the similar ED50’s of MCF-7 WT 
and MCF-7 TMX, but through its high toxicity observed in MDA-MB-231 
suggests collaborative potentiation through pathways endogenous to classical 
oestrogen receptor suppression. The evidence from this study suggests that 
further exploration of the nature of this relationship could yield clinical benefit in 
the resensitization and treatment of many forms of breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
 
5.0 Further Studies 
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5.0 Further Studies 
The results from the present study suggested significant potentiation of 
chloroquine on the efficacy of tamoxifen (as evident in the decrease in ED50) on 
each the three breast cancer cell lines investigated, however, the favoured 
mechanism of cell death, and thus the feasibility of its clinical application 
pertaining to tolerance and side effects remains unclear. Thus, further study 
would be necessary to determine the effect of these cells on the favoured mode 
of cell death. In this initial investigation, the presence of annexin-V and capsase 
3 activity as seen through ELISA and spectrophotometry served as a snapshot 
to match the 48-hour treatment examined quantitatively with MTT and Neutral 
Red analysis however it has been suggested that such a study represents the 
activity of metabolites at a time point that may not infer their peak activity which 
may have a large discrepancy due to the disparate nature of the cell lines (Arif 
et al, 2015) thus an appropriate time course would be necessary. Moreover, to 
discern between apoptotic and necrotic populations within sample, annexin-V 
flow cytometry with propidium iodide, which was not within the fiscal scope of 
the present study would have been favourable to the ELISA assay to visualise 
the disparate populations. Additionally, LDH (Lactate Dehydrogenase) assays 
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have been used in the independent analysis of necrosis in other choloroquine 
related potentiation study (Fan et al., 2006; Cufí et al., 2013) and would also be 
pertinent to any future investigation.  
Qualitative analysis for the visualisation of the lysosomotropic 
phenomena that occurred in the present study were not specific to lysosomes 
but all acidic vesicles within the cell. LC3-II (microtubule associated protein light 
chain 3) immunocytochemistry, while dearer, would be the ideal choice in any 
future investigation of lysosome-specific activity (Mizushima and Yoshimori, 
2007; Cufí et al., 2013). The utilisation of scanning electron microscopy would 
serve to better observe cell ultrastructure and document any fine morphological 
changes which may not have been obvious in the present study (Jaafar, Sharif 
and Murtey, 2012). 
The resistance to tamoxifen of the cell line MCF-TMX, an offshoot of the 
parent line MCF-7 is one that was selectively induced. Chloroquine resistance 
in human disease has not yet been investigated and studies in the facilitation 
of chloroquine resistance and subsequent response to the drug panel of the 
present study may prove to an area of unique interest, especially pertaining to 
future prospects in clinical application. 
The Bcl-2 (B-cell lymphoma/leukaemia 2) family plays a role in cell 
survival and oncogenesis (Cory, Huang and Adams, 2003). The gene encodes 
an integral outer mitochondrial membrane protein that prevents the apoptosis 
in certain cells such as lymphocytes and has been characterised in many types 
of cancers and attributed to their survival. In some studies, cell death by 
tamoxifen has been linked with a down-regulation of bcl-2 (Zhang et al., 1999; 
El-Sheemy et al., 2015) thus it may be of interest to investigate if the 
potentiative effect of tamoxifen and chloroquine combination is preceded by a 
further drop in Bcl-2. 
The present study was used to assess the three cell lines after a 48-hour 
treatment period using drug concentrations standardised to give a visible effect 
after this time period and the results from which are pertinent to the immediate 
effect of the drugs over this time scale. However, clinical doses of tamoxifen 
would rarely exceed 0.2µM in serum and 2µM in tissue (Vaillant et al., 2013) 
and thus a protracted study at such a range of drug over a longer time scale 
may be warranted to appraise a clinically relevant study. 
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The handful of data that exists on the effects of radiation on cells 
resistant to hormonal therapy also implies that they are resistant to radiation. 
Chloroquine has already been reported to independently sensitise cells to 
radiation thus after some standardisation, it would be of interest to see whether 
the tamoxifen-chloroquine modality infers any further potentiation with radiation 
treatment. 
 As stated before, tamoxifen exposure in MCF-7 WT cells has been linked 
with an overexpression of CD44, negatively affecting their sensitivity to the drug 
and promoting resistance and aggressiveness over time (Sheridan et al., 2006; 
Hiscox et al., 2012). Chloroquine on the other hand has been seen to exact the 
opposite response and has been identified as a candidate for CD44+/CD22-/low 
cancer stem cell treatment (Choi et al., 2014). As the present study has shown 
that tamoxifen-chloroquine combination treatment potentiates cell death in the 
three cell lines investigated, it would be applicable to investigate whether this 
response is accompanied by any changes in the CD44+/CD22-/low population of 
the breast cancer cell lines. 
 Janus Kinase 2 has been found to be integral in the activation of the Stat 
1 transcription signaling pathway expressed in breast cancers (Watson and 
Hughes, 2014). Moreover, chloroquine has been seen to perturb Jak2 
activation, eliminating cancer stem cells. Thus the monitoring and comparison 
of differences Jak2 synthesis between treatment systems may serve to further 
support this narrative.   
 Another such mechanism to investigate is that of p53 oncogene up-
regulation by chloroquine. p53 protein is tumor suppressor that potently inhibits 
cell growth through the halting of proliferation and apoptotic pathways 
(Vogelstein, Lane and Levine, 2000). Chloroquine has been found to stimulate 
the up-regulation of this protein and is believed that p53 mediated apoptosis is 
a key component of chloroquine facilitated cell death (Kim et al., 2010; 
Loehberg et al., 2012). Tamoxifen, on the other hand has been shown to not 
cause any notable effects on p53 levels, thus an investigation on the effect on 
the role of this protein in tamoxifen-chloroquine synergy would be of great 
interest as to further understand the nature of their relationship (Zhang et al., 
1999). 
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7.1 Appendix 1: 2way ANOVA with Dunnet’s multiple comparisons test for 
all MTT Assays against Control 
Within each row, compare columns 
(simple effects within rows)     
Number of families 1    
Number of comparisons per family 96    
Alpha 0.05    
Dunnett's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary 
0     
Control vs. WT x T 0.0 -19.80 to 19.80 No ns 
Control vs. WT x TCQ 0.0 -19.80 to 19.80 No ns 
Control vs. TMX x T 0.0 -19.80 to 19.80 No ns 
Control vs. TMX x TCQ 0.0 -19.80 to 19.80 No ns 
Control vs. MDA x T 0.0 -19.80 to 19.80 No ns 
Control vs. MDA x TCQ 0.0 -19.80 to 19.80 No ns 
2     
Control vs. WT x T 1.736 -15.98 to 19.45 No ns 
Control vs. WT x TCQ 22.72 5.005 to 40.43 Yes ** 
Control vs. TMX x T -5.330 -23.04 to 12.38 No ns 
Control vs. TMX x TCQ -3.468 -21.18 to 14.25 No ns 
Control vs. MDA x T 1.932 -15.78 to 19.65 No ns 
Control vs. MDA x TCQ 17.49 -0.2283 to 35.20 No ns 
4     
Control vs. WT x T -5.385 -23.10 to 12.33 No ns 
Control vs. WT x TCQ 26.00 8.291 to 43.72 Yes *** 
Control vs. TMX x T -4.995 -22.71 to 12.72 No ns 
Control vs. TMX x TCQ 7.611 -10.10 to 25.32 No ns 
Control vs. MDA x T 4.650 -13.06 to 22.36 No ns 
Control vs. MDA x TCQ 18.71 0.9989 to 36.43 Yes * 
6     
Control vs. WT x T -0.5273 -18.24 to 17.19 No ns 
Control vs. WT x TCQ 39.52 19.71 to 59.32 Yes **** 
Control vs. TMX x T -7.154 -24.87 to 10.56 No ns 
Control vs. TMX x TCQ 18.97 1.256 to 36.68 Yes * 
Control vs. MDA x T 2.682 -15.03 to 20.40 No ns 
Control vs. MDA x TCQ 16.20 -1.510 to 33.92 No ns 
8     
Control vs. WT x T -3.081 -20.79 to 14.63 No ns 
Control vs. WT x TCQ 53.01 35.30 to 70.73 Yes **** 
Control vs. TMX x T -5.690 -23.40 to 12.02 No ns 
Control vs. TMX x TCQ 20.26 2.543 to 37.97 Yes * 
Control vs. MDA x T 5.985 -11.73 to 23.70 No ns 
Control vs. MDA x TCQ 21.44 3.727 to 39.15 Yes ** 
10     
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Control vs. WT x T 2.196 -15.52 to 19.91 No ns 
Control vs. WT x TCQ 58.02 40.31 to 75.74 Yes **** 
Control vs. TMX x T -2.121 -19.83 to 15.59 No ns 
Control vs. TMX x TCQ 28.51 10.79 to 46.22 Yes **** 
Control vs. MDA x T 7.713 -10.00 to 25.43 No ns 
Control vs. MDA x TCQ 31.46 13.75 to 49.17 Yes **** 
12     
Control vs. WT x T 17.12 -0.5918 to 34.84 No ns 
Control vs. WT x TCQ 71.96 54.25 to 89.67 Yes **** 
Control vs. TMX x T -2.575 -20.29 to 15.14 No ns 
Control vs. TMX x TCQ 57.00 39.28 to 74.71 Yes **** 
Control vs. MDA x T 11.41 -6.301 to 29.13 No ns 
Control vs. MDA x TCQ 49.95 32.24 to 67.67 Yes **** 
14     
Control vs. WT x T 32.30 14.58 to 50.01 Yes **** 
Control vs. WT x TCQ 69.49 51.77 to 87.20 Yes **** 
Control vs. TMX x T 5.180 -12.53 to 22.89 No ns 
Control vs. TMX x TCQ 65.92 48.20 to 83.63 Yes **** 
Control vs. MDA x T 19.57 1.853 to 37.28 Yes * 
Control vs. MDA x TCQ 70.73 53.01 to 88.44 Yes **** 
16     
Control vs. WT x T 56.19 38.48 to 73.90 Yes **** 
Control vs. WT x TCQ 82.16 64.45 to 99.88 Yes **** 
Control vs. TMX x T 23.95 6.239 to 41.67 Yes *** 
Control vs. TMX x TCQ 65.90 48.19 to 83.61 Yes **** 
Control vs. MDA x T 41.60 23.89 to 59.32 Yes **** 
Control vs. MDA x TCQ 78.47 60.75 to 96.18 Yes **** 
18     
Control vs. WT x T 64.84 47.13 to 82.56 Yes **** 
Control vs. WT x TCQ 97.18 79.47 to 114.9 Yes **** 
Control vs. TMX x T 51.20 33.48 to 68.91 Yes **** 
Control vs. TMX x TCQ 92.94 75.23 to 110.7 Yes **** 
Control vs. MDA x T 68.39 50.68 to 86.10 Yes **** 
Control vs. MDA x TCQ 88.06 70.34 to 105.8 Yes **** 
20     
Control vs. WT x T 85.21 67.49 to 102.9 Yes **** 
Control vs. WT x TCQ 98.85 81.14 to 116.6 Yes **** 
Control vs. TMX x T 85.88 68.17 to 103.6 Yes **** 
Control vs. TMX x TCQ 97.37 79.66 to 115.1 Yes **** 
Control vs. MDA x T 98.41 80.69 to 116.1 Yes **** 
Control vs. MDA x TCQ 97.94 80.23 to 115.7 Yes **** 
22     
Control vs. WT x T 98.28 80.57 to 116.0 Yes **** 
Control vs. WT x TCQ 98.74 81.02 to 116.4 Yes **** 
Control vs. TMX x T 99.73 82.01 to 117.4 Yes **** 
Control vs. TMX x TCQ 99.57 81.86 to 117.3 Yes **** 
Control vs. MDA x T 98.97 81.25 to 116.7 Yes **** 
Control vs. MDA x TCQ 99.07 81.36 to 116.8 Yes **** 
24     
Control vs. WT x T 99.09 81.38 to 116.8 Yes **** 
Control vs. WT x TCQ 98.52 80.80 to 116.2 Yes **** 
Control vs. TMX x T 99.10 81.39 to 116.8 Yes **** 
Control vs. TMX x TCQ 99.06 81.35 to 116.8 Yes **** 
Control vs. MDA x T 98.32 80.60 to 116.0 Yes **** 
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Control vs. MDA x TCQ 100.0 82.29 to 117.7 Yes **** 
26     
Control vs. WT x T 99.90 82.19 to 117.6 Yes **** 
Control vs. WT x TCQ 99.11 81.39 to 116.8 Yes **** 
Control vs. TMX x T 99.53 81.81 to 117.2 Yes **** 
Control vs. TMX x TCQ 99.79 82.07 to 117.5 Yes **** 
Control vs. MDA x T 99.02 81.31 to 116.7 Yes **** 
Control vs. MDA x TCQ 100.0 82.29 to 117.7 Yes **** 
28     
Control vs. WT x T 99.68 81.97 to 117.4 Yes **** 
Control vs. WT x TCQ 98.61 80.90 to 116.3 Yes **** 
Control vs. TMX x T 99.52 81.80 to 117.2 Yes **** 
Control vs. TMX x TCQ 100.0 82.29 to 117.7 Yes **** 
Control vs. MDA x T 98.57 80.86 to 116.3 Yes **** 
Control vs. MDA x TCQ 100.0 82.29 to 117.7 Yes **** 
30     
Control vs. WT x T 100.0 82.29 to 117.7 Yes **** 
Control vs. WT x TCQ 100.0 82.29 to 117.7 Yes **** 
Control vs. TMX x T 100.0 82.29 to 117.7 Yes **** 
Control vs. TMX x TCQ 100.0 82.29 to 117.7 Yes **** 
Control vs. MDA x T 100.0 82.29 to 117.7 Yes **** 
Control vs. MDA x TCQ 100.0 82.29 to 117.7 Yes **** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2 Appendix 2: 2way ANOVA with Tukey’s multiple comparisons test for 
all MTT Assays; cross comparison 
Within each row, compare columns 
(simple effects within rows)     
Number of families 1    
Number of comparisons per family 336    
Alpha 0.05    
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary 
0     
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WT x T vs. WT x TCQ 0.0 -23.37 to 23.37 No ns 
WT x T vs. TMX x T 0.0 -23.37 to 23.37 No ns 
WT x T vs. TMX x TCQ 0.0 -23.37 to 23.37 No ns 
WT x T vs. MDA x T 0.0 -23.37 to 23.37 No ns 
WT x T vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
WT x T vs. Control 0.0 -26.13 to 26.13 No ns 
WT x TCQ vs. TMX x T 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. TMX x TCQ 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. MDA x T 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. Control 0.0 -26.13 to 26.13 No ns 
TMX x T vs. TMX x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x T vs. MDA x T 0.0 -23.37 to 23.37 No ns 
TMX x T vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x T vs. Control 0.0 -26.13 to 26.13 No ns 
TMX x TCQ vs. MDA x T 0.0 -23.37 to 23.37 No ns 
TMX x TCQ vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x TCQ vs. Control 0.0 -26.13 to 26.13 No ns 
MDA x T vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
MDA x T vs. Control 0.0 -26.13 to 26.13 No ns 
MDA x TCQ vs. Control 0.0 -26.13 to 26.13 No ns 
2     
WT x T vs. WT x TCQ 20.98 -2.389 to 44.35 No ns 
WT x T vs. TMX x T -7.066 -30.44 to 16.31 No ns 
WT x T vs. TMX x TCQ -5.205 -28.58 to 18.17 No ns 
WT x T vs. MDA x T 0.1960 -23.18 to 23.57 No ns 
WT x T vs. MDA x TCQ 15.75 -7.622 to 39.12 No ns 
WT x T vs. Control -1.736 -25.11 to 21.64 No ns 
WT x TCQ vs. TMX x T -28.05 -51.42 to -4.677 Yes ** 
WT x TCQ vs. TMX x TCQ -26.19 -49.56 to -2.815 Yes ** 
WT x TCQ vs. MDA x T -20.79 -44.16 to 2.585 No ns 
WT x TCQ vs. MDA x TCQ -5.233 -28.60 to 18.14 No ns 
WT x TCQ vs. Control -22.72 -46.09 to 0.6531 No ns 
TMX x T vs. TMX x TCQ 1.861 -21.51 to 25.23 No ns 
TMX x T vs. MDA x T 7.262 -16.11 to 30.63 No ns 
TMX x T vs. MDA x TCQ 22.81 -0.5563 to 46.19 No ns 
TMX x T vs. Control 5.330 -18.04 to 28.70 No ns 
TMX x TCQ vs. MDA x T 5.401 -17.97 to 28.77 No ns 
TMX x TCQ vs. MDA x TCQ 20.95 -2.418 to 44.32 No ns 
TMX x TCQ vs. Control 3.468 -19.90 to 26.84 No ns 
MDA x T vs. MDA x TCQ 15.55 -7.818 to 38.92 No ns 
MDA x T vs. Control -1.932 -25.30 to 21.44 No ns 
MDA x TCQ vs. Control -17.49 -40.86 to 5.886 No ns 
4     
WT x T vs. WT x TCQ 31.39 8.017 to 54.76 Yes **** 
WT x T vs. TMX x T 0.3894 -22.98 to 23.76 No ns 
WT x T vs. TMX x TCQ 13.00 -10.38 to 36.37 No ns 
WT x T vs. MDA x T 10.03 -13.34 to 33.41 No ns 
WT x T vs. MDA x TCQ 24.10 0.7257 to 47.47 Yes * 
WT x T vs. Control 5.385 -17.99 to 28.76 No ns 
WT x TCQ vs. TMX x T -31.00 -54.37 to -7.628 Yes **** 
WT x TCQ vs. TMX x TCQ -18.39 -41.76 to 4.978 No ns 
WT x TCQ vs. MDA x T -21.35 -44.73 to 2.017 No ns 
WT x TCQ vs. MDA x TCQ -7.292 -30.66 to 16.08 No ns 
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WT x TCQ vs. Control -26.00 -49.38 to -2.633 Yes ** 
TMX x T vs. TMX x TCQ 12.61 -10.77 to 35.98 No ns 
TMX x T vs. MDA x T 9.645 -13.73 to 33.02 No ns 
TMX x T vs. MDA x TCQ 23.71 0.3362 to 47.08 Yes * 
TMX x T vs. Control 4.995 -18.38 to 28.37 No ns 
TMX x TCQ vs. MDA x T -2.961 -26.33 to 20.41 No ns 
TMX x TCQ vs. MDA x TCQ 11.10 -12.27 to 34.47 No ns 
TMX x TCQ vs. Control -7.611 -30.98 to 15.76 No ns 
MDA x T vs. MDA x TCQ 14.06 -9.308 to 37.43 No ns 
MDA x T vs. Control -4.650 -28.02 to 18.72 No ns 
MDA x TCQ vs. Control -18.71 -42.08 to 4.659 No ns 
6     
WT x T vs. WT x TCQ 40.04 13.91 to 66.17 Yes **** 
WT x T vs. TMX x T -6.627 -30.00 to 16.74 No ns 
WT x T vs. TMX x TCQ 19.50 -3.875 to 42.87 No ns 
WT x T vs. MDA x T 3.210 -20.16 to 26.58 No ns 
WT x T vs. MDA x TCQ 16.73 -6.641 to 40.10 No ns 
WT x T vs. Control 0.5273 -22.84 to 23.90 No ns 
WT x TCQ vs. TMX x T -46.67 -72.80 to -20.54 Yes **** 
WT x TCQ vs. TMX x TCQ -20.55 -46.68 to 5.583 No ns 
WT x TCQ vs. MDA x T -36.83 -62.96 to -10.70 Yes **** 
WT x TCQ vs. MDA x TCQ -23.31 -49.44 to 2.817 No ns 
WT x TCQ vs. Control -39.52 -65.65 to -13.39 Yes **** 
TMX x T vs. TMX x TCQ 26.12 2.752 to 49.49 Yes ** 
TMX x T vs. MDA x T 9.837 -13.53 to 33.21 No ns 
TMX x T vs. MDA x TCQ 23.36 -0.01383 to 46.73 No ns 
TMX x T vs. Control 7.154 -16.22 to 30.53 No ns 
TMX x TCQ vs. MDA x T -16.29 -39.66 to 7.084 No ns 
TMX x TCQ vs. MDA x TCQ -2.766 -26.14 to 20.61 No ns 
TMX x TCQ vs. Control -18.97 -42.34 to 4.402 No ns 
MDA x T vs. MDA x TCQ 13.52 -9.851 to 36.89 No ns 
MDA x T vs. Control -2.682 -26.05 to 20.69 No ns 
MDA x TCQ vs. Control -16.20 -39.57 to 7.168 No ns 
8     
WT x T vs. WT x TCQ 56.09 32.72 to 79.46 Yes **** 
WT x T vs. TMX x T -2.609 -25.98 to 20.76 No ns 
WT x T vs. TMX x TCQ 23.34 -0.03423 to 46.71 No ns 
WT x T vs. MDA x T 9.066 -14.31 to 32.44 No ns 
WT x T vs. MDA x TCQ 24.52 1.150 to 47.89 Yes * 
WT x T vs. Control 3.081 -20.29 to 26.45 No ns 
WT x TCQ vs. TMX x T -58.70 -82.07 to -35.33 Yes **** 
WT x TCQ vs. TMX x TCQ -32.76 -56.13 to -9.385 Yes **** 
WT x TCQ vs. MDA x T -47.03 -70.40 to -23.66 Yes **** 
WT x TCQ vs. MDA x TCQ -31.57 -54.94 to -8.200 Yes **** 
WT x TCQ vs. Control -53.01 -76.38 to -29.64 Yes **** 
TMX x T vs. TMX x TCQ 25.95 2.575 to 49.32 Yes ** 
TMX x T vs. MDA x T 11.67 -11.70 to 35.05 No ns 
TMX x T vs. MDA x TCQ 27.13 3.759 to 50.50 Yes ** 
TMX x T vs. Control 5.690 -17.68 to 29.06 No ns 
TMX x TCQ vs. MDA x T -14.27 -37.64 to 9.100 No ns 
TMX x TCQ vs. MDA x TCQ 1.185 -22.19 to 24.56 No ns 
TMX x TCQ vs. Control -20.26 -43.63 to 3.115 No ns 
MDA x T vs. MDA x TCQ 15.46 -7.916 to 38.83 No ns 
MDA x T vs. Control -5.985 -29.36 to 17.39 No ns 
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MDA x TCQ vs. Control -21.44 -44.81 to 1.930 No ns 
10     
WT x T vs. WT x TCQ 55.83 32.46 to 79.20 Yes **** 
WT x T vs. TMX x T -4.317 -27.69 to 19.05 No ns 
WT x T vs. TMX x TCQ 26.31 2.939 to 49.68 Yes ** 
WT x T vs. MDA x T 5.517 -17.85 to 28.89 No ns 
WT x T vs. MDA x TCQ 29.26 5.893 to 52.64 Yes *** 
WT x T vs. Control -2.196 -25.57 to 21.18 No ns 
WT x TCQ vs. TMX x T -60.15 -83.52 to -36.77 Yes **** 
WT x TCQ vs. TMX x TCQ -29.52 -52.89 to -6.146 Yes *** 
WT x TCQ vs. MDA x T -50.31 -73.68 to -26.94 Yes **** 
WT x TCQ vs. MDA x TCQ -26.56 -49.93 to -3.192 Yes ** 
WT x TCQ vs. Control -58.02 -81.39 to -34.65 Yes **** 
TMX x T vs. TMX x TCQ 30.63 7.257 to 54.00 Yes *** 
TMX x T vs. MDA x T 9.835 -13.54 to 33.21 No ns 
TMX x T vs. MDA x TCQ 33.58 10.21 to 56.95 Yes **** 
TMX x T vs. Control 2.121 -21.25 to 25.49 No ns 
TMX x TCQ vs. MDA x T -20.79 -44.16 to 2.578 No ns 
TMX x TCQ vs. MDA x TCQ 2.954 -20.42 to 26.33 No ns 
TMX x TCQ vs. Control -28.51 -51.88 to -5.135 Yes *** 
MDA x T vs. MDA x TCQ 23.75 0.3759 to 47.12 Yes * 
MDA x T vs. Control -7.713 -31.08 to 15.66 No ns 
MDA x TCQ vs. Control -31.46 -54.83 to -8.089 Yes **** 
12     
WT x T vs. WT x TCQ 54.84 31.47 to 78.21 Yes **** 
WT x T vs. TMX x T -19.70 -43.07 to 3.674 No ns 
WT x T vs. TMX x TCQ 39.88 16.50 to 63.25 Yes **** 
WT x T vs. MDA x T -5.709 -29.08 to 17.66 No ns 
WT x T vs. MDA x TCQ 32.83 9.460 to 56.20 Yes **** 
WT x T vs. Control -17.12 -40.49 to 6.250 No ns 
WT x TCQ vs. TMX x T -74.54 -97.91 to -51.17 Yes **** 
WT x TCQ vs. TMX x TCQ -14.96 -38.33 to 8.408 No ns 
WT x TCQ vs. MDA x T -60.55 -83.92 to -37.18 Yes **** 
WT x TCQ vs. MDA x TCQ -22.01 -45.38 to 1.364 No ns 
WT x TCQ vs. Control -71.96 -95.33 to -48.59 Yes **** 
TMX x T vs. TMX x TCQ 59.57 36.20 to 82.94 Yes **** 
TMX x T vs. MDA x T 13.99 -9.384 to 37.36 No ns 
TMX x T vs. MDA x TCQ 52.53 29.16 to 75.90 Yes **** 
TMX x T vs. Control 2.575 -20.80 to 25.95 No ns 
TMX x TCQ vs. MDA x T -45.59 -68.96 to -22.21 Yes **** 
TMX x TCQ vs. MDA x TCQ -7.045 -30.42 to 16.33 No ns 
TMX x TCQ vs. Control -57.00 -80.37 to -33.63 Yes **** 
MDA x T vs. MDA x TCQ 38.54 15.17 to 61.91 Yes **** 
MDA x T vs. Control -11.41 -34.78 to 11.96 No ns 
MDA x TCQ vs. Control -49.95 -73.32 to -26.58 Yes **** 
14     
WT x T vs. WT x TCQ 37.19 13.82 to 60.56 Yes **** 
WT x T vs. TMX x T -27.12 -50.49 to -3.744 Yes ** 
WT x T vs. TMX x TCQ 33.62 10.25 to 56.99 Yes **** 
WT x T vs. MDA x T -12.73 -36.10 to 10.64 No ns 
WT x T vs. MDA x TCQ 38.43 15.06 to 61.80 Yes **** 
WT x T vs. Control -32.30 -55.67 to -8.925 Yes **** 
WT x TCQ vs. TMX x T -64.31 -87.68 to -40.93 Yes **** 
WT x TCQ vs. TMX x TCQ -3.570 -26.94 to 19.80 No ns 
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WT x TCQ vs. MDA x T -49.92 -73.29 to -26.55 Yes **** 
WT x TCQ vs. MDA x TCQ 1.242 -22.13 to 24.61 No ns 
WT x TCQ vs. Control -69.49 -92.86 to -46.11 Yes **** 
TMX x T vs. TMX x TCQ 60.74 37.36 to 84.11 Yes **** 
TMX x T vs. MDA x T 14.39 -8.985 to 37.76 No ns 
TMX x T vs. MDA x TCQ 65.55 42.18 to 88.92 Yes **** 
TMX x T vs. Control -5.180 -28.55 to 18.19 No ns 
TMX x TCQ vs. MDA x T -46.35 -69.72 to -22.98 Yes **** 
TMX x TCQ vs. MDA x TCQ 4.812 -18.56 to 28.18 No ns 
TMX x TCQ vs. Control -65.92 -89.29 to -42.54 Yes **** 
MDA x T vs. MDA x TCQ 51.16 27.79 to 74.53 Yes **** 
MDA x T vs. Control -19.57 -42.94 to 3.805 No ns 
MDA x TCQ vs. Control -70.73 -94.10 to -47.36 Yes **** 
16     
WT x T vs. WT x TCQ 25.97 2.604 to 49.35 Yes ** 
WT x T vs. TMX x T -32.24 -55.61 to -8.865 Yes **** 
WT x T vs. TMX x TCQ 9.710 -13.66 to 33.08 No ns 
WT x T vs. MDA x T -14.58 -37.96 to 8.786 No ns 
WT x T vs. MDA x TCQ 22.28 -1.092 to 45.65 No ns 
WT x T vs. Control -56.19 -79.56 to -32.82 Yes **** 
WT x TCQ vs. TMX x T -58.21 -81.58 to -34.84 Yes **** 
WT x TCQ vs. TMX x TCQ -16.26 -39.64 to 7.106 No ns 
WT x TCQ vs. MDA x T -40.56 -63.93 to -17.19 Yes **** 
WT x TCQ vs. MDA x TCQ -3.696 -27.07 to 19.68 No ns 
WT x TCQ vs. Control -82.16 -105.5 to -58.79 Yes **** 
TMX x T vs. TMX x TCQ 41.95 18.57 to 65.32 Yes **** 
TMX x T vs. MDA x T 17.65 -5.720 to 41.02 No ns 
TMX x T vs. MDA x TCQ 54.52 31.14 to 77.89 Yes **** 
TMX x T vs. Control -23.95 -47.32 to -0.5815 Yes * 
TMX x TCQ vs. MDA x T -24.29 -47.67 to -0.9237 Yes * 
TMX x TCQ vs. MDA x TCQ 12.57 -10.80 to 35.94 No ns 
TMX x TCQ vs. Control -65.90 -89.27 to -42.53 Yes **** 
MDA x T vs. MDA x TCQ 36.86 13.49 to 60.24 Yes **** 
MDA x T vs. Control -41.60 -64.98 to -18.23 Yes **** 
MDA x TCQ vs. Control -78.47 -101.8 to -55.10 Yes **** 
18     
WT x T vs. WT x TCQ 32.34 8.969 to 55.71 Yes **** 
WT x T vs. TMX x T -13.65 -37.02 to 9.726 No ns 
WT x T vs. TMX x TCQ 28.10 4.726 to 51.47 Yes ** 
WT x T vs. MDA x T 3.550 -19.82 to 26.92 No ns 
WT x T vs. MDA x TCQ 23.22 -0.1558 to 46.59 No ns 
WT x T vs. Control -64.84 -88.21 to -41.47 Yes **** 
WT x TCQ vs. TMX x T -45.99 -69.36 to -22.61 Yes **** 
WT x TCQ vs. TMX x TCQ -4.243 -27.61 to 19.13 No ns 
WT x TCQ vs. MDA x T -28.79 -52.16 to -5.419 Yes *** 
WT x TCQ vs. MDA x TCQ -9.124 -32.50 to 14.25 No ns 
WT x TCQ vs. Control -97.18 -120.6 to -73.81 Yes **** 
TMX x T vs. TMX x TCQ 41.74 18.37 to 65.11 Yes **** 
TMX x T vs. MDA x T 17.20 -6.176 to 40.57 No ns 
TMX x T vs. MDA x TCQ 36.86 13.49 to 60.23 Yes **** 
TMX x T vs. Control -51.20 -74.57 to -27.82 Yes **** 
TMX x TCQ vs. MDA x T -24.55 -47.92 to -1.176 Yes * 
TMX x TCQ vs. MDA x TCQ -4.882 -28.25 to 18.49 No ns 
TMX x TCQ vs. Control -92.94 -116.3 to -69.57 Yes **** 
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MDA x T vs. MDA x TCQ 19.67 -3.705 to 43.04 No ns 
MDA x T vs. Control -68.39 -91.76 to -45.02 Yes **** 
MDA x TCQ vs. Control -88.06 -111.4 to -64.69 Yes **** 
20     
WT x T vs. WT x TCQ 13.64 -9.727 to 37.02 No ns 
WT x T vs. TMX x T 0.6737 -22.70 to 24.04 No ns 
WT x T vs. TMX x TCQ 12.16 -11.21 to 35.54 No ns 
WT x T vs. MDA x T 13.20 -10.17 to 36.57 No ns 
WT x T vs. MDA x TCQ 12.74 -10.63 to 36.11 No ns 
WT x T vs. Control -85.21 -108.6 to -61.84 Yes **** 
WT x TCQ vs. TMX x T -12.97 -36.34 to 10.40 No ns 
WT x TCQ vs. TMX x TCQ -1.480 -24.85 to 21.89 No ns 
WT x TCQ vs. MDA x T -0.4460 -23.82 to 22.93 No ns 
WT x TCQ vs. MDA x TCQ -0.9078 -24.28 to 22.46 No ns 
WT x TCQ vs. Control -98.85 -122.2 to -75.48 Yes **** 
TMX x T vs. TMX x TCQ 11.49 -11.88 to 34.86 No ns 
TMX x T vs. MDA x T 12.52 -10.85 to 35.90 No ns 
TMX x T vs. MDA x TCQ 12.06 -11.31 to 35.43 No ns 
TMX x T vs. Control -85.88 -109.3 to -62.51 Yes **** 
TMX x TCQ vs. MDA x T 1.034 -22.34 to 24.40 No ns 
TMX x TCQ vs. MDA x TCQ 0.5719 -22.80 to 23.94 No ns 
TMX x TCQ vs. Control -97.37 -120.7 to -74.00 Yes **** 
MDA x T vs. MDA x TCQ -0.4618 -23.83 to 22.91 No ns 
MDA x T vs. Control -98.41 -121.8 to -75.03 Yes **** 
MDA x TCQ vs. Control -97.94 -121.3 to -74.57 Yes **** 
22     
WT x T vs. WT x TCQ 0.4546 -22.92 to 23.83 No ns 
WT x T vs. TMX x T 1.446 -21.92 to 24.82 No ns 
WT x T vs. TMX x TCQ 1.291 -22.08 to 24.66 No ns 
WT x T vs. MDA x T 0.6856 -22.69 to 24.06 No ns 
WT x T vs. MDA x TCQ 0.7901 -22.58 to 24.16 No ns 
WT x T vs. Control -98.28 -121.7 to -74.91 Yes **** 
WT x TCQ vs. TMX x T 0.9917 -22.38 to 24.36 No ns 
WT x TCQ vs. TMX x TCQ 0.8360 -22.54 to 24.21 No ns 
WT x TCQ vs. MDA x T 0.2310 -23.14 to 23.60 No ns 
WT x TCQ vs. MDA x TCQ 0.3354 -23.04 to 23.71 No ns 
WT x TCQ vs. Control -98.74 -122.1 to -75.36 Yes **** 
TMX x T vs. TMX x TCQ -0.1558 -23.53 to 23.22 No ns 
TMX x T vs. MDA x T -0.7608 -24.13 to 22.61 No ns 
TMX x T vs. MDA x TCQ -0.6563 -24.03 to 22.71 No ns 
TMX x T vs. Control -99.73 -123.1 to -76.36 Yes **** 
TMX x TCQ vs. MDA x T -0.6050 -23.98 to 22.77 No ns 
TMX x TCQ vs. MDA x TCQ -0.5005 -23.87 to 22.87 No ns 
TMX x TCQ vs. Control -99.57 -122.9 to -76.20 Yes **** 
MDA x T vs. MDA x TCQ 0.1045 -23.27 to 23.48 No ns 
MDA x T vs. Control -98.97 -122.3 to -75.60 Yes **** 
MDA x TCQ vs. Control -99.07 -122.4 to -75.70 Yes **** 
24     
WT x T vs. WT x TCQ -0.5754 -23.95 to 22.80 No ns 
WT x T vs. TMX x T 0.01167 -23.36 to 23.38 No ns 
WT x T vs. TMX x TCQ -0.02642 -23.40 to 23.34 No ns 
WT x T vs. MDA x T -0.7752 -24.15 to 22.60 No ns 
WT x T vs. MDA x TCQ 0.9088 -22.46 to 24.28 No ns 
WT x T vs. Control -99.09 -122.5 to -75.72 Yes **** 
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WT x TCQ vs. TMX x T 0.5871 -22.78 to 23.96 No ns 
WT x TCQ vs. TMX x TCQ 0.5490 -22.82 to 23.92 No ns 
WT x TCQ vs. MDA x T -0.1998 -23.57 to 23.17 No ns 
WT x TCQ vs. MDA x TCQ 1.484 -21.89 to 24.86 No ns 
WT x TCQ vs. Control -98.52 -121.9 to -75.14 Yes **** 
TMX x T vs. TMX x TCQ -0.03809 -23.41 to 23.33 No ns 
TMX x T vs. MDA x T -0.7868 -24.16 to 22.58 No ns 
TMX x T vs. MDA x TCQ 0.8971 -22.47 to 24.27 No ns 
TMX x T vs. Control -99.10 -122.5 to -75.73 Yes **** 
TMX x TCQ vs. MDA x T -0.7487 -24.12 to 22.62 No ns 
TMX x TCQ vs. MDA x TCQ 0.9352 -22.44 to 24.31 No ns 
TMX x TCQ vs. Control -99.06 -122.4 to -75.69 Yes **** 
MDA x T vs. MDA x TCQ 1.684 -21.69 to 25.06 No ns 
MDA x T vs. Control -98.32 -121.7 to -74.94 Yes **** 
MDA x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
26     
WT x T vs. WT x TCQ -0.7952 -24.17 to 22.58 No ns 
WT x T vs. TMX x T -0.3746 -23.75 to 23.00 No ns 
WT x T vs. TMX x TCQ -0.1157 -23.49 to 23.26 No ns 
WT x T vs. MDA x T -0.8817 -24.25 to 22.49 No ns 
WT x T vs. MDA x TCQ 0.09859 -23.27 to 23.47 No ns 
WT x T vs. Control -99.90 -123.3 to -76.53 Yes **** 
WT x TCQ vs. TMX x T 0.4206 -22.95 to 23.79 No ns 
WT x TCQ vs. TMX x TCQ 0.6795 -22.69 to 24.05 No ns 
WT x TCQ vs. MDA x T -0.08650 -23.46 to 23.28 No ns 
WT x TCQ vs. MDA x TCQ 0.8938 -22.48 to 24.26 No ns 
WT x TCQ vs. Control -99.11 -122.5 to -75.74 Yes **** 
TMX x T vs. TMX x TCQ 0.2589 -23.11 to 23.63 No ns 
TMX x T vs. MDA x T -0.5071 -23.88 to 22.86 No ns 
TMX x T vs. MDA x TCQ 0.4732 -22.90 to 23.84 No ns 
TMX x T vs. Control -99.53 -122.9 to -76.16 Yes **** 
TMX x TCQ vs. MDA x T -0.7660 -24.14 to 22.61 No ns 
TMX x TCQ vs. MDA x TCQ 0.2143 -23.16 to 23.59 No ns 
TMX x TCQ vs. Control -99.79 -123.2 to -76.41 Yes **** 
MDA x T vs. MDA x TCQ 0.9803 -22.39 to 24.35 No ns 
MDA x T vs. Control -99.02 -122.4 to -75.65 Yes **** 
MDA x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
28     
WT x T vs. WT x TCQ -1.069 -24.44 to 22.30 No ns 
WT x T vs. TMX x T -0.1663 -23.54 to 23.20 No ns 
WT x T vs. TMX x TCQ 0.3171 -23.05 to 23.69 No ns 
WT x T vs. MDA x T -1.109 -24.48 to 22.26 No ns 
WT x T vs. MDA x TCQ 0.3171 -23.05 to 23.69 No ns 
WT x T vs. Control -99.68 -123.1 to -76.31 Yes **** 
WT x TCQ vs. TMX x T 0.9026 -22.47 to 24.27 No ns 
WT x TCQ vs. TMX x TCQ 1.386 -21.99 to 24.76 No ns 
WT x TCQ vs. MDA x T -0.03975 -23.41 to 23.33 No ns 
WT x TCQ vs. MDA x TCQ 1.386 -21.99 to 24.76 No ns 
WT x TCQ vs. Control -98.61 -122.0 to -75.24 Yes **** 
TMX x T vs. TMX x TCQ 0.4834 -22.89 to 23.85 No ns 
TMX x T vs. MDA x T -0.9424 -24.31 to 22.43 No ns 
TMX x T vs. MDA x TCQ 0.4834 -22.89 to 23.85 No ns 
TMX x T vs. Control -99.52 -122.9 to -76.15 Yes **** 
TMX x TCQ vs. MDA x T -1.426 -24.80 to 21.95 No ns 
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TMX x TCQ vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
MDA x T vs. MDA x TCQ 1.426 -21.95 to 24.80 No ns 
MDA x T vs. Control -98.57 -121.9 to -75.20 Yes **** 
MDA x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
30     
WT x T vs. WT x TCQ -1.987e-008 -23.37 to 23.37 No ns 
WT x T vs. TMX x T -1.987e-008 -23.37 to 23.37 No ns 
WT x T vs. TMX x TCQ -1.987e-008 -23.37 to 23.37 No ns 
WT x T vs. MDA x T -1.987e-008 -23.37 to 23.37 No ns 
WT x T vs. MDA x TCQ -1.987e-008 -23.37 to 23.37 No ns 
WT x T vs. Control -100.0 -123.4 to -76.63 Yes **** 
WT x TCQ vs. TMX x T 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. TMX x TCQ 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. MDA x T 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
WT x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
TMX x T vs. TMX x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x T vs. MDA x T 0.0 -23.37 to 23.37 No ns 
TMX x T vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x T vs. Control -100.0 -123.4 to -76.63 Yes **** 
TMX x TCQ vs. MDA x T 0.0 -23.37 to 23.37 No ns 
TMX x TCQ vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
TMX x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
MDA x T vs. MDA x TCQ 0.0 -23.37 to 23.37 No ns 
MDA x T vs. Control -100.0 -123.4 to -76.63 Yes **** 
MDA x TCQ vs. Control -100.0 -123.4 to -76.63 Yes **** 
7.3 Appendix 3: 2way ANOVA with Dunnet’s multiple comparisons test for 
all MTT Assays against Control 
Within each row, compare columns 
(simple effects within rows)     
Number of families 15    
Number of comparisons per family 6    
Alpha 0.05    
Dunnett's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary 
0     
Control vs. WT x T 0.0 -37.88 to 37.88 No ns 
Control vs. WTxTCQ 0.0 -37.88 to 37.88 No ns 
Control vs. TMX x T 0.0 -37.88 to 37.88 No ns 
Control vs. TMX x TCQ 0.0 -37.88 to 37.88 No ns 
Control vs. MDA x T 0.0 -37.88 to 37.88 No ns 
Control vs. MDA x TCQ 0.0 -37.88 to 37.88 No ns 
2     
Control vs. WT x T -4.709 -42.59 to 33.17 No ns 
Control vs. WTxTCQ -26.78 -64.66 to 11.10 No ns 
Control vs. TMX x T -26.44 -64.32 to 11.44 No ns 
Control vs. TMX x TCQ 0.8320 -37.05 to 38.71 No ns 
Control vs. MDA x T -0.5747 -38.45 to 37.31 No ns 
Control vs. MDA x TCQ -83.21 -121.1 to -45.33 Yes **** 
4     
Control vs. WT x T 0.5978 -37.28 to 38.48 No ns 
Control vs. WTxTCQ -22.26 -60.14 to 15.62 No ns 
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Control vs. TMX x T -24.79 -62.67 to 13.09 No ns 
Control vs. TMX x TCQ -3.540 -41.42 to 34.34 No ns 
Control vs. MDA x T 13.77 -24.11 to 51.65 No ns 
Control vs. MDA x TCQ -86.87 -124.7 to -48.99 Yes **** 
6     
Control vs. WT x T -4.854 -42.73 to 33.03 No ns 
Control vs. WTxTCQ -30.12 -68.00 to 7.762 No ns 
Control vs. TMX x T -40.11 -77.99 to -2.232 Yes * 
Control vs. TMX x TCQ -27.69 -65.58 to 10.19 No ns 
Control vs. MDA x T 23.11 -14.77 to 60.99 No ns 
Control vs. MDA x TCQ -83.28 -121.2 to -45.40 Yes **** 
8     
Control vs. WT x T -4.653 -42.53 to 33.23 No ns 
Control vs. WTxTCQ -25.06 -67.41 to 17.29 No ns 
Control vs. TMX x T -62.31 -100.2 to -24.43 Yes *** 
Control vs. TMX x TCQ -77.70 -115.6 to -39.82 Yes **** 
Control vs. MDA x T 30.57 -7.306 to 68.45 No ns 
Control vs. MDA x TCQ -86.00 -123.9 to -48.12 Yes **** 
10     
Control vs. WT x T -4.614 -42.49 to 33.27 No ns 
Control vs. WTxTCQ -12.00 -49.88 to 25.88 No ns 
Control vs. TMX x T -41.59 -79.47 to -3.708 Yes * 
Control vs. TMX x TCQ -61.74 -99.62 to -23.86 Yes *** 
Control vs. MDA x T 35.11 -2.772 to 72.99 No ns 
Control vs. MDA x TCQ -70.56 -108.4 to -32.68 Yes **** 
12     
Control vs. WT x T -16.51 -54.39 to 21.37 No ns 
Control vs. WTxTCQ 6.216 -31.66 to 44.10 No ns 
Control vs. TMX x T -33.00 -70.88 to 4.883 No ns 
Control vs. TMX x TCQ -0.8876 -38.77 to 36.99 No ns 
Control vs. MDA x T 38.04 0.1580 to 75.92 Yes * 
Control vs. MDA x TCQ -37.44 -75.32 to 0.4409 No ns 
14     
Control vs. WT x T -3.096 -40.98 to 34.78 No ns 
Control vs. WTxTCQ 40.32 -2.030 to 82.67 No ns 
Control vs. TMX x T -18.24 -56.12 to 19.64 No ns 
Control vs. TMX x TCQ -1.370 -39.25 to 36.51 No ns 
Control vs. MDA x T 49.02 11.14 to 86.90 Yes ** 
Control vs. MDA x TCQ -2.012 -39.89 to 35.87 No ns 
16     
Control vs. WT x T 17.89 -19.99 to 55.77 No ns 
Control vs. WTxTCQ 78.29 40.41 to 116.2 Yes **** 
Control vs. TMX x T -18.75 -56.63 to 19.13 No ns 
Control vs. TMX x TCQ 25.41 -12.47 to 63.29 No ns 
Control vs. MDA x T 68.74 30.86 to 106.6 Yes **** 
Control vs. MDA x TCQ 55.17 17.29 to 93.05 Yes ** 
18     
Control vs. WT x T 34.42 -7.927 to 76.78 No ns 
Control vs. WTxTCQ 78.95 36.59 to 121.3 Yes **** 
Control vs. TMX x T 5.003 -32.88 to 42.88 No ns 
Control vs. TMX x TCQ 56.68 18.80 to 94.56 Yes *** 
Control vs. MDA x T 80.32 42.44 to 118.2 Yes **** 
Control vs. MDA x TCQ 48.85 10.97 to 86.73 Yes ** 
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20     
Control vs. WT x T 61.26 23.38 to 99.14 Yes *** 
Control vs. WTxTCQ 105.0 62.62 to 147.3 Yes **** 
Control vs. TMX x T 20.13 -17.75 to 58.01 No ns 
Control vs. TMX x TCQ 87.80 49.92 to 125.7 Yes **** 
Control vs. MDA x T 90.46 52.58 to 128.3 Yes **** 
Control vs. MDA x TCQ 70.74 32.86 to 108.6 Yes **** 
22     
Control vs. WT x T 56.86 18.98 to 94.74 Yes *** 
Control vs. WTxTCQ 98.48 60.60 to 136.4 Yes **** 
Control vs. TMX x T 92.97 55.09 to 130.9 Yes **** 
Control vs. TMX x TCQ 100.0 62.12 to 137.9 Yes **** 
Control vs. MDA x T 94.91 57.03 to 132.8 Yes **** 
Control vs. MDA x TCQ 74.02 36.14 to 111.9 Yes **** 
24     
Control vs. WT x T 64.84 26.96 to 102.7 Yes **** 
Control vs. WTxTCQ 94.37 40.80 to 147.9 Yes **** 
Control vs. TMX x T 95.91 58.03 to 133.8 Yes **** 
Control vs. TMX x TCQ 100.0 62.12 to 137.9 Yes **** 
Control vs. MDA x T 95.36 57.48 to 133.2 Yes **** 
Control vs. MDA x TCQ 87.69 49.81 to 125.6 Yes **** 
26     
Control vs. WT x T 76.36 38.48 to 114.2 Yes **** 
Control vs. WTxTCQ 78.57 36.22 to 120.9 Yes **** 
Control vs. TMX x T 95.91 58.03 to 133.8 Yes **** 
Control vs. TMX x TCQ 100.0 62.12 to 137.9 Yes **** 
Control vs. MDA x T 95.59 57.71 to 133.5 Yes **** 
Control vs. MDA x TCQ 89.51 51.63 to 127.4 Yes **** 
28     
Control vs. WT x T 64.93 27.05 to 102.8 Yes **** 
Control vs. WTxTCQ 94.37 40.80 to 147.9 Yes **** 
Control vs. TMX x T 100.0 62.12 to 137.9 Yes **** 
Control vs. TMX x TCQ 100.0 62.12 to 137.9 Yes **** 
Control vs. MDA x T 100.6 62.71 to 138.5 Yes **** 
Control vs. MDA x TCQ 100.0 62.12 to 137.9 Yes **** 
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7.4 Appendix 3: 2way ANOVA with Tukey’s multiple comparisons test for 
all MTT Assays; cross comparison 
 
Within each row, compare columns 
(simple effects within rows)     
Number of families 15    
Number of comparisons per family 15    
Alpha 0.05    
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary 
0     
WT x T vs. WTxTCQ 0.0 -45.74 to 45.74 No ns 
WT x T vs. TMX x T 0.0 -45.74 to 45.74 No ns 
WT x T vs. TMX x TCQ 0.0 -45.74 to 45.74 No ns 
WT x T vs. MDA x T 0.0 -45.74 to 45.74 No ns 
WT x T vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
WTxTCQ vs. TMX x T 0.0 -45.74 to 45.74 No ns 
WTxTCQ vs. TMX x TCQ 0.0 -45.74 to 45.74 No ns 
WTxTCQ vs. MDA x T 0.0 -45.74 to 45.74 No ns 
WTxTCQ vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
TMX x T vs. TMX x TCQ 0.0 -45.74 to 45.74 No ns 
TMX x T vs. MDA x T 0.0 -45.74 to 45.74 No ns 
TMX x T vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
TMX x TCQ vs. MDA x T 0.0 -45.74 to 45.74 No ns 
TMX x TCQ vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
MDA x T vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
2     
WT x T vs. WTxTCQ -22.07 -67.81 to 23.68 No ns 
WT x T vs. TMX x T -21.73 -67.47 to 24.02 No ns 
WT x T vs. TMX x TCQ 5.541 -40.20 to 51.28 No ns 
WT x T vs. MDA x T 4.134 -41.61 to 49.88 No ns 
WT x T vs. MDA x TCQ -78.51 -124.2 to -32.76 Yes **** 
WTxTCQ vs. TMX x T 0.3406 -45.40 to 46.08 No ns 
WTxTCQ vs. TMX x TCQ 27.61 -18.13 to 73.35 No ns 
WTxTCQ vs. MDA x T 26.20 -19.54 to 71.94 No ns 
WTxTCQ vs. MDA x TCQ -56.44 -102.2 to -10.70 Yes ** 
TMX x T vs. TMX x TCQ 27.27 -18.48 to 73.01 No ns 
TMX x T vs. MDA x T 25.86 -19.88 to 71.60 No ns 
TMX x T vs. MDA x TCQ -56.78 -102.5 to -11.04 Yes ** 
TMX x TCQ vs. MDA x T -1.407 -47.15 to 44.34 No ns 
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TMX x TCQ vs. MDA x TCQ -84.05 -129.8 to -38.30 Yes **** 
MDA x T vs. MDA x TCQ -82.64 -128.4 to -36.90 Yes **** 
4     
WT x T vs. WTxTCQ -22.85 -68.60 to 22.89 No ns 
WT x T vs. TMX x T -25.38 -71.13 to 20.36 No ns 
WT x T vs. TMX x TCQ -4.138 -49.88 to 41.60 No ns 
WT x T vs. MDA x T 13.18 -32.57 to 58.92 No ns 
WT x T vs. MDA x TCQ -87.47 -133.2 to -41.72 Yes **** 
WTxTCQ vs. TMX x T -2.530 -48.27 to 43.21 No ns 
WTxTCQ vs. TMX x TCQ 18.72 -27.03 to 64.46 No ns 
WTxTCQ vs. MDA x T 36.03 -9.713 to 81.77 No ns 
WTxTCQ vs. MDA x TCQ -64.61 -110.4 to -18.87 Yes *** 
TMX x T vs. TMX x TCQ 21.25 -24.50 to 66.99 No ns 
TMX x T vs. MDA x T 38.56 -7.183 to 84.30 No ns 
TMX x T vs. MDA x TCQ -62.08 -107.8 to -16.34 Yes ** 
TMX x TCQ vs. MDA x T 17.31 -28.43 to 63.06 No ns 
TMX x TCQ vs. MDA x TCQ -83.33 -129.1 to -37.59 Yes **** 
MDA x T vs. MDA x TCQ -100.6 -146.4 to -54.90 Yes **** 
6     
WT x T vs. WTxTCQ -25.26 -71.01 to 20.48 No ns 
WT x T vs. TMX x T -35.26 -81.00 to 10.48 No ns 
WT x T vs. TMX x TCQ -22.84 -68.58 to 22.90 No ns 
WT x T vs. MDA x T 27.96 -17.78 to 73.71 No ns 
WT x T vs. MDA x TCQ -78.43 -124.2 to -32.69 Yes **** 
WTxTCQ vs. TMX x T -9.994 -55.74 to 35.75 No ns 
WTxTCQ vs. TMX x TCQ 2.423 -43.32 to 48.17 No ns 
WTxTCQ vs. MDA x T 53.23 7.485 to 98.97 Yes * 
WTxTCQ vs. MDA x TCQ -53.16 -98.91 to -7.421 Yes * 
TMX x T vs. TMX x TCQ 12.42 -33.33 to 58.16 No ns 
TMX x T vs. MDA x T 63.22 17.48 to 109.0 Yes ** 
TMX x T vs. MDA x TCQ -43.17 -88.91 to 2.572 No ns 
TMX x TCQ vs. MDA x T 50.80 5.062 to 96.55 Yes * 
TMX x TCQ vs. MDA x TCQ -55.59 -101.3 to -9.844 Yes ** 
MDA x T vs. MDA x TCQ -106.4 -152.1 to -60.65 Yes **** 
8     
WT x T vs. WTxTCQ -20.41 -71.55 to 30.73 No ns 
WT x T vs. TMX x T -57.66 -103.4 to -11.91 Yes ** 
WT x T vs. TMX x TCQ -73.04 -118.8 to -27.30 Yes *** 
WT x T vs. MDA x T 35.23 -10.52 to 80.97 No ns 
WT x T vs. MDA x TCQ -81.35 -127.1 to -35.61 Yes **** 
WTxTCQ vs. TMX x T -37.25 -88.39 to 13.90 No ns 
WTxTCQ vs. TMX x TCQ -52.63 -103.8 to -1.492 Yes * 
WTxTCQ vs. MDA x T 55.64 4.494 to 106.8 Yes * 
WTxTCQ vs. MDA x TCQ -60.94 -112.1 to -9.801 Yes ** 
TMX x T vs. TMX x TCQ -15.39 -61.13 to 30.36 No ns 
TMX x T vs. MDA x T 92.88 47.14 to 138.6 Yes **** 
TMX x T vs. MDA x TCQ -23.70 -69.44 to 22.05 No ns 
TMX x TCQ vs. MDA x T 108.3 62.53 to 154.0 Yes **** 
TMX x TCQ vs. MDA x TCQ -8.309 -54.05 to 37.43 No ns 
MDA x T vs. MDA x TCQ -116.6 -162.3 to -70.84 Yes **** 
10     
WT x T vs. WTxTCQ -7.386 -53.13 to 38.36 No ns 
WT x T vs. TMX x T -36.97 -82.72 to 8.769 No ns 
WT x T vs. TMX x TCQ -57.12 -102.9 to -11.38 Yes ** 
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WT x T vs. MDA x T 39.72 -6.020 to 85.47 No ns 
WT x T vs. MDA x TCQ -65.94 -111.7 to -20.20 Yes *** 
WTxTCQ vs. TMX x T -29.59 -75.33 to 16.16 No ns 
WTxTCQ vs. TMX x TCQ -49.74 -95.48 to -3.994 Yes * 
WTxTCQ vs. MDA x T 47.11 1.366 to 92.85 Yes * 
WTxTCQ vs. MDA x TCQ -58.56 -104.3 to -12.81 Yes ** 
TMX x T vs. TMX x TCQ -20.15 -65.89 to 25.59 No ns 
TMX x T vs. MDA x T 76.70 30.95 to 122.4 Yes **** 
TMX x T vs. MDA x TCQ -28.97 -74.71 to 16.77 No ns 
TMX x TCQ vs. MDA x T 96.85 51.10 to 142.6 Yes **** 
TMX x TCQ vs. MDA x TCQ -8.820 -54.56 to 36.92 No ns 
MDA x T vs. MDA x TCQ -105.7 -151.4 to -59.92 Yes **** 
12     
WT x T vs. WTxTCQ 22.73 -23.02 to 68.47 No ns 
WT x T vs. TMX x T -16.49 -62.23 to 29.25 No ns 
WT x T vs. TMX x TCQ 15.62 -30.12 to 61.36 No ns 
WT x T vs. MDA x T 54.55 8.805 to 100.3 Yes ** 
WT x T vs. MDA x TCQ -20.93 -66.67 to 24.81 No ns 
WTxTCQ vs. TMX x T -39.21 -84.96 to 6.530 No ns 
WTxTCQ vs. TMX x TCQ -7.103 -52.85 to 38.64 No ns 
WTxTCQ vs. MDA x T 31.82 -13.92 to 77.57 No ns 
WTxTCQ vs. MDA x TCQ -43.65 -89.40 to 2.088 No ns 
TMX x T vs. TMX x TCQ 32.11 -13.63 to 77.85 No ns 
TMX x T vs. MDA x T 71.04 25.29 to 116.8 Yes *** 
TMX x T vs. MDA x TCQ -4.442 -50.18 to 41.30 No ns 
TMX x TCQ vs. MDA x T 38.93 -6.817 to 84.67 No ns 
TMX x TCQ vs. MDA x TCQ -36.55 -82.29 to 9.191 No ns 
MDA x T vs. MDA x TCQ -75.48 -121.2 to -29.73 Yes **** 
14     
WT x T vs. WTxTCQ 43.42 -7.725 to 94.56 No ns 
WT x T vs. TMX x T -15.15 -60.89 to 30.60 No ns 
WT x T vs. TMX x TCQ 1.727 -44.02 to 47.47 No ns 
WT x T vs. MDA x T 52.11 6.369 to 97.85 Yes * 
WT x T vs. MDA x TCQ 1.085 -44.66 to 46.83 No ns 
WTxTCQ vs. TMX x T -58.56 -109.7 to -7.422 Yes * 
WTxTCQ vs. TMX x TCQ -41.69 -92.83 to 9.451 No ns 
WTxTCQ vs. MDA x T 8.694 -42.45 to 59.84 No ns 
WTxTCQ vs. MDA x TCQ -42.33 -93.47 to 8.809 No ns 
TMX x T vs. TMX x TCQ 16.87 -28.87 to 62.62 No ns 
TMX x T vs. MDA x T 67.26 21.52 to 113.0 Yes *** 
TMX x T vs. MDA x TCQ 16.23 -29.51 to 61.97 No ns 
TMX x TCQ vs. MDA x T 50.38 4.642 to 96.13 Yes * 
TMX x TCQ vs. MDA x TCQ -0.6420 -46.38 to 45.10 No ns 
MDA x T vs. MDA x TCQ -51.03 -96.77 to -5.284 Yes * 
16     
WT x T vs. WTxTCQ 60.41 14.66 to 106.1 Yes ** 
WT x T vs. TMX x T -36.64 -82.38 to 9.106 No ns 
WT x T vs. TMX x TCQ 7.522 -38.22 to 53.27 No ns 
WT x T vs. MDA x T 50.85 5.104 to 96.59 Yes * 
WT x T vs. MDA x TCQ 37.28 -8.460 to 83.03 No ns 
WTxTCQ vs. TMX x T -97.04 -142.8 to -51.30 Yes **** 
WTxTCQ vs. TMX x TCQ -52.88 -98.63 to -7.140 Yes * 
WTxTCQ vs. MDA x T -9.559 -55.30 to 36.18 No ns 
WTxTCQ vs. MDA x TCQ -23.12 -68.87 to 22.62 No ns 
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TMX x T vs. TMX x TCQ 44.16 -1.584 to 89.90 No ns 
TMX x T vs. MDA x T 87.48 41.74 to 133.2 Yes **** 
TMX x T vs. MDA x TCQ 73.92 28.18 to 119.7 Yes **** 
TMX x TCQ vs. MDA x T 43.32 -2.419 to 89.07 No ns 
TMX x TCQ vs. MDA x TCQ 29.76 -15.98 to 75.50 No ns 
MDA x T vs. MDA x TCQ -13.56 -59.31 to 32.18 No ns 
18     
WT x T vs. WTxTCQ 44.52 -11.50 to 100.5 No ns 
WT x T vs. TMX x T -29.42 -80.56 to 21.72 No ns 
WT x T vs. TMX x TCQ 22.25 -28.89 to 73.39 No ns 
WT x T vs. MDA x T 45.90 -5.243 to 97.04 No ns 
WT x T vs. MDA x TCQ 14.43 -36.71 to 65.57 No ns 
WTxTCQ vs. TMX x T -73.94 -125.1 to -22.80 Yes *** 
WTxTCQ vs. TMX x TCQ -22.27 -73.41 to 28.87 No ns 
WTxTCQ vs. MDA x T 1.378 -49.76 to 52.52 No ns 
WTxTCQ vs. MDA x TCQ -30.09 -81.23 to 21.05 No ns 
TMX x T vs. TMX x TCQ 51.67 5.931 to 97.42 Yes * 
TMX x T vs. MDA x T 75.32 29.58 to 121.1 Yes **** 
TMX x T vs. MDA x TCQ 43.85 -1.893 to 89.59 No ns 
TMX x TCQ vs. MDA x T 23.65 -22.10 to 69.39 No ns 
TMX x TCQ vs. MDA x TCQ -7.823 -53.57 to 37.92 No ns 
MDA x T vs. MDA x TCQ -31.47 -77.21 to 14.27 No ns 
20     
WT x T vs. WTxTCQ 43.72 -7.424 to 94.86 No ns 
WT x T vs. TMX x T -41.12 -86.87 to 4.620 No ns 
WT x T vs. TMX x TCQ 26.55 -19.20 to 72.29 No ns 
WT x T vs. MDA x T 29.20 -16.54 to 74.94 No ns 
WT x T vs. MDA x TCQ 9.485 -36.26 to 55.23 No ns 
WTxTCQ vs. TMX x T -84.84 -136.0 to -33.70 Yes **** 
WTxTCQ vs. TMX x TCQ -17.17 -68.31 to 33.97 No ns 
WTxTCQ vs. MDA x T -14.52 -65.66 to 36.63 No ns 
WTxTCQ vs. MDA x TCQ -34.23 -85.38 to 16.91 No ns 
TMX x T vs. TMX x TCQ 67.67 21.93 to 113.4 Yes *** 
TMX x T vs. MDA x T 70.33 24.58 to 116.1 Yes *** 
TMX x T vs. MDA x TCQ 50.61 4.865 to 96.35 Yes * 
TMX x TCQ vs. MDA x T 2.655 -43.09 to 48.40 No ns 
TMX x TCQ vs. MDA x TCQ -17.06 -62.80 to 28.68 No ns 
MDA x T vs. MDA x TCQ -19.72 -65.46 to 26.03 No ns 
22     
WT x T vs. WTxTCQ 41.62 -4.122 to 87.36 No ns 
WT x T vs. TMX x T 36.11 -9.630 to 81.86 No ns 
WT x T vs. TMX x TCQ 43.14 -2.602 to 88.88 No ns 
WT x T vs. MDA x T 38.06 -7.687 to 83.80 No ns 
WT x T vs. MDA x TCQ 17.16 -28.58 to 62.91 No ns 
WTxTCQ vs. TMX x T -5.509 -51.25 to 40.23 No ns 
WTxTCQ vs. TMX x TCQ 1.520 -44.22 to 47.26 No ns 
WTxTCQ vs. MDA x T -3.566 -49.31 to 42.18 No ns 
WTxTCQ vs. MDA x TCQ -24.46 -70.20 to 21.28 No ns 
TMX x T vs. TMX x TCQ 7.028 -38.71 to 52.77 No ns 
TMX x T vs. MDA x T 1.943 -43.80 to 47.69 No ns 
TMX x T vs. MDA x TCQ -18.95 -64.69 to 26.79 No ns 
TMX x TCQ vs. MDA x T -5.085 -50.83 to 40.66 No ns 
TMX x TCQ vs. MDA x TCQ -25.98 -71.72 to 19.76 No ns 
MDA x T vs. MDA x TCQ -20.89 -66.64 to 24.85 No ns 
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24     
WT x T vs. WTxTCQ 29.53 -35.16 to 94.22 No ns 
WT x T vs. TMX x T 31.07 -14.67 to 76.81 No ns 
WT x T vs. TMX x TCQ 35.16 -10.59 to 80.90 No ns 
WT x T vs. MDA x T 30.52 -15.23 to 76.26 No ns 
WT x T vs. MDA x TCQ 22.85 -22.89 to 68.59 No ns 
WTxTCQ vs. TMX x T 1.543 -63.15 to 66.23 No ns 
WTxTCQ vs. TMX x TCQ 5.629 -59.06 to 70.32 No ns 
WTxTCQ vs. MDA x T 0.9882 -63.70 to 65.68 No ns 
WTxTCQ vs. MDA x TCQ -6.677 -71.37 to 58.01 No ns 
TMX x T vs. TMX x TCQ 4.087 -41.66 to 49.83 No ns 
TMX x T vs. MDA x T -0.5544 -46.30 to 45.19 No ns 
TMX x T vs. MDA x TCQ -8.220 -53.96 to 37.52 No ns 
TMX x TCQ vs. MDA x T -4.641 -50.38 to 41.10 No ns 
TMX x TCQ vs. MDA x TCQ -12.31 -58.05 to 33.44 No ns 
MDA x T vs. MDA x TCQ -7.665 -53.41 to 38.08 No ns 
26     
WT x T vs. WTxTCQ 2.217 -48.92 to 53.36 No ns 
WT x T vs. TMX x T 19.56 -26.18 to 65.30 No ns 
WT x T vs. TMX x TCQ 23.64 -22.10 to 69.39 No ns 
WT x T vs. MDA x T 19.24 -26.50 to 64.98 No ns 
WT x T vs. MDA x TCQ 13.16 -32.58 to 58.90 No ns 
WTxTCQ vs. TMX x T 17.34 -33.80 to 68.48 No ns 
WTxTCQ vs. TMX x TCQ 21.43 -29.71 to 72.57 No ns 
WTxTCQ vs. MDA x T 17.02 -34.12 to 68.16 No ns 
WTxTCQ vs. MDA x TCQ 10.94 -40.20 to 62.08 No ns 
TMX x T vs. TMX x TCQ 4.087 -41.66 to 49.83 No ns 
TMX x T vs. MDA x T -0.3187 -46.06 to 45.42 No ns 
TMX x T vs. MDA x TCQ -6.399 -52.14 to 39.34 No ns 
TMX x TCQ vs. MDA x T -4.405 -50.15 to 41.34 No ns 
TMX x TCQ vs. MDA x TCQ -10.49 -56.23 to 35.26 No ns 
MDA x T vs. MDA x TCQ -6.080 -51.82 to 39.66 No ns 
28     
WT x T vs. WTxTCQ 29.44 -35.25 to 94.13 No ns 
WT x T vs. TMX x T 35.07 -10.67 to 80.81 No ns 
WT x T vs. TMX x TCQ 35.07 -10.67 to 80.81 No ns 
WT x T vs. MDA x T 35.66 -10.09 to 81.40 No ns 
WT x T vs. MDA x TCQ 35.07 -10.67 to 80.81 No ns 
WTxTCQ vs. TMX x T 5.629 -59.06 to 70.32 No ns 
WTxTCQ vs. TMX x TCQ 5.629 -59.06 to 70.32 No ns 
WTxTCQ vs. MDA x T 6.217 -58.47 to 70.91 No ns 
WTxTCQ vs. MDA x TCQ 5.629 -59.06 to 70.32 No ns 
TMX x T vs. TMX x TCQ 0.0 -45.74 to 45.74 No ns 
TMX x T vs. MDA x T 0.5881 -45.15 to 46.33 No ns 
TMX x T vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
TMX x TCQ vs. MDA x T 0.5881 -45.15 to 46.33 No ns 
TMX x TCQ vs. MDA x TCQ 0.0 -45.74 to 45.74 No ns 
MDA x T vs. MDA x TCQ -0.5881 -46.33 to 45.15 No ns 
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7.5 Appendix 4: Annexin V Standard Curve 
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7.6 Preliminary Combination Graphs 
MCF-7 WT with Tamoxifen combined with 10, 20, 30 and 40µM of CQ independently 
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Figure 7.1: MTT cytotoxicity assay highlighting the difference in response in the combined effect of tamoxifen and chloroquine on MCF-7 WT 
with different doses of chloroquine (±SE, n=3). WTxT – No CQ, WTxTCQ – 10µM CQ, WTxTCQ40 – 40µm CQ.  The ED50 concentrations read at 
16µM of tamoxifen for WTxT, 12µM for WTxTCQ and 1µM for WTxTCQ40. 
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MTT MCF-7 TMX with Tamoxifen combined with 10, 20, 30 and 40µM of CQ independently 
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Figure 7.2: MTT cytotoxicity assay highlighting the difference in response in the combined effect of tamoxifen and chloroquine on MCF-7 TMX 
with different doses of Chloroquine (±SE, n=3). WTxT – No CQ, WTxTCQ – 10µM CQ, WTxTCQ40 – 40µm CQ. The ED50 concentration reads at 
18µM of tamoxifen for TMXxT, 15µM for TMXxTCQ and 2.5µM for TMXxTCQ40. 
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MTT MDA-MB-231 with Tamoxifen combined with 10, 20, 30 and 40µM of CQ independently 
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Figure 7.3: MTT cytotoxicity assay highlighting the difference in response in the combined effect of tamoxifen and chloroquine on MDA-MB-231 
with different doses of Chloroquine. WTxT – No CQ, WTxTCQ – 10µM CQ, WTxTCQ40 – 40µm CQ. The ED50 concentration reads at 19µM of 
tamoxifen for MDAxT, 12µM for MDAxTCQ and 2.5µM for MDAxTCQ40. 
 
 
 
 
